0001437749-22-025382 | 10-Q | XBRL Viewer | Horizon Technology Finance Corp

Document And Entity Information - shares	9 Months Ended
Document And Entity Information - shares	Sep. 30, 2022	Nov. 01, 2022
Document Information [Line Items]
Entity Central Index Key	0001487428
Entity Registrant Name	Horizon Technology Finance Corp
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Document Fiscal Period Focus	Q3
Document Fiscal Year Focus	2022
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Sep. 30, 2022
Document Transition Report	false
Entity File Number	814-00802
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	27-2114934
Entity Address, Address Line One	312 Farmington Avenue
Entity Address, City or Town	Farmington
Entity Address, State or Province	CT
Entity Address, Postal Zip Code	06032
City Area Code	860
Local Phone Number	676‑8654
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		26,401,476
The 6.25% Notes due 2027 [Member]
Document Information [Line Items]
Title of 12(b) Security	6.25% Notes due 2027
Trading Symbol	HTFC
Security Exchange Name	NYSE
The 4.875% Notes due 2026 [Member]
Document Information [Line Items]
Title of 12(b) Security	4.875% Notes due 2026
Trading Symbol	HTFB
Security Exchange Name	NYSE
Common Stock [Member]
Document Information [Line Items]
Title of 12(b) Security	Common Stock, par value $0.001 per share
Trading Symbol	HRZN
Security Exchange Name	NASDAQ

Consolidated Statements of Assets and Liabilities (Current Period Unaudited) - USD ($) $ in Thousands	Sep. 30, 2022	Dec. 31, 2021
Assets
Investments at fair value	$ 634,624	$ 458,075
Cash	23,839	38,054
Investments in money market funds	7,732	7,868
Restricted investments in money market funds	1,617	1,359
Interest receivable	10,975	6,154
Other assets	2,602	2,450
Total assets	681,389	513,960
Liabilities
Borrowings (Note 7)	359,011	257,613
Distributions payable	7,918	6,365
Base management fee payable (Note 3)	1,870	706
Incentive fee payable (Note 3)	2,784	2,015
Other accrued expenses	2,119	1,926
Total liabilities	373,702	268,625
Commitments and contingencies (Note 8)
Net assets
Preferred stock, par value $0.001 per share, 1,000,000 shares authorized, zero shares issued and outstanding as of September 30, 2022 and December 31, 2021	0	0
Common stock, par value $0.001 per share, 100,000,000 shares authorized, 26,561,238 and 21,384,925 shares issued and 26,393,773 and 21,217,460 shares outstanding as of September 30, 2022 and December 31, 2021, respectively	27	22
Paid-in capital in excess of par	369,334	301,359
Distributable earnings	(61,674)	(56,046)
Total net assets	307,687	245,335
Total liabilities and net assets	$ 681,389	$ 513,960
Net asset value per common share (in dollars per share)	$ 11.66	$ 11.56
Non-affiliate [Member]
Assets
Investments at fair value	$ 634,624	$ 458,075
Affiliate [Member]
Assets
Investments at fair value	$ 0	$ 0

Consolidated Statements of Assets and Liabilities (Current Period Unaudited) (Parentheticals) - USD ($) $ in Thousands	Sep. 30, 2022	Dec. 31, 2021
Investments at cost	$ 629,216	$ 453,837
Preferred stock, par value (in dollars per share)	$ 0.001	$ 0.001
Preferred stock, shares authorized (in shares)	1,000,000	1,000,000
Preferred stock, shares issued (in shares)	0	0
Preferred stock, shares oustanding (in shares)	0	0
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common stock, shares authorized (in shares)	100,000,000	100,000,000
Common stock, shares issued (in shares)	26,561,238	21,384,925
Common stock, shares outstanding (in shares)	26,393,773	21,217,460
Non-affiliate [Member]
Investments at cost	$ 629,216	$ 452,387
Affiliate [Member]
Investments at cost	$ 0	$ 1,450

Consolidated Statements of Operations (Unaudited) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Investment income
Interest income on investments	$ 22,745	$ 14,035	$ 54,317	$ 39,178
Total fee income	509	2,332	1,729	3,892
Total investment income	23,254	16,367	56,046	43,070
Expenses
Interest expense	5,339	3,112	12,987	8,781
Base management fee (Note 3)	2,788	1,997	7,555	5,595
Performance based incentive fee (Note 3)	2,784	2,012	6,353	5,040
Administrative fee (Note 3)	412	251	1,147	829
Professional fees	314	559	1,163	1,348
General and administrative	381	333	1,088	1,142
Total expenses	12,018	8,264	30,293	22,735
Net investment income before excise tax	11,236	8,103	25,753	20,335
Provision for excise tax	100	56	306	174
Net investment income	11,136	8,047	25,447	20,161
Net realized and unrealized (loss) gain
Net realized (loss) gain on investments	(8,585)	1,344	(9,484)	(2,372)
Net realized loss on extinguishment of debt	0	0	0	(395)
Net realized (loss) gain	(8,585)	1,344	(9,484)	(2,767)
Net unrealized (depreciation) appreciation on investments	3,442	3,376	1,169	8,122
Net realized and unrealized (loss) gain	(5,143)	4,720	(8,315)	5,355
Net increase in net assets resulting from operations	$ 5,993	$ 12,767	$ 17,132	$ 25,516
Net investment income per common share (in dollars per share)	$ 0.43	$ 0.40	$ 1.06	$ 1.02
Net increase in net assets resulting from operations per common share (in dollars per share)	0.23	0.63	0.71	1.29
Distributions declared per share (in dollars per share)	$ 0.30	$ 0.30	$ 0.90	$ 0.90
Weighted average shares outstanding (in shares)	25,738,054	20,269,813	23,995,369	19,826,790
Non-affiliate [Member]
Investment income
Interest income on investments	$ 22,745	$ 14,035	$ 54,317	$ 38,965
Prepayment fee income on non-affiliate investments	450	1,204	1,542	2,460
Success fee income on non-affiliate investments	0	1,100	0	1,100
Fee income on investments	59	28	187	320
Net realized and unrealized (loss) gain
Net realized (loss) gain on investments	(8,665)	1,344	(8,364)	(2,372)
Net unrealized (depreciation) appreciation on investments	3,442	3,929	(281)	10,314
Affiliate [Member]
Investment income
Interest income on investments	0	0	0	213
Fee income on investments	0	0	0	12
Non-controlled Affiliate [Member]
Net realized and unrealized (loss) gain
Net realized (loss) gain on investments	30	0	30	0
Net unrealized (depreciation) appreciation on investments	0	(228)	0	(1,867)
Controlled Affiliate [Member]
Net realized and unrealized (loss) gain
Net realized (loss) gain on investments	50	0	(1,150)	0
Net unrealized (depreciation) appreciation on investments	$ 0	$ (325)	$ 1,450	$ (325)

Consolidated Statements of Changes in Net Assets (Unaudited) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021	Dec. 31, 2021
Common Stock Outstanding [Member]
Balance (in shares)	24,857,104	20,024,241	21,217,460	19,286,356	19,286,356
Issuance of common stock, net of offering costs (in shares)	1,523,519	395,068	5,141,920	1,122,516
Issuance of common stock under dividend reinvestment plan (in shares)	13,150	5,866	34,393	16,303
Balance (in shares)	26,393,773	20,425,175	26,393,773	20,425,175	21,217,460
Common Stock [Member]
Balance	$ 26	$ 20	$ 22	$ 19	$ 19
Issuance of common stock, net of offering costs	1	1	5	2
Net investment income, net of excise tax	0	0	0	0
Net realized gain on investments	0	0	0	0
Unrealized Gain (Loss) on Investments	0	0	0	0
Issuance of common stock under dividend reinvestment plan	0	0	0	0
Distributions declared	0	0	0	0
Net unrealized appreciation on investments	0	0	0	0
Net realized loss on extinguishment of debt				0
Balance	27	21	27	21	22
Additional Paid-in Capital [Member]
Balance	350,173	282,136	301,359	271,287	271,287
Issuance of common stock, net of offering costs	18,995	6,624	67,519	17,312
Net investment income, net of excise tax	0	0	0	0
Net realized gain on investments	0	0	0	0
Unrealized Gain (Loss) on Investments	0	0	0	0
Issuance of common stock under dividend reinvestment plan	166	101	456	262
Distributions declared	0	0	0	0
Net unrealized appreciation on investments	0	0	0	0
Net realized loss on extinguishment of debt				0
Balance	369,334	288,861	369,334	288,861	301,359
Retained Earnings [Member]
Balance	(59,594)	(57,892)	(56,046)	(58,709)	(58,709)
Issuance of common stock, net of offering costs	0	0	0	0
Net investment income, net of excise tax	11,136	8,047	25,447	20,161
Net realized gain on investments	(8,585)	1,344	(9,484)	(2,372)
Unrealized Gain (Loss) on Investments	3,442	3,376	1,169	8,122
Issuance of common stock under dividend reinvestment plan	0	0	0	0
Distributions declared	(8,073)	(6,167)	(22,760)	(18,099)
Net unrealized appreciation on investments	3,442	3,376	1,169	8,122
Net realized loss on extinguishment of debt				(395)
Balance	(61,674)	(51,292)	(61,674)	(51,292)	(56,046)
Balance	290,605	224,264	245,335	212,597	212,597
Issuance of common stock, net of offering costs	18,996	6,625	67,524	17,314
Net investment income, net of excise tax	11,136	8,047	25,447	20,161
Net realized gain on investments	(8,585)	1,344	(9,484)	(2,372)
Unrealized Gain (Loss) on Investments	3,442	3,376	1,169	8,122
Issuance of common stock under dividend reinvestment plan	166	101	456	262
Distributions declared	(8,073)	(6,167)	(22,760)	(18,099)
Net unrealized appreciation on investments	3,442	3,376	1,169	8,122
Net realized loss on extinguishment of debt	0	0	0	(395)
Balance	$ 307,687	$ 237,590	$ 307,687	$ 237,590	$ 245,335

Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021	Dec. 31, 2021
Cash flows from operating activities:
Net increase in net assets resulting from operations	$ 5,993	$ 12,767	$ 17,132	$ 25,516
Adjustments to reconcile net increase in net assets resulting from operations to net cash used in operating activities:
Amortization of debt issuance costs	400	200	1,142	744
Net realized loss on investments			9,484	2,372
Net realized loss on extinguishment of debt	0	0	0	395
Net unrealized appreciation on investments	(3,442)	(3,376)	(1,169)	(8,122)
Purchase of investments			(348,347)	(217,252)
Principal payments received on investments			114,433	119,260
Proceeds from sale of investments			49,681	5,285
Changes in assets and liabilities:
Increase in interest receivable			(2,175)	(661)
Increase in end-of-term payments			(3,003)	(1,100)
Decrease in unearned income			(274)	(854)
Decrease (increase) in other assets			115	(507)
Increase in other accrued expenses			193	76
Increase in base management fee payable			1,164	135
Increase in incentive fee payable			769	1,037
Net cash used in operating activities			(160,855)	(73,676)
Cash flows from financing activities:
Proceeds from issuance of common stock, net of offering costs			67,525	17,312
Advances on Credit Facilities			119,000	89,000
Repayment of Credit Facilities			(47,000)	(36,000)
Debt issuance costs			(2,470)	(2,648)
Distributions paid			(20,752)	(17,493)
Net cash provided by financing activities			146,762	70,296
Net decrease in cash, cash equivalents and restricted cash			(14,093)	(3,380)
Cash, cash equivalents and restricted cash:
Beginning of period			47,281	47,758	$ 47,758
End of period	33,188	44,378	33,188	44,378	47,281
Supplemental disclosure of cash flow information:
Cash paid for interest			11,543	7,785
Supplemental non-cash investing and financing activities:
Warrant investments received and recorded as unearned income			2,969	2,924
Distributions payable	7,918	6,128	7,918	6,128	6,365
End-of-term payments receivable			8,240	4,993
Non-cash income			4,504	3,523
Cash	23,839	20,817	23,839	20,817	38,054
Investments in money market funds	7,732	22,057	7,732	22,057	$ 7,868
Restricted investments in money market funds	1,617	1,504	1,617	1,504
Total cash, cash equivalents and restricted cash	$ 33,188	$ 44,378	33,188	44,378
The 2027 Notes [Member]
Cash flows from financing activities:
Proceeds from issuance of notes			57,500	0
The 2026 Notes [Member]
Cash flows from financing activities:
Proceeds from issuance of notes			0	57,500
Asset-Backed Notes [Member]
Cash flows from financing activities:
Repayment of notes			(27,041)	0
The 2022 Notes [Member]
Cash flows from financing activities:
Repayment of notes			$ 0	$ (37,375)

Note 2 - Basis of Presentation and Significant Accounting Policies

9 Months Ended

Sep. 30, 2022

Notes to Financial Statements

Basis of Presentation and Significant Accounting Policies [Text Block]

Note 2. Basis of presentation and significant accounting policies

The consolidated financial statements of the Company have been prepared in accordance with U.S. generally accepted accounting principles (“GAAP”) and pursuant to the requirements for reporting on Form 10‑Q and Articles 6 and 10 of Regulation S-X (“Regulation S-X”) under the Securities Act of 1933, as amended (the “Securities Act”). In the opinion of management, the consolidated financial statements reflect all adjustments and reclassifications, consisting solely of normal recurring accruals, that are necessary for the fair presentation of financial results as of and for the periods presented. All intercompany balances and transactions have been eliminated. The current period’s results of operations are not necessarily indicative of results that ultimately may be achieved for the year. Therefore, the unaudited financial statements and notes should be read in conjunction with the audited financial statements and notes thereto for the year ended December 31, 2021.

Principles of consolidation

As required under GAAP and Regulation S-X, the Company will generally consolidate its investment in a company that is an investment company subsidiary or a controlled operating company whose business consists of providing services to the Company. Accordingly, the Company consolidated the results of the Company’s wholly-owned subsidiaries in its consolidated financial statements.

Assets related to transactions that do not meet Accounting Standards Codification (“ASC”) Topic 860, Transfers and Servicing requirements for accounting sale treatment are reflected in the Company’s Consolidated Statements of Assets and Liabilities as investments. Those assets are owned by special purpose entities, including 2019‑1 Entities, that are consolidated in the Company’s consolidated financial statements. The creditors of the special purpose entities have received security interests in such assets and such assets are not intended to be available to the creditors of the Company (or any affiliate of the Company).

Use of estimates

In preparing the consolidated financial statements in accordance with GAAP, management is required to make estimates and assumptions that affect the reported amounts of assets and liabilities, and disclosures of contingent assets and liabilities, as of the date of the balance sheet and income and expenses for the period. Actual results could differ from those estimates. Material estimates that are particularly susceptible to significant change in the near term relate to the valuation of investments.

Fair value

The Company records all of its investments at fair value in accordance with relevant GAAP, which establishes a framework used to measure fair value and requires disclosures for fair value measurements. The Company has categorized its investments carried at fair value, based on the priority of the valuation technique, into a three-level fair value hierarchy as more fully described in Note 6. Fair value is a market-based measure considered from the perspective of the market participant who holds the financial instrument rather than an entity specific measure. Therefore, when market assumptions are not readily available, the Company’s own assumptions are set to reflect those that management believes market participants would use in pricing the financial instrument at the measurement date.

The availability of observable inputs can vary depending on the financial instrument and is affected by a wide variety of factors, including, for example, the type of product, whether the product is new, whether the product is traded on an active exchange or in the secondary market and the current market conditions. To the extent that the valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. Accordingly, the degree of judgment exercised by the Company in determining fair value is greatest for financial instruments classified as Level 3.

See Note 6 for additional information regarding fair value.

Segments

The Company has determined that it has a single reporting segment and operating unit structure. The Company lends to and invests in portfolio companies in various technology, life science, healthcare information and services and sustainability industries. The Company separately evaluates the performance of each of its lending and investment relationships. However, because each of these debt investments and investment relationships has similar business and economic characteristics, they have been aggregated into a single lending and investment segment.

Investments

Investments are recorded at fair value. Pursuant to the amended SEC Rule 2a-5 of the 1940 Act, on July 29, 2022, the Board designated the Advisor as the Company’s “valuation designee.” The valuation designee determines the fair value of the Company’s portfolio investments and the Company's board of directors (the “Board”) oversees the valuation designee. The Company has the intent to hold its debt investments for the foreseeable future or until maturity or payoff.

Interest on debt investments is accrued and included in income based on contractual rates applied to principal amounts outstanding. Interest income is determined using a method that results in a level rate of return on principal amounts outstanding. Generally, when a debt investment becomes 90 days or more past due, or if the Company otherwise does not expect to receive interest and principal repayments, the debt investment is placed on non-accrual status and the recognition of interest income may be discontinued. Interest payments received on non-accrual debt investments may be recognized as income, on a cash basis, or applied to principal depending upon management’s judgment at the time the debt investment is placed on non-accrual status. As of September 30, 2022, there were no investments on nonaccrual status. As of December 31, 2021, there was one investment on non-accrual status with a cost of $11.5 million and a fair value of $6.9 million. For the three and nine months ended September 30, 2022, the Company did not recognize any interest income from debt investments on non-accrual status. For the three months ended September 30, 2021, the Company did not recognize any interest income from debt investments on non-accrual status. For the nine months ended September 30, 2021, the Company recognized, as interest income, payments of $1.3 million received from one portfolio company whose debt investment was on non-accrual status.

The Company receives a variety of fees from borrowers in the ordinary course of conducting its business, including advisory fees, commitment fees, amendment fees, non-utilization fees, success fees and prepayment fees. In a limited number of cases, the Company may also receive a non-refundable deposit earned upon the termination of a transaction. Debt investment origination fees, net of certain direct origination costs, are deferred and, along with unearned income, are amortized as a level-yield adjustment over the respective term of the debt investment. All other income is recognized when earned. Fees for counterparty debt investment commitments with multiple debt investments are allocated to each debt investment based upon each debt investment’s relative fair value. When a debt investment is placed on non-accrual status, the amortization of the related fees and unearned income is discontinued until the debt investment is returned to accrual status.

Certain debt investment agreements also require the borrower to make an ETP, that is accrued into interest receivable and taken into income over the life of the debt investment to the extent such amounts are expected to be collected. The Company will generally cease accruing the income if there is insufficient value to support the accrual or the Company does not expect the borrower to be able to pay the ETP when due. The proportion of the Company’s total investment income that resulted from the portion of ETPs not received in cash for the three months ended September 30, 2022 and 2021 was 7.0% and 5.2%, respectively. The proportion of the Company’s total investment income that resulted from the portion of ETPs not received in cash for the nine months ended September 30, 2022 and 2021 was 7.5% and 6.7%, respectively.

In connection with substantially all lending arrangements, the Company receives warrants to purchase shares of stock from the borrower. The warrants are recorded as assets at estimated fair value on the grant date using the Black-Scholes valuation model. The warrants are considered loan fees and are recorded as unearned income on the grant date. The unearned income is recognized as interest income over the contractual life of the related debt investment in accordance with the Company’s income recognition policy. Subsequent to debt investment origination, the fair value of the warrants is determined using the Black-Scholes valuation model. Any adjustment to fair value is recorded through earnings as net unrealized appreciation or depreciation on investments. Gains and losses from the disposition of the warrants or stock acquired from the exercise of warrants are recognized as realized gains and losses on investments.

Realized gains or losses on the sale of investments, or upon the determination that an investment balance, or portion thereof, is not recoverable, are calculated using the specific identification method. The Company measures realized gains or losses by calculating the difference between the net proceeds from the repayment or sale and the amortized cost basis of the investment. Net change in unrealized appreciation or depreciation reflects the change in the fair values of the Company’s portfolio investments during the reporting period, including any reversal of previously recorded unrealized appreciation or depreciation when gains or losses are realized.

Debt issuance costs

Debt issuance costs are fees and other direct incremental costs incurred by the Company in obtaining debt financing from its lenders and issuing debt securities. The unamortized balance of debt issuance costs as of September 30, 2022 and December 31, 2021 was $5.6 million and $4.3 million, respectively. These amounts are amortized and included in interest expense in the consolidated statements of operations over the life of the borrowings. The accumulated amortization balances as of September 30, 2022 and December 31, 2021 were $4.4 million and $3.2 million, respectively. The amortization expense for the three months ended September 30, 2022 and 2021 was $0.4 million and $0.2 million, respectively. The amortization expense for the nine months ended September 30, 2022 and 2021 was $1.1 million and $0.7 million, respectively.

Income taxes

As a BDC, the Company has elected to be treated as a RIC under Subchapter M of the Code and operates in a manner so as to qualify for the tax treatment applicable to RICs. In order to qualify as a RIC and to avoid the imposition of corporate-level income tax on the portion of its taxable income distributed to stockholders, among other things, the Company is required to meet certain source of income and asset diversification requirements and to timely distribute dividends out of assets legally available for distribution to its stockholders of an amount generally at least equal to 90% of its investment company taxable income, as defined by the Code and determined without regard to any deduction for dividends paid, for each tax year. The Company, among other things, has made and intends to continue to make the requisite distributions to its stockholders, which generally relieves the Company from corporate-level U.S. federal income taxes. Accordingly, no provision for federal income tax has been recorded in the financial statements. Differences between taxable income and net increase in net assets resulting from operations either can be temporary, meaning they will reverse in the future, or permanent. In accordance with ASC Topic 946, Financial Services—Investment Companies, as amended, of the Financial Accounting Standards Board (“FASB”), permanent tax differences, such as non-deductible excise taxes paid, are reclassified from distributions in excess of net investment income and net realized loss on investments to paid-in-capital at the end of each fiscal year. These permanent book-to-tax differences are reclassified on the consolidated statements of changes in net assets to reflect their tax character but have no impact on total net assets. For the year ended December 31, 2021, the Company reclassified $0.4 million to paid-in capital from distributions in excess of net investment income, which related to excise taxes payable.

Depending on the level of taxable income earned in a tax year, the Company may choose to carry forward taxable income in excess of current year distributions into the next tax year and incur a 4% U.S. federal excise tax on such income, as required. To the extent that the Company determines that its estimated current year annual taxable income will be in excess of estimated current year distributions, the Company accrues excise tax, if any, on estimated excess taxable income as taxable income is earned. For the three and nine months ended September 30, 2022, $0.1 million and $0.3 million, respectively, was accrued for U.S. federal excise tax. For the three and nine months ended September 30, 2021, $0.1 million and $0.2 million, respectively, was recorded for U.S. federal excise tax.

The Company evaluates tax positions taken in the course of preparing the Company’s tax returns to determine whether the tax positions are “more-likely-than-not” to be sustained by the applicable tax authority in accordance with ASC Topic 740, Income Taxes, as modified by ASC Topic 946. Tax benefits of positions not deemed to meet the more-likely-than-not threshold, or uncertain tax positions, would be recorded as a tax expense in the current year. It is the Company’s policy to recognize accrued interest and penalties related to uncertain tax benefits in income tax expense. The Company had no material uncertain tax positions at September 30, 2022 and December 31, 2021. The Company’s income tax returns for the 2021, 2020 and 2019 tax years remain subject to examination by U.S. federal and state tax authorities.

Distributions

Distributions to common stockholders are recorded on the declaration date. The amount to be paid out as distributions is determined by the Board. Net realized capital gains, if any, may be distributed, although the Company may decide to retain such net realized gains for investment.

The Company has adopted a dividend reinvestment plan that provides for reinvestment of cash distributions on behalf of its stockholders, unless a stockholder elects to receive cash. As a result, if the Board declares a cash distribution, then stockholders who have not “opted out” of the dividend reinvestment plan will have their cash distributions automatically reinvested in additional shares of the Company’s common stock, rather than receiving the cash distribution. The Company may issue new shares or purchase shares in the open market to fulfill its obligations under the plan.

Stockholders’ Equity

On July 30, 2020, the Company entered into an At-The-Market (“ATM”) sales agreement (the “2020 Equity Distribution Agreement”), with Goldman Sachs & Co. LLC and B. Riley FBR, Inc. (each a “Sales Agent” and, collectively, the “Sales Agents”). The 2020 Equity Distribution Agreement provided that the Company may offer and sell its shares from time to time through the Sales Agents up to $100.0 million worth of its common stock, in amounts and at times to be determined by the Company.

On August 2, 2021, the Company terminated the 2020 Equity Distribution Agreement and entered into a new ATM sales agreement (the “2021 Equity Distribution Agreement”), with the Sales Agents. The remaining shares available under the 2020 Equity Distribution Agreement are no longer available for issuance. The 2021 Equity Distribution Agreement provides that the Company may offer and sell its shares from time to time through the Sales Agents up to $100.0 million worth of its common stock, in amounts and at times to be determined by the Company. Sales of the Company’s common stock, if any, may be made in negotiated transactions or transactions that are deemed to be “at-the-market,” as defined in Rule 415 under the Securities Act, including sales made directly on the NASDAQ or similar securities exchange or sales made to or through a market maker other than on an exchange, at prices related to the prevailing market prices or at negotiated prices.

During the three months ended September 30, 2022, the Company sold 1,523,519 shares of common stock under the 2021 Equity Distribution Agreement. For the same period, the Company received total accumulated net proceeds of approximately $19.0 million, including $0.4 million of offering expenses, from these sales.

During the three months ended September 30, 2021, the Company sold 395,068 shares of common stock under the 2020 Equity Distribution Agreement and the 2021 Equity Distribution Agreement. For the same period, the Company received total accumulated net proceeds of approximately $6.6 million, including $0.2 million of offering expenses, from these sales.

During the nine months ended September 30, 2022, the Company sold 2,641,920 shares of common stock under the 2021 Equity Distribution Agreement. For the same period, the Company received total accumulated net proceeds of approximately $33.2 million, including $0.6 million of offering expenses, from these sales.

During the nine months ended September 30, 2021, the Company sold 1,122,516 shares of common stock under the 2020 Equity Distribution Agreement and the 2021 Equity Distribution Agreement. For the same period, the Company received total accumulated net proceeds of approximately $17.3 million, including $0.5 million of offering expenses, from these sales.

The Company generally uses net proceeds from these offerings to make investments, to pay down liabilities and for general corporate purposes. As of September 30, 2022, shares representing approximately $48.9 million of its common stock remain available for issuance and sale under the Equity Distribution Agreement.

Stock Repurchase Program

On April 29, 2022, the Board extended a previously authorized stock repurchase program which allows the Company to repurchase up to $5.0 million of its common stock at prices below the Company’s net asset value per share as reported in its most recent consolidated financial statements. Under the repurchase program, the Company may, but is not obligated to, repurchase shares of its outstanding common stock in the open market or in privately negotiated transactions from time to time. Any repurchases by the Company will comply with the requirements of Rule 10b‑18 under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and any applicable requirements of the 1940 Act. Unless extended by the Board, the repurchase program will terminate on the earlier of June 30, 2023 or the repurchase of $5.0 million of the Company’s common stock. During the three and nine months ended September 30, 2022 and 2021, the Company did not make any repurchases of its common stock. From the inception of the stock repurchase program through September 30, 2022, the Company repurchased 167,465 shares of its common stock at an average price of $11.22 on the open market at a total cost of $1.9 million.

Transfers of financial assets

Assets related to transactions that do not meet the requirements under ASC Topic 860, Transfers and Servicing for sale treatment under GAAP are reflected in the Company’s consolidated statements of assets and liabilities as investments. Those assets are owned by special purpose entities that are consolidated in the Company’s financial statements. The creditors of the special purpose entities have received security interests in such assets and such assets are not intended to be available to the creditors of the Company (or any other affiliate of the Company).

Transfers of financial assets are accounted for as sales when control over the assets has been surrendered. Control over transferred assets is deemed to be surrendered when (1) the assets have been isolated from the Company — put presumptively beyond the reach of the transferor and its creditors, even in bankruptcy or other receivership, (2) the transferee obtains the right (free of conditions that constrain it from taking advantage of that right) to pledge or exchange the transferred assets and (3) the transferor does not maintain effective control over the transferred assets through either (a) an agreement that both entitles and obligates the transferor to repurchase or redeem the assets before maturity or (b) the ability to unilaterally cause the holder to return specific assets, other than through a cleanup call.

Recently issued accounting pronouncements

In March 2020, the FASB issued Accounting Standards Update No. 2020-04, Reference Rate Reform (Topic 848): Facilitation of the Effects of Reference Rate Reform on Financial Reporting (“ASU 2020-04”). ASU 2020-04 provides optional expedients and exceptions for applying GAAP to contract modifications and hedging relationships, subject to meeting certain criteria, that reference LIBOR or another rate that is expected to be discontinued. The amendments in ASU 2020-04 are effective for all entities as of March 12, 2020 through December 31, 2022. The Company is currently assessing the impact of ASU 2020-04 and the LIBOR transition on its consolidated financial statements.

In June 2022, the FASB issues Accounting Standards Update No. 2022-03, Fair Value Measurement of Equity Securities Subject to Contractual Sale Restrictions (“ASU 2022-03”). ASU 2022-03 clarifies the guidance when measuring the fair value of an equity security subject to contractual restrictions that prohibit the sale of the security. The amendments in ASU 2022-03 are effective for public companies for fiscal years beginning after December 15, 2023, and interim periods within those fiscal years. The Company is currently assessing the impact of ASU 2022-03 on its consolidated financial statements.

Note 3 - Related Party Transactions

9 Months Ended

Sep. 30, 2022

Notes to Financial Statements

Note 3. Related party transactions

Investment Management Agreement

At a special meeting of the stockholders on October 30, 2018, the stockholders approved a new Investment Management Agreement which became effective on March 7, 2019. The new Investment Management Agreement replaced the previously effective Amended and Restated Investment Management Agreement dated as of October 28, 2010 and amended effective July 1, 2014. On October 28, 2022, the Board unanimously approved the renewal of the Investment Management Agreement. Under the terms of the Investment Management Agreement, the Advisor determines the composition of the Company’s investment portfolio, the nature and timing of the changes to the investment portfolio and the manner of implementing such changes; identifies, evaluates and negotiates the structure of the investments the Company makes (including performing due diligence on the Company’s prospective portfolio companies); and closes, monitors and administers the investments the Company makes, including the exercise of any voting or consent rights.

The Advisor’s services under the Investment Management Agreement are not exclusive to the Company, and the Advisor is free to furnish similar services to other entities so long as its services to the Company are not impaired. The Advisor is a registered investment adviser with the SEC. The Advisor receives fees for providing services to the Company under the Investment Management Agreement, consisting of two components, a base management fee and an incentive fee.

The base management fee will be calculated at an annual rate of 2.00% of the Company’s gross assets (less cash and cash equivalents) including any assets acquired with the proceeds of leverage; provided, that, to the extent the Company’s gross assets (less cash and cash equivalents) exceed $250 million, the base management fee on the amount of such excess over $250 million will be calculated at an annual rate of 1.60% of the Company’s gross assets (less cash and cash equivalents) including any assets acquired with the proceeds of leverage. The base management fee is payable monthly in arrears and is prorated for any partial month.

The base management fee payable at September 30, 2022 and December 31, 2021 was $1.9 million and $0.7 million, respectively. The base management fee expense was $2.8 million and $2.0 million for the three months ended September 30, 2022 and 2021, respectively. The base management fee expense was $7.6 million and $5.6 million for the nine months ended September 30, 2022 and 2021, respectively.

The incentive fee has two parts, as follows:

The first part, which is subject to the Incentive Fee Cap and Deferral Mechanism, as defined below, is calculated and payable quarterly in arrears based on the Company’s pre-incentive fee net investment income for the immediately preceding calendar quarter. For this purpose, “Pre-Incentive Fee Net Investment Income” means interest income, dividend income and any other income (including any other fees (other than fees for providing managerial assistance), such as commitment, origination, structuring, diligence and consulting fees or other fees received from portfolio companies) accrued during the calendar quarter, minus expenses for the quarter (including the base management fee, expenses payable under the Administration Agreement (as defined below), and any interest expense and any dividends paid on any issued and outstanding preferred stock, but excluding the incentive fee). Pre-Incentive Fee Net Investment Income includes, in the case of investments with a deferred interest feature (such as original issue discount, debt instruments with PIK interest and zero coupon securities), accrued income the Company has not yet received in cash. The incentive fee with respect to the Pre-Incentive Fee Net Investment Income is 20.00% of the amount, if any, by which the Pre-Incentive Fee Net Investment Income for the immediately preceding calendar quarter exceeds a hurdle rate of 1.75% (which is 7.00% annualized) of the Company’s net assets at the end of the immediately preceding calendar quarter, adjusted for any share issuances or repurchases during the relevant quarter, subject to a “catch-up” provision measured as of the end of each calendar quarter. Under this provision, in any calendar quarter, the Advisor receives no incentive fee until the Pre-Incentive Fee Net Investment Income equals the hurdle rate of 1.75%, but then receives, as a “catch-up,” 100.00% of the Pre-Incentive Fee Net Investment Income with respect to that portion of such Pre-Incentive Fee Net Investment Income, if any, that exceeds the hurdle rate but is less than 2.1875% quarterly (which is 8.75% annualized). The effect of this “catch-up” provision is that, if Pre-Incentive Fee Net Investment Income exceeds 2.1875% in any calendar quarter, the Advisor will receive 20.00% of the Pre-Incentive Fee Net Investment Income as if the hurdle rate did not apply.

Pre-Incentive Fee Net Investment Income does not include any realized capital gains, realized capital losses or unrealized capital appreciation or depreciation. Because of the structure of the incentive fee, it is possible that the Company may pay an incentive fee in a quarter in which the Company incurs a loss. For example, if the Company receives Pre-Incentive Fee Net Investment Income in excess of the quarterly minimum hurdle rate, the Company will pay the applicable incentive fee up to the Incentive Fee Cap, defined below, even if the Company has incurred a loss in that quarter due to realized and unrealized capital losses. The Company’s net investment income used to calculate this part of the incentive fee is also included in the amount of the Company’s gross assets used to calculate the 2.00% base management fee. These calculations are appropriately prorated for any period of less than three months and adjusted for any share issuances or repurchases during the current quarter.

The incentive fee on Pre-Incentive Fee Net Investment Income is subject to a fee cap and deferral mechanism which is determined based upon a look-back period of up to three years and is expensed when incurred. For this purpose, the look-back period for the incentive fee based on Pre-Incentive Fee Net Investment Income (the “Incentive Fee Look-back Period”) includes the relevant calendar quarter and the 11 preceding full calendar quarters. Each quarterly incentive fee payable on Pre-Incentive Fee Net Investment Income is subject to a cap (the “Incentive Fee Cap”) and a deferral mechanism through which the Advisor may recoup a portion of such deferred incentive fees (collectively, the “Incentive Fee Cap and Deferral Mechanism”). The Incentive Fee Cap is equal to (a) 20.00% of Cumulative Pre-Incentive Fee Net Return (as defined below) during the Incentive Fee Look-back Period less (b) cumulative incentive fees of any kind paid to the Advisor during the Incentive Fee Look-back Period. To the extent the Incentive Fee Cap is zero or a negative value in any calendar quarter, the Company will not pay an incentive fee on Pre-Incentive Fee Net Investment Income to the Advisor in that quarter. To the extent that the payment of incentive fees on Pre-Incentive Fee Net Investment Income is limited by the Incentive Fee Cap, the payment of such fees will be deferred and paid in subsequent calendar quarters up to three years after their date of deferment, subject to certain limitations, which are set forth in the Investment Management Agreement. The Company only pays incentive fees on Pre-Incentive Fee Net Investment Income to the extent allowed by the Incentive Fee Cap and Deferral Mechanism. “Cumulative Pre-Incentive Fee Net Return” during any Incentive Fee Look-back Period means the sum of (a) Pre-Incentive Fee Net Investment Income and the base management fee for each calendar quarter during the Incentive Fee Look-back Period and (b) the sum of cumulative realized capital gains and losses, cumulative unrealized capital appreciation and cumulative unrealized capital depreciation during the applicable Incentive Fee Look-back Period.

The second part of the incentive fee is determined and payable in arrears as of the end of each calendar year (or, upon termination of the Investment Management Agreement, as of the termination date), and equals 20.00% of the Company’s realized capital gains, if any, on a cumulative basis from the date of the election to be a BDC through the end of each calendar year, computed net of all realized capital losses and unrealized capital depreciation on a cumulative basis through the end of such year, less all previous amounts paid in respect of the capital gain incentive fee. However, in accordance with GAAP, the Company is required to include the aggregate unrealized capital appreciation on investments in the calculation and accrue a capital gain incentive fee on a quarterly basis, as if such unrealized capital appreciation were realized, even though such unrealized capital appreciation is not permitted to be considered in calculating the fee actually payable under the Investment Management Agreement.

The performance based incentive fee expense was $2.8 million and $2.0 million for the three months ended September 30, 2022 and 2021, respectively. The performance based incentive fee expense was $6.4 million and $5.0 million for the nine months ended September 30, 2022 and 2021, respectively. The incentive fee on Pre-Incentive Fee Net Investment Income was not subject to the Incentive Fee Cap and Deferral Mechanism for the three and nine months ended September 30, 2022 and 2021. The performance based incentive fee payable as of September 30, 2022 and December 31, 2021 was $2.8 million and $2.0 million, respectively. The entire incentive fee payable as of September 30, 2022 and December 31, 2021 represented part one of the incentive fee.

Administration Agreement

The Company entered into an administration agreement (the “Administration Agreement”) with the Advisor to provide administrative services to the Company. For providing these services, facilities and personnel, the Company reimburses the Advisor for the Company’s allocable portion of overhead and other expenses incurred by the Advisor in performing its obligations under the Administration Agreement, including rent, the fees and expenses associated with performing compliance functions and the Company’s allocable portion of the costs of compensation and related expenses of the Company’s Chief Financial Officer and Chief Compliance Officer and their respective staffs. The administrative fee expense was $0.4 million and $0.3 million for the three months ended September 30, 2022 and 2021, respectively. The administrative fee expense was $1.1 million and $0.8 million for the nine months ended September 30, 2022 and 2021, respectively.

Note 4 - Investments

9 Months Ended

Sep. 30, 2022

Notes to Financial Statements

Investment Holdings [Text Block]

Note 4. Investments

The following table shows the Company’s investments as of September 30, 2022 and December 31, 2021:

	*September 30, 2022*				*December 31, 2021*
	*Cost*		*Fair Value*		*Cost*		*Fair Value*
	(In thousands)
Investments
Debt	$	612,478	$	609,032	$	441,885	$	437,317
Warrants		11,971		22,113		10,023		20,200
Other		1,200		1,300		1,450		200
Equity		3,567		2,179		479		358
Total investments	$	629,216	$	634,624	$	453,837	$	458,075

The following table shows the Company’s investments by industry sector as of September 30, 2022 and December 31, 2021:

	*September 30, 2022*				*December 31, 2021*
	*Cost*		*Fair Value*		*Cost*		*Fair Value*
	(In thousands)
Life Science
Biotechnology	$	148,952	$	147,442	$	109,899	$	107,902
Medical Device		114,364		116,967		88,681		84,567
Technology
Communications		22,883		26,070		22,853		25,920
Consumer-Related		109,906		108,301		92,158		93,194
Data Storage		476		1,211		476		1,047
Internet and Media		329		1,299		569		3,305
Networking		13,551		13,413		17,390		17,964
Power Management		1,585		2,254		1,585		2,609
Semiconductors		56		—		101		—
Software		108,910		107,441		60,902		60,807
Sustainability
Other Sustainability		77,024		77,700		46,595		47,011
Healthcare Information and Services
Diagnostics		9,840		9,844		12,393		12,377
Other		7,621		8,682		175		1,177
Software		13,719		14,000		60		195
Total investments	$	629,216	$	634,624	$	453,837	$	458,075

Note 5 - Transactions With Affiliated Companies

9 Months Ended

Sep. 30, 2022

Notes to Financial Statements

Investments in and Advances to Affiliates, Schedule of Investments [Text Block]

Note 5. Transactions with affiliated companies

A non-controlled affiliated company is generally a portfolio company in which the Company owns 5% or more of such portfolio company’s voting securities but not more than 25% of such portfolio company’s voting securities.

For the three and nine months ended September 30, 2022, there were no transactions related to investments in non-controlled affiliated companies.

Transactions related to investments in non-controlled affiliated companies for the year ended December 31, 2021 were as follows:

					Year ended December 31, 2021
	*Fair value at*							*Transfers*					*Net*						*Fair value at*
Portfolio	*December 31,*				*Principal*			*in/(out) at*			*Discount*		*unrealized*			*Net realized*			*December 31,*		*Interest*
Company	*2020*		*Purchases*		*Payments*			*fair value*			*accretion*		*gain/(loss)*			*gain/(loss)*			*2021*		*income*
	(In thousands)
Decisyon, Inc. (1)	$	1,181	$	—	$	—		$	(1,181	)	$	—	$	—		$	—		$	—	$	41
		626		—		—			(638	)		12		—			—			—		21
		227		—		—			(227	)		—		—			—			—		7
		228		—		—			(228	)		—		—			—			—		7
		685		—		—			(685	)		—		—			—			—		22
		276		—		—			(276	)		—		—			—			—		9
		183		—		—			(183	)		—		—			—			—		6
		120		—		—			(120	)		—		—			—			—		—
MVI (ABC) LLC fka StereoVision, Inc.		2,382		—		(2,783	)		—			—		—			401			—		139
		—		250		(250	)		—			—		—			—			—		—
		—		70		(70	)		—			—		—			—			—		—
		—		330		(330	)		—			—		—						—		—
		—		150		(150	)		—			—		—			—			—		—
		1,639		—		—			—			—		(848	)		(791	)		—		—
Total non-controlled affiliates	$	7,547	$	800	$	(3,583	)	$	(3,538	)	$	12	$	(848	)	$	(390	)	$	—	$	252

(1) As of December 31, 2021, the Company no longer owns 5% or more of the portfolio company.

A controlled affiliated company is generally a portfolio company in which the Company owns more than 25% of such portfolio company’s voting securities or has the power to exercise control over management or policies of such portfolio company (including through a management agreement). Transactions related to investments in controlled affiliated companies for the nine months ended September 30, 2022 were as follows:

					*Nine months ended September 30, 2022*

	*Fair value at*							*Transfers*				*Net*					*Fair value at*
Portfolio	*December 31,*							*in/(out) at*		*Dividends*		*unrealized*		*Net realized*			*September 30,*		*Dividend*
Company	*2021*		*Purchases*		*Sales*			*fair value*		*declared*		*gain/(loss)*		*gain/(loss)*			*2021*		*income*
	(In thousands)
HESP LLC		—		—		(300	)		—		—		1,450		(1,150	)		—		—
Total controlled affiliates	$	—	$	—	$	(300	)	$	—	$	—	$	1,450	$	(1,150	)	$	—	$	—

Transactions related to investments in controlled affiliated companies for the year ended December 31, 2021 were as follows:

					Year ended December 31, 2021

	*Fair value at*							*Transfers*				*Net*					*Fair value at*
Portfolio	*December 31,*							*in/(out) at*		*Dividends*		*unrealized*			*Net realized*		*December 31,*		*Dividend*
Company	*2020*		*Purchases*		*Sales*			*fair value*		*declared*		*gain/(loss)*			*gain/(loss)*		*2021*		*income*
	(In thousands)
HESP LLC		1,500		—		(50	)		—		—		(1,450	)		—		—		—
Total controlled affiliates	$	1,500	$	—	$	(50	)	$	—	$	—	$	(1,450	)	$	—	$	—	$	—

Note 6 - Fair Value

9 Months Ended

Sep. 30, 2022

Notes to Financial Statements

Fair Value Disclosures [Text Block]

Note 6. Fair value

Prior to July 30, 2022, the Board determined the fair value of the Company’s investments. Pursuant to the amended SEC Rule 2a-5 of the 1940 Act, on July 29, 2022, the Board designated the Advisor as the Company’s “valuation designee.” The Board is responsible for oversight of the valuation designee. The valuation designee has established a Valuation Committee to determine in good faith the fair value of the Company’s investments, based on input of the Advisor’s management and personnel and independent valuation firms which are engaged at the direction of the Valuation Committee to assist in the valuation of certain portfolio investments lacking a readily available market quotation at least once during a trailing twelve-month period. The Valuation Committee determines fair values pursuant to a valuation policy approved by the Board and pursuant to a consistently applied valuation process. This valuation process is conducted at the end of each fiscal quarter, with at least 25% (based on fair value) of the Company’s valuation of portfolio companies lacking readily available market quotations subject to review by an independent valuation firm.

The Company uses fair value measurements made by the valuation designee to record fair value adjustments to certain assets and liabilities and to determine fair value disclosures. Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. Fair value is best determined based upon quoted market prices. However, in certain instances, there are no quoted market prices for certain assets or liabilities. In cases where quoted market prices are not available, fair values are based on estimates using present value or other valuation techniques. Those techniques are significantly affected by the assumptions used, including the discount rate and estimates of future cash flows. Accordingly, the fair value estimates may not be realized in an immediate settlement of the asset or liability.

Fair value measurements focus on exit prices in an orderly transaction (that is, not a forced liquidation or distressed sale) between market participants at the measurement date under current market conditions. If there has been a significant decrease in the volume and level of activity for the asset or liability, a change in valuation technique or the use of multiple valuation techniques may be appropriate. In such instances, determining the price at which willing market participants would transact at the measurement date under current market conditions depends on the facts and circumstances and requires the use of significant judgment.

The Company’s fair value measurements are classified into a fair value hierarchy in accordance with ASC Topic 820, Fair Value Measurement, based on the markets in which the assets and liabilities are traded and the reliability of the assumptions used to determine fair value. The three categories within the hierarchy are as follows:

Level 1

Quoted prices in active markets for identical assets and liabilities.

Level 2

Observable inputs other than Level 1 prices such as quoted prices for similar assets or liabilities in active markets, quoted prices in markets that are not active, and model-based valuation techniques for which all significant inputs are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.

Level 3

Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. Level 3 assets and liabilities include financial instruments whose value is determined using pricing models, discounted cash flow methodologies or similar techniques, as well as instruments for which the determination of fair value requires significant management judgment or estimation.

Due to the inherent uncertainty of determining the fair value of investments that do not have a readily available market value, the fair value of the Company’s investments may fluctuate from period to period. Additionally, the fair value of the Company’s investments may differ significantly from the values that would have been used had a ready market existed for such investments and may differ materially from the values that the Company may ultimately realize. Further, such investments are generally subject to legal and other restrictions on resale or otherwise are less liquid than publicly traded securities. If the Company was required to liquidate a portfolio investment in a forced or liquidation sale, the Company could realize significantly less than the value at which the Company has recorded such portfolio investment.

Cash and interest receivable: The carrying amount is a reasonable estimate of fair value. These financial instruments are not recorded at fair value on a recurring basis and are categorized as Level 1 within the fair value hierarchy described above.

Money market funds: The carrying amounts are valued at their net asset value as of the close of business on the day of valuation. These financial instruments are recorded at fair value on a recurring basis and are categorized as Level 2 within the fair value hierarchy described above as these funds can be redeemed daily.

Debt investments: The fair value of debt investments is estimated by discounting the expected future cash flows using the period end rates at which similar debt investments would be made to borrowers with similar credit ratings and for the same remaining maturities. At September 30, 2022 and December 31, 2021, the hypothetical market yields used ranged from 3% to 25% and 3% to 23%, respectively. Significant increases (decreases) in this unobservable input would result in a significantly lower (higher) fair value measurement. These assets are recorded at fair value on a recurring basis and are categorized as Level 3 within the fair value hierarchy described above.

Under certain circumstances, the Company may use an alternative technique to value debt investments that better reflects their fair value such as the use of multiple probability weighted cash flow models when the expected future cash flows contain elements of variability.

Warrant investments: The Company values it's warrants using the Black-Scholes valuation model incorporating the following material assumptions:

●

Underlying asset value of the issuer is estimated based on information available, including any information regarding the most recent rounds of borrower funding. Significant increases (decreases) in this unobservable input would result in a significantly higher (lower) fair value measurement.

●

Volatility, or the amount of uncertainty or risk about the size of the changes in the warrant price, is based on indices of publicly traded companies similar in nature to the underlying company issuing the warrant. A total of seven such indices are used. Significant increases (decreases) in this unobservable input would result in a significantly higher (lower) fair value measurement.

●

The risk-free interest rates are derived from the U.S. Treasury yield curve. The risk-free interest rates are calculated based on a weighted average of the risk-free interest rates that correspond closest to the expected remaining life of the warrant.

●

Other adjustments, including a marketability discount on private company warrants, are estimated based on management’s judgment about the general industry environment.

●

Historical portfolio experience on cancellations and exercises of the Company’s warrants are utilized as the basis for determining the estimated time to exit of the warrants in each financial reporting period. Warrants may be exercised in the event of acquisitions, mergers or initial public offerings, and cancelled due to events such as bankruptcies, restructuring activities or additional financings. These events cause the expected remaining life assumption to be shorter than the contractual term of the warrants. Significant increases (decreases) in this unobservable input would result in significantly higher (lower) fair value measurement.

Under certain circumstances the Company may use an alternative technique to value warrants that better reflects the warrants’ fair value, such as an expected settlement of a warrant in the near term or a model that incorporates a put feature associated with the warrant. The fair value may be determined based on the expected proceeds to be received from such settlement or based on the net present value of the expected proceeds from the put option.

The fair value of the Company’s warrants held in publicly traded companies is determined based on inputs that are readily available in public markets or can be derived from information available in public markets. Therefore, the Company has categorized these warrants as Level 2 within the fair value hierarchy described above. The fair value of the Company’s warrants held in private companies is determined using both observable and unobservable inputs and represents management’s best estimate of what market participants would use in pricing the warrants at the measurement date. Therefore, the Company has categorized these warrants as Level 3 within the fair value hierarchy described above. These assets are recorded at fair value on a recurring basis.

Equity investments: The fair value of an equity investment in a privately held company is initially the face value of the amount invested. The Company adjusts the fair value of equity investments in private companies upon the completion of a new third-party round of equity financing. The Company may make adjustments to fair value, absent a new equity financing event, based upon positive or negative changes in a portfolio company’s financial or operational performance. Significant increases (decreases) in this unobservable input would result in a significantly higher (lower) fair value measurement. The Company has categorized these equity investments as Level 3 within the fair value hierarchy described above. The fair value of an equity investment in a publicly traded company is based upon the closing public share price on the date of measurement. Therefore, the Company has categorized these equity investments as Level 1 within the fair value hierarchy described above. These assets are recorded at fair value on a recurring basis.

Other investments: Other investments are valued based on the facts and circumstances of the underlying contractual agreement. The Company currently values these contractual agreements using a multiple probability weighted cash flow model as the contractual future cash flows contain elements of variability. Significant changes in the estimated cash flows and probability weightings would result in a significantly higher or lower fair value measurement. The Company has categorized these other investments as Level 3 within the fair value hierarchy described above. These other investments are recorded at fair value on a recurring basis.

The following tables provide a summary of quantitative information about the Company’s Level 3 fair value measurements of the Company's investments as of September 30, 2022 and December 31, 2021. In addition to the techniques and inputs noted in the table below, according to the Company’s valuation policy, the Company may also use other valuation techniques and methodologies when determining its fair value measurements.

The following table is not intended to be all-inclusive, but rather provides information on the significant Level 3 inputs as they relate to the Company’s fair value measurements as of September 30, 2022:

*September 30, 2022*
	*Fair*		*Valuation Techniques/*	*Unobservable*		*Weighted*
Investment Type	*Value*		*Methodologies*	*Input*	*Range*	*Average(1)*
			(Dollars in thousands, except per share data)
Debt investments	$	605,719	Discounted Expected Future Cash Flows	Hypothetical Market Yield	3% – 25%		14	%

		3,313	Multiple Probability Weighted Cash Flow Model	Probability Weighting	25%		25	%

Warrant investments		21,894	Black-Scholes Valuation Model	Price Per Share	0.000 –1,89999	$	64.53
				Average Industry Volatility	25%		25	%
				Marketability Discount	20%		20	%
				Estimated Time to Exit (in years)	1 to 4		2

Other investments		1,300	Multiple Probability Weighted Cash Flow Model	Discount Rate	25%		25	%
				Probability Weighting	100%		100	%

Equity investments		2,033	Last Equity Financing	Price Per Share	1.000 –215.0303	$	30.09

Total Level 3 investments	$	634,259

(1)	Weighted average is calculated by multiplying (a) the unobservable input for each investment in the investment type by (b) (1) the fair value of the related investment in the investment type divided by (2) the total fair value of the investment type.

December 31, 2021
	Fair		Valuation Techniques/	Unobservable		Weighted
Investment Type	Value		Methodologies	Input	Range	Average⁽¹⁾
			(Dollars in thousands, except per share data)
Debt investments	$	430,417	Discounted Expected Future Cash Flows	Hypothetical Market Yield	3% –23%		12	%

		6,900	Multiple Probability Weighted Cash Flow Model	Probability Weighting	20% - 50%		33	%

Warrant investments		19,837	Black-Scholes Valuation Model	Price Per Share	0.000 –980.0000	$	20.35
				Average Industry Volatility	25%		25	%
				Marketability Discount	20%		20	%
				Estimated Time to Exit (in years)	1 to 4		2

Other investments		200	Multiple Probability Weighted Cash Flow Model	Discount Rate	25%		25	%
				Probability Weighting	0% –100%		100	%

Equity investments		203	Last Equity Financing	Price Per Share	0.000 –1.0000	$	0.41

Total Level 3 investments	$	457,557

(1)	Weighted average is calculated by multiplying (a) the unobservable input for each investment in the investment type by (b) (1) the fair value of the related investment in the investment type divided by (2) the total fair value of the investment type.

Borrowings: The Key Facility and the NYL Facility approximate fair value due to the variable interest rate of the facilities and are categorized as Level 2 within the fair value hierarchy described above. Additionally, the Company considers its creditworthiness in determining the fair value of such borrowings. The fair value of the fixed-rate 2026 Notes (as defined in Note 7) is based on the closing public share price on the date of measurement. On September 30, 2022, the closing price of the 2026 Notes on the New York Stock Exchange was $24.37 per note and had an aggregate fair value of $56.1 million. Therefore, the Company has categorized these borrowing as Level 1 within the fair value hierarchy described above. The fair value of the fixed-rate 2027 Notes (as defined in Note 7) is based on the closing public share price on the date of measurement. On September 30, 2022, the closing price of the 2027 Notes on the New York Stock Exchange was $23.18 per note and had an aggregate fair value of $53.3 million. Therefore, the Company has categorized these borrowing as Level 1 within the fair value hierarchy described above. Based on market quotations on September 30, 2022, the Asset-Backed Notes were trading at par value and had an aggregate par value of $43.5 million, and are categorized as Level 3 within the fair value hierarchy described above. These borrowings are not recorded at fair value on a recurring basis.

Off-balance-sheet instruments: Fair values for off-balance-sheet lending commitments are based on fees currently charged to enter into similar agreements, taking into account the remaining terms of the agreements and the counterparties’ credit standings. Therefore, the Company has categorized these instruments as Level 3 within the fair value hierarchy described above.

The following tables detail the assets that are carried at fair value and measured at fair value on a recurring basis as of September 30, 2022 and December 31, 2021 and indicate the fair value hierarchy of the valuation techniques utilized by the Company to determine the fair value:

	*September 30, 2022*
	*Level 1*		*Level 2*		*Level 3*		*Total*
	(In thousands)
Investments in money market funds	$	—	$	7,732	$	—	$	7,732
Restricted investments in money market funds	$	—	$	1,617	$	—	$	1,617
Debt investments	$	—	$	—	$	609,032	$	609,032
Warrant investments		—		219		21,894		22,113
Other investments		—		—		1,300		1,300
Equity investments		146		—		2,033		2,179
Total investments	$	146	$	219	$	634,259	$	634,624

	December 31, 2021
	Level 1		Level 2		Level 3		Total
	(In thousands)
Investments in money market funds	$	—	$	7,868	$	—	$	7,868
Restricted investments in money market funds	$	—	$	1,359	$	—	$	1,359
Debt investments	$	—	$	—	$	437,317	$	437,317
Warrant investments		—		363		19,837		20,200
Other investments		—		—		200		200
Equity investments		155		—		203		358
Total investments	$	155	$	363	$	457,557	$	458,075

The following table shows a reconciliation of the beginning and ending balances for Level 3 assets measured at fair value on a recurring basis for the three months ended September 30, 2022:

	*Three months ended September 30, 2022*
	*Debt*			*Warrant*			*Equity*			*Other*
	*Investments*			*Investments*			*Investments*			*Investments*			*Total*
	(In thousands)
Level 3 assets, beginning of period	$	551,560		$	25,167		$	453		$	200		$	577,380
Purchase of investments		94,627			—			—			—			94,627
Warrants and equity received and classified as Level 3		—			964			—			—			964
Principal payments received on investments		(26,929	)		—			—			(31	)		(26,960	)
Proceeds from sale of investments		(6,088	)		(38	)		—			—			(6,126	)
Net realized (loss) gain on investments		(8,492	)		266			—			31			(8,195	)
Unrealized appreciation (depreciation) included in earnings		8,095			(3,348	)		(420	)		(100	)		4,227
Transfer out of Level 3		—			(1,117	)		—						(1,117	)
Transfer out of debt investments		(3,200	)		—			2,000			1,200			—
Other		(541	)		—			—			—			(541	)
Level 3 assets, end of period	$	609,032		$	21,894		$	2,033		$	1,300		$	634,259

During the three months ended September 30, 2022, there were two transfers out of Level 3. One transfer out of Level 3 related to warrants held in one portfolio company with an aggregate fair value of $0.04 million that was transferred to Level 2 upon the portfolio company becoming a public company. One transfer out of Level 3 related to warrants held in one portfolio company with an aggregate fair value of $1.1 million that was transferred to Level 1 upon the portfolio company becoming a public company.

The following table shows a reconciliation of the beginning and ending balances for Level 3 assets measured at fair value on a recurring basis for the three months ended September 30, 2021:

	*Three months ended September 30, 2021*
	*Debt*			*Warrant*			*Equity*		*Other*
	*Investments*			*Investments*			*Investments*		*Investments*			*Total*
	(In thousands)
Level 3 assets, beginning of period	$	385,814		$	15,102		$	237	$	1,700		$	402,853
Purchase of investments		98,592			—			—		—			98,592
Warrants and equity received and classified as Level 3		—			1,394			—		—			1,394
Principal payments received on investments		(53,588	)		—			—		—			(53,588	)
Proceeds from sale of investments		(34	)		(1,519	)		—		—			(1,553	)
Net realized (loss) gain on investments		(40	)		1,384			—		—			1,344
Unrealized appreciation (depreciation) included in earnings		798			3,353			149		(375	)		3,925
Other		(1,606	)		—			—		—			(1,606	)
Level 3 assets, end of period	$	429,936		$	19,714		$	386	$	1,325		$	451,361

During the three months ended September 30, 2021, there were no transfers in or out of Level 3.

The following table shows a reconciliation of the beginning and ending balances for Level 3 assets measured at fair value on a recurring basis for the nine months ended September 30, 2022:

	*Nine months ended September 30, 2022*
	*Debt*			*Warrant*			*Equity*			*Other*
	*Investments*			*Investments*			*Investments*			*Investments*			*Total*
	(In thousands)
Level 3 assets, beginning of period	$	437,317		$	19,837		$	203		$	200		$	457,557
Purchase of investments		348,097			—			250			—			348,347
Warrants and equity received and classified as Level 3		—			2,441			—			—			2,441
Principal payments received on investments		(114,120	)		—			—			(313	)		(114,433	)
Proceeds from sale of investments		(49,088	)		(464	)		—			—			(49,552	)
Net realized (loss) gain on investments		(8,492	)		535			—			(1,137	)		(9,094	)
Unrealized appreciation (depreciation) included in earnings		1,128			662			(420	)		1,350			2,720
Transfer out of Level 3		—			(1,117	)		—						(1,117	)
Transfer out of debt investments		(3,200	)		—			2,000			1,200			—
Other		(2,610	)		—			—			—			(2,610	)
Level 3 assets, end of period	$	609,032		$	21,894		$	2,033		$	1,300		$	634,259

During the nine months ended September 30, 2022, there were two transfers out of Level 3. One transfer out of Level 3 related to warrants held in one portfolio company with an aggregate fair value of $0.04 million that was transferred to Level 2 upon the portfolio company becoming a public company. One transfer out of Level 3 related to warrants held in one portfolio company with an aggregate fair value of $1.1 million that was transferred to Level 1 upon the portfolio company becoming a public company.

The change in unrealized appreciation included in the consolidated statement of operations attributable to Level 3 investments still held at September 30, 2022 includes $3.5 million in unrealized depreciation on debt and other investments, $1.2 million in unrealized appreciation on warrant investments and $0.4 million in unrealized depreciation on equity investments.

The following table shows a reconciliation of the beginning and ending balances for Level 3 assets measured at fair value on a recurring basis for the nine months ended September 30, 2021:

	*Nine months ended September 30, 2021*
	*Debt*			*Warrant*			*Equity*			*Other*
	*Investments*			*Investments*			*Investments*			*Investments*			*Total*
	(In thousands)
Level 3 assets, beginning of period	$	333,495		$	12,736		$	2,117		$	1,700		$	350,048
Purchase of investments		217,252			—			—			—			217,252
Warrants and equity received and classified as Level 3		—			2,313			—			—			2,313
Principal payments received on investments		(119,260	)		—			—			—			(119,260	)
Proceeds from sale of investments		(135	)		(3,159	)		—			(13	)		(3,307	)
Net realized (loss) gain on investments		(5,035	)		2,566			—			—			(2,469	)
Unrealized appreciation (depreciation) included in earnings		5,609			5,329			(1,682	)		(362	)		8,894
Transfer out of Level 3		—			(71	)		(49	)		—			(120	)
Other		(1,990	)		—			—			—			(1,990	)
Level 3 assets, end of period	$	429,936		$	19,714		$	386		$	1,325		$	451,361

During the nine months ended September 30, 2021, there were two transfers out of Level 3. One transfer out of Level 3 related to warrants held in one portfolio company with an aggregate fair value of $0.1 million that was transferred to Level 2 upon the portfolio company becoming a public company. One transfer out of Level 3 related to equity held in one portfolio company with an aggregate fair value of $0.1 million that was transferred to Level 1 upon the portfolio company becoming a public company.

The change in unrealized appreciation included in the consolidated statement of operations attributable to Level 3 investments still held at September 30, 2021 includes $0.3 million in unrealized depreciation on debt and other investments, $6.3 million in unrealized appreciation on warrant investments and $1.5 million in unrealized depreciation on equity investments.

The Company discloses fair value information about financial instruments, whether or not recognized in the consolidated statement of assets and liabilities, for which it is practicable to estimate that value. Certain financial instruments are excluded from the disclosure requirements. Accordingly, the aggregate fair value amounts presented do not represent the underlying value of the Company.

The fair value amounts have been measured as of the reporting date and have not been reevaluated or updated for purposes of these financial statements subsequent to that date. As such, the fair values of these financial instruments subsequent to the reporting date may be different than amounts reported.

As of September 30, 2022 and December 31, 2021, all of the balances of all the Company’s financial instruments were recorded at fair value, except for the Company’s borrowings, as previously described.

Market risk

The Company assumes interest rate risk (the risk that general interest rate levels will change) as a result of its normal operations. As a result, the fair values of the Company’s financial instruments will change when interest rate levels change, and that change may be either favorable or unfavorable to the Company. Management attempts to match maturities of assets and liabilities to the extent believed necessary to minimize interest rate risk. Management monitors rates and maturities of assets and liabilities and attempts to minimize interest rate risk by adjusting terms of new debt investments and by investing in securities with terms that mitigate the Company’s overall interest rate risk.

- Definition

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References + Details

Note 7 - Borrowings

9 Months Ended

Sep. 30, 2022

Notes to Financial Statements

Debt Disclosure [Text Block]

Note 7. Borrowings

The following table shows the Company’s borrowings as of September 30, 2022 and December 31, 2021:

	*September 30, 2022*							*December 31, 2021*
	*Total*		*Balance*			*Unused*		*Total*		*Balance*			*Unused*
	*Commitment*		*Outstanding*			*Commitment*		*Commitment*		*Outstanding*			*Commitment*
	(In thousands)
Key Facility	$	125,000	$	67,500		$	57,500	$	125,000	$	53,500		$	71,500
NYL Facility		200,000		136,750			63,250		100,000		78,750			21,250
Asset-Backed Notes		43,461		43,461			—		70,500		70,500			—
2027 Notes		57,500		57,500			—		—		—			—
2026 Notes		57,500		57,500			—		57,500		57,500			—
Total before debt issuance costs		483,461		362,711			120,750		353,000		260,250			92,750
Unamortized debt issuance costs attributable to term borrowings		—		(3,700	)		—		—		(2,637	)		—
Total borrowings outstanding, net	$	483,461	$	359,011		$	120,750	$	353,000	$	257,613		$	92,750

As of September 30, 2022, with certain limited exceptions, the Company, as a BDC, is only allowed to borrow amounts such that the Company’s asset coverage, as defined in the 1940 Act, is at least 150% after such borrowings. As of September 30, 2022, the asset coverage for borrowed amounts was 185%.

The Company entered into the Key Facility with Key effective November 4, 2013. On June 22, 2021, the Company amended the Key Facility, among other things, to amend the interest rate applied to the outstanding principal balance and to extend the period during which we may request advances under the Key Facility to June 22, 2024. The Key Facility has an accordion feature which allows for an increase in the total loan commitment to $150 million from the $125 million commitment. The Key Facility is collateralized by all debt investments and warrants held by Credit II and permits an advance rate of up to 60% of eligible debt investments held by Credit II. The Key Facility contains covenants that, among other things, require the Company to maintain a minimum net worth and to restrict the debt investments securing the Key Facility to certain criteria for qualified debt investments and includes portfolio company concentration limits as defined in the related loan agreement. The Key Facility is scheduled to mature on June 22, 2026. Through June 21, 2021, the interest rate on the Key Facility was based upon the one-month LIBOR plus a spread of 3.25%, with a LIBOR floor of 1.00%. From and after June 30, 2021, the interest rate on the Key Facility is based on the rate of interest published in The Wall Street Journal as the prime rate in the United States plus 0.25%, with a prime rate floor of 4.25%. The prime rate was 6.25% and 3.25% on September 30, 2022 and December 31, 2021, respectively. The average interest rate for the three months ended September 30, 2022 and 2021 was 5.60% and 4.25%, respectively. The average interest rate for the nine months ended September 30, 2022 and 2021 was 4.75% and 4.25%, respectively. The Key Facility requires the payment of an unused line fee in an amount up to 0.50% on an annualized basis of any unborrowed amount available under the facility. As of September 30, 2022 and December 31, 2021, the Company had borrowing capacity under the Key Facility of $57.5 million and $71.5 million, respectively. At September 30, 2022 and December 31, 2021, $28.0 million and $19.8 million, respectively, was available for borrowing, subject to existing terms and advance rates.

On September 29, 2017, the Company issued and sold an aggregate principal amount of $32.5 million of 6.25% notes due in 2022 and on October 11, 2017, pursuant to the underwriters’ 30 day option to purchase additional notes, the Company sold an additional $4.9 million of such notes (collectively, the “2022 Notes”). The 2022 Notes had a stated maturity of September 15, 2022 and were redeemable in whole or in part at the Company’s option at any time or from time to time on or after September 15, 2019 at a redemption price of $25 per security plus accrued and unpaid interest. The 2022 Notes bore interest at a rate of 6.25% per year, payable quarterly on March 15, June 15, September 15 and December 15 of each year. The 2022 Notes were the Company’s direct unsecured obligations and (i) ranked equally in right of payment with the Company’s current and future unsecured indebtedness; (ii) were senior in right of payment to any of the Company’s future indebtedness that expressly provides it is subordinated to the 2022 Notes; (iii) were effectively subordinated to all of the Company’s existing and future secured indebtedness (including indebtedness that is initially unsecured to which the Company subsequently grants security), to the extent of the value of the assets securing such indebtedness, and (iv) were structurally subordinated to all existing and future indebtedness and other obligations of any of the Company’s subsidiaries. On April 24, 2021 (the “Redemption Date”), the Company redeemed all of the issued and outstanding 2022 Notes in an aggregate principal amount of $37.4 million and paid accrued interest of $0.3 million. The Company accelerated $0.4 million of unamortized debt issuance costs related to the 2022 Notes. The 2022 Notes were delisted effective on the Redemption Date.

On March 30, 2021, the Company issued and sold an aggregate principal amount of $57.5 million of 4.875% notes due in 2026 (the “2026 Notes”). The amount of 2026 Notes issued and sold included the full exercise by the underwriters of their option to purchase $7.5 million aggregate principal of additional notes. The 2026 Notes have a stated maturity of March 30, 2026 and may be redeemed in whole or in part at the Company’s option at any time or from time to time on or after March 30, 2023 at a redemption price of $25 per security plus accrued and unpaid interest. The 2026 Notes bear interest at a rate of 4.875% per year, payable quarterly on March 30, June 30, September 30 and December 30 of each year. The 2026 Notes are the Company’s direct unsecured obligations and (i) rank equally in right of payment with the Company’s current and future unsecured indebtedness; (ii) are senior in right of payment to any of the Company’s future indebtedness that expressly provides it is subordinated to the 2026 Notes; (iii) are effectively subordinated to all of the Company’s existing and future secured indebtedness (including indebtedness that is initially unsecured to which the Company subsequently grants security), to the extent of the value of the assets securing such indebtedness, and (iv) are structurally subordinated to all existing and future indebtedness and other obligations of any of the Company’s subsidiaries. As of September 30, 2022, the Company was in material compliance with the terms of the 2026 Notes. The 2026 Notes are listed on the New York Stock Exchange under the symbol “HTFB”.

On June 15, 2022, the Company issued and sold an aggregate principal amount of $50.0 million of 6.25% notes due in 2027 and on July 11, 2022, pursuant to the underwriters’ 30 day option to purchase additional notes, the Company sold an additional $7.5 million of such notes (collectively, the “2027 Notes”). The 2027 Notes have a stated maturity of June 15, 2027 and may be redeemed in whole or in part at the Company’s option at any time or from time to time on or after June 15, 2024 at a redemption price of $25 per security plus accrued and unpaid interest. The 2027 Notes bear interest at a rate of 6.25% per year, payable quarterly on March 30, June 30, September 30 and December 30 of each year, commencing on September 30, 2022. The 2027 Notes are the Company’s direct unsecured obligations and (i) rank equally in right of payment with the Company’s current and future unsecured indebtedness; (ii) are senior in right of payment to any of the Company’s future indebtedness that expressly provides it is subordinated to the 2027 Notes; (iii) are effectively subordinated to all of the Company’s existing and future secured indebtedness (including indebtedness that is initially unsecured to which the Company subsequently grants security), to the extent of the value of the assets securing such indebtedness, and (iv) are structurally subordinated to all existing and future indebtedness and other obligations of any of the Company’s subsidiaries. As of September 30, 2022, the Company was in material compliance with the terms of the 2027 Notes. The 2027 Notes are listed on the New York Stock Exchange under the symbol “HTFC”.

On August 13, 2019, the Company completed a term debt securitization in connection with which an affiliate of the Company made an offering of the Asset-Backed Notes. The Asset-Backed Notes were rated A+(sf) by Morningstar Credit Ratings, LLC on August 13, 2019. There has been no change in the rating since August 13, 2019.

The Asset-Backed Notes were issued by the 2019‑1 Trust pursuant to a note purchase agreement, dated as of August 13, 2019, by and among the Company and Keybanc Capital Markets Inc. as Initial Purchaser, and are backed by a pool of loans made to certain portfolio companies of the Company and secured by certain assets of those portfolio companies and are to be serviced by the Company. Interest on the Asset-Backed Notes will be paid, to the extent of funds available, at a fixed rate of 4.21% per annum. The reinvestment period of the Asset-Backed Notes ended July 15, 2021 and the maturity date is September 15, 2027.

At September 30, 2022 and December 31, 2021, the Asset-Backed Notes had an outstanding principal balance of $43.5 million and $70.5 million, respectively.

Under the terms of the Asset-Backed Notes, the Company is required to maintain a reserve cash balance, funded through proceeds from the sale of the Asset-Backed Notes, which may be used to pay monthly interest and principal payments on the Asset-Backed Notes. The Company has segregated these funds and classified them as restricted investments in money market funds. At September 30, 2022 and December 31, 2021, there were approximately $0.6 million and $0.9 million of restricted investments, respectively.

On April 21, 2020, the Company purchased all of the limited liability company interests of Arena in HSLFI, which is a party to the NYL Facility. HFI entered into the NYL Facility with the NYL Noteholders for an aggregate purchase price of up to $100.0 million, with an accordion feature of up to $200.0 million at the mutual discretion and agreement of HSLFI and the NYL Noteholders. On June 1, 2018, HSLFI sold or contributed to HFI certain secured loans made to certain portfolio companies pursuant to the Sale and Servicing Agreement. Any notes issued by HFI are collateralized by all investments held by HFI and permit an advance rate of up to 67% of the aggregate principal amount of eligible debt investments. The notes were issued pursuant to the Indenture. The interest rate on the notes issued under the NYL Facility is based on the three year USD mid-market swap rate plus a margin of between 3.55% and 5.15% with an interest rate floor, depending on the rating of such notes at the time of issuance.

On February 25, 2022, the Company amended its NYL Facility, increasing the commitment by $100.0 million to enable its wholly-owned subsidiary to issue up to $200.0 million of secured notes. The amendment to the NYL Facility extends the investment period to June 2023 and the maturity date to June 2028. In addition, the amendment, among other things, reduces the applicable margin used to calculate the credit facility’s interest rate on the Company’s borrowings above $100.0 million. Such borrowings will be priced at the three-year USD mid-market swap rate plus 3.00%.

There were $136.8 million and $78.8 million in advances made by the NYL Noteholders as of September 30, 2022 and December 31, 2021, respectively. The interest rate as of September 30, 2022 and December 31, 2021 was 5.11%. and 4.62%, respectively. As of September 30, 2022 and December 31, 2021, the Company had borrowing capacity under the NYL Facility of $63.2 million and $21.2 million, respectively. At September 30, 2022 and December 31, 2021, $49.2 million and $5.7 million, respectively, was available for borrowing, subject to existing terms and advance rates.

- Definition

The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-URI https://asc.fasb.org/topic&trid=2208564

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1B
-Subparagraph (h)
-URI https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1C
-Subparagraph (c)
-URI https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1I
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1I
-Subparagraph (d)
-URI https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(c))
-URI https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1B
-Subparagraph (g)
-URI https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1C
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1C
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1E
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1B
-URI https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1I
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 20
-Section 50
-Paragraph 1B
-Subparagraph (i)
-URI https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611

+ Details

Note 8 - Financial Instruments With Off-balance-sheet Risk

9 Months Ended

Sep. 30, 2022

Notes to Financial Statements

Financial Instruments Disclosure [Text Block]

Note 8. Financial instruments with off-balance-sheet risk

In the normal course of business, the Company is party to financial instruments with off-balance-sheet risk to meet the financing needs of its borrowers. These financial instruments include commitments to extend credit and involve, to varying degrees, elements of credit risk in excess of the amount recognized in the consolidated statement of assets and liabilities. The Company attempts to limit its credit risk by conducting extensive due diligence and obtaining collateral where appropriate.

The balance of unfunded commitments to extend credit was $214.5 million and $114.5 million as of September 30, 2022 and December 31, 2021, respectively. Commitments to extend credit consist principally of the unused portions of commitments that obligate the Company to extend credit, often subject to financial or non-financial milestones and other conditions to borrow that must be achieved before the commitment can be drawn. In addition, the commitments generally have fixed expiration dates or other termination clauses. Since commitments may expire without being drawn upon, the total commitment amounts do not necessarily represent future cash requirements.

The following table provides the Company’s unfunded commitments by portfolio company as of September 30, 2022:

	September 30, 2022
			Fair Value of
			Unfunded
	*Principal*		*Commitment*
	*Balance*		*Liability*
	(In thousands)
Better Place Forests Co.	$	5,000	$	6
BrightInsight, Inc.		21,000		278
Britecore Holdings, Inc.		5,000		66
Canary Medical Inc.		2,500		34
Castle Creek Biosciences		4,000		72
Ceribell, Inc.		2,500		4
Divergent Technologies, Inc.		30,000		315
DropOff, Inc.		7,500		188
Embody, Inc.		2,000		20
Engage3, LLC		8,000		40
Hound Labs, Inc.		7,500		87
Interior Define, Inc.		5,000		65
KSQ Therapeutics, Inc.		10,000		100
Lytics, Inc.		1,250		—
Magnolia Medical Technologies, Inc.		10,000		122
Native Microbials, Inc.		8,750		64
Optoro, Inc.		15,000		38
PDS Biotechnology Corporation		10,000		158
Scientia Vascular, Inc.		10,000		110
Slingshot Aerospace, Inc.		5,000		64
Soli, Inc.		7,500		147
Sonex Health, Inc.		2,500		45
Swift Health Systems Inc.		25,500		105
Temperpack Technologies, Inc.		9,000		19
Total	$	214,500	$	2,147

The table above also provides the fair value of the Company’s unfunded commitment liability as of September 30, 2022, which totaled $2.1 million. The fair value at inception of the delay draw credit agreements is equal to the fees and/or warrants received to enter into these agreements, taking into account the remaining terms of the agreements and the counterparties’ credit profile. The unfunded commitment liability reflects the fair value of these future funding commitments and is included in the Company’s consolidated statement of assets and liabilities.

Note 9 - Concentrations of Credit Risk

9 Months Ended

Sep. 30, 2022

Notes to Financial Statements

Concentration Risk Disclosure [Text Block]

Note 9. Concentrations of credit risk

The Company’s debt investments consist primarily of loans to development-stage companies at various stages of development in the technology, life science, healthcare information and services and sustainability industries. Many of these companies may have relatively limited operating histories and also may experience variation in operating results. Many of these companies conduct business in regulated industries and could be affected by changes in government regulations. Most of the Company’s borrowers will need additional capital to satisfy their continuing working capital needs and other requirements, and in many instances, to service the interest and principal payments on the loans.

The Company’s largest debt investments may vary from period to period as new debt investments are recorded and existing debt investments are repaid. The Company’s five largest debt investments, at cost, represented 22% and 26% of total debt investments outstanding as of September 30, 2022 and December 31, 2021, respectively. No single debt investment represented more than 10% of the total debt investments as of September 30, 2022 and December 31, 2021. Investment income, consisting of interest and fees, can fluctuate significantly upon repayment of large debt investments. Interest income from the five largest debt investments accounted for 18% and 21% of total interest and fee income on investments for the three months ended September 30, 2022 and 2021, respectively. Interest income from the five largest debt investments accounted for 18% and 13% of total interest and fee income on investments for the nine months ended September 30, 2022 and 2021, respectively.

Note 10 - Distributions

9 Months Ended

Sep. 30, 2022

Notes to Financial Statements

Stockholders' Equity Note Disclosure [Text Block]

Note 10. Distributions

The Company’s distributions are recorded on the declaration date. The following table summarizes the Company’s distribution activity for the nine months ended September 30, 2022 and for the year ended December 31, 2021:

							*DRIP*		*DRIP*
Date			*Amount*		*Cash*		*Shares*		*Share*
Declared	*Record Date*	*Payment Date*	*Per Share*		*Distribution*		*Issued*		*Value*
			(In thousands, except share and per share data)
Nine Months Ended September 30, 2022
7/29/2022	11/17/22	12/15/22	$	0.10	$	—		—	$	—
7/29/2022	10/18/22	11/15/22		0.10		—		—		—
7/29/2022	9/19/22	10/14/22		0.10		2,558		7,703		81
4/29/2022	8/18/22	9/15/22		0.10		2,528		4,925		60
4/29/2022	7/19/22	8/16/22		0.10		2,484		3,939		55
4/29/2022	6/17/22	7/15/22		0.10		2,434		4,286		51
2/25/2022	5/18/22	6/15/22		0.10		2,378		4,428		50
2/25/2022	4/19/22	5/16/22		0.10		2,349		4,088		49
2/25/2022	3/18/22	4/14/22		0.10		2,352		3,221		46
			$	0.90	$	17,083		32,590	$	392
Year Ended December 31, 2021
10/22/21	2/18/22	3/16/22	$	0.10	$	2,100		3,409	$	46
10/22/21	1/19/22	2/16/22		0.10		2,096		2,680		43
10/22/21	12/17/21	1/14/22		0.10		2,031		3,417		56
10/22/21	11/18/21	12/15/21		0.05		1,013		1,197		20
7/23/21	11/18/21	12/15/21		0.10		2,027		2,395		38
7/23/21	10/19/21	11/16/21		0.10		2,010		1,907		34
7/23/21	9/17/21	10/15/21		0.10		2,008		2,068		36
4/23/21	8/18/21	9/15/21		0.10		1,996		2,041		34
4/23/21	7/20/21	8/16/21		0.10		1,983		1,937		34
4/23/21	6/17/21	7/16/21		0.10		1,964		1,888		33
2/26/21	5/18/21	6/15/21		0.10		1,964		1,671		29
2/26/21	4/20/21	5/14/21		0.10		1,937		1,794		29
2/26/21	3/18/21	4/16/21		0.10		1,938		1,653		28
			$	1.25	$	25,067		28,057	$	460

On October 28, 2022, the Board declared monthly distributions per share and a special dividend per share, payable as set forth in the following table:

Monthly distributions

Ex-Dividend Date	*Record Date*	*Payment Date*	*Distributions Declared*
December 16, 2022	December 19, 2022	January 13, 2023	$	0.11
January 17, 2023	January 18, 2023	February 15, 2023	$	0.11
February 16, 2023	February 17, 2023	March 15, 2023	$	0.11

Special distribution

Ex-Dividend Date	Record Date	Payment Date		Distributions Declared
November 16, 2022	November 17, 2022	December 15, 2022		$	0.05

After paying distributions of $0.30 per share and earning net investment income of $0.43 per share for the quarter, the Company’s undistributed spillover income as of September 30, 2022 was $0.67 per share. Spillover income includes any ordinary income and net capital gains from the preceding tax years that were not distributed during such tax years.

- Definition

The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-URI https://asc.fasb.org/topic&trid=2208762

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 13
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 13
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 14
-Subparagraph (c)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 14
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 18
-Subparagraph (d)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 13
-Subparagraph (g)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 18
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 13
-Subparagraph (h)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 14
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 18
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 16
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496180-112644

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 13
-Subparagraph (i)
-URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(e)(1))
-URI https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 40
-Section 50
-Paragraph 6
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126731327&loc=SL126733271-114008

+ Details

Note 11 - Financial Highlights

9 Months Ended

Sep. 30, 2022

Notes to Financial Statements

Investment Company, Financial Highlights [Text Block]

Note 11. Financial highlights

The following table shows financial highlights for the Company:

	Nine months ended September 30,
	2022			2021
	(In thousands, except share and per share data)
Per share data:
Net asset value at beginning of period	$	11.56		$	11.02
Net investment income		1.06			1.02
Realized loss		(0.40	)		(0.14	)
Unrealized appreciation on investments		0.05			0.41
Net increase in net assets resulting from operations		0.71			1.29
Distributions declared ⁽¹⁾		(0.90	)		(0.90	)
From net investment income		(0.90	)		(0.90	)
From net realized gain on investments		—			—
Return of capital		—			—
Other ⁽²⁾		0.29			0.22
Net asset value at end of period	$	11.66		$	11.63
Per share market value, beginning of period	$	15.92		$	13.24
Per share market value, end of period	$	10.01		$	16.26
Total return based on a market value ⁽³⁾		(31.5	)%		29.6	%
Shares outstanding at end of period		26,393,773			20,425,175
Ratios to average net assets:
Expenses without incentive value ⁽⁴⁾		11.4	%		10.6	%
Incentive fees ⁽⁴⁾		3.0	%		3.0	%
Net expenses ⁽⁴⁾		14.4	%		13.6	%
Net investment income with incentive fees ⁽⁴⁾		12.1	%		12.1	%
Net assets at the end of the period	$	307,687		$	237,590
Average net asset value	$	280,904		$	223,031
Average debt per share	$	13.32		$	11.07
Portfolio turnover ratio ⁽⁵⁾		14.9	%		29.0	%

(1)

Distributions are determined based on taxable income calculated in accordance with income tax regulations, which may differ from amounts determined under GAAP due to (i) changes in unrealized appreciation and depreciation, (ii) temporary and permanent differences in income and expense recognition, and (iii) the amount of spillover income carried over from a given tax year for distribution in the following tax year. The final determination of taxable income for each tax year, as well as the tax attributes for distributions in such tax year, will be made after the close of the tax year.

(2)

Includes the impact of the different share amounts as a result of calculating per share data based on the weighted average basic shares outstanding during the period and certain per share data based on the shares outstanding as of a period end or transaction date. The issuance of common stock on a per share basis reflects the incremental net asset value changes as a result of the issuance of common stock in the Company’s continuous public offering and pursuant to the Company’s distribution reinvestment plan. The issuance of common stock at an offering price, net of sales commissions and dealer manager fees, that is greater than the net asset value per share results in an increase in net asset value per share.

(3)	The total return equals the change in the ending market value over the beginning of period price per share plus distributions paid per share during the period, divided by the beginning price.

(4)	Annualized.

(5)	Calculated by dividing the lesser of purchases or the sum of (1) principal prepayments and (2) maturities by the monthly average debt investment balance.

Note 12 - Subsequent Events

9 Months Ended

Sep. 30, 2022

Notes to Financial Statements

Subsequent Events [Text Block]

Note 12. Subsequent Events

On October 21, 2022, the Company funded a $0.4 million equity investment to an existing portfolio company, Emalex Biosciences, Inc.

On October 21, 2022, the Company funded a $7.0 million debt investment to a new portfolio company, Robin Healthcare, Inc.

On October 26, 2022, the Company priced a securitization of secured debt investments through Horizon Funding Trust 2022-1, an indirect, bankruptcy-remote subsidiary of the Company. The Horizon Funding Trust 2022-1 securitization is a private securitization under Rule 144A and to persons outside the United States pursuant to Regulation S under the Securities Act in which the Company expects to sell a pool of loans with an aggregate principal balance of approximately $160 million to a securitization trust and receive proceeds from the issuance and sale of $100.0 million aggregate principal amount of rated notes with a coupon of 7.56% ("7.56% Notes"). Following pricing, total proceeds, including cash and securities, are expected to be $98.8 million before fees and expenses. The transaction is scheduled to close on November 9, 2022, subject to customary closing conditions.

This disclosure does not constitute an offer to sell or a solicitation of an offer to buy any of the 7.56% Notes, nor shall there be any offer, solicitation or sale in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful.

On October 28, 2022, the Company funded a $2.5 million debt investment to an existing portfolio company, Sonex Health, Inc.

Significant Accounting Policies (Policies)	9 Months Ended
Significant Accounting Policies (Policies)	Sep. 30, 2022
Accounting Policies [Abstract]
Consolidation, Policy [Policy Text Block]	*Principles of consolidation* As required under GAAP and Regulation S-X, the Company will generally consolidate its investment in a company that is an investment company subsidiary or a controlled operating company whose business consists of providing services to the Company. Accordingly, the Company consolidated the results of the Company’s wholly-owned subsidiaries in its consolidated financial statements. Assets related to transactions that do not meet Accounting Standards Codification (“ASC”) Topic 860, Transfers and Servicing requirements for accounting sale treatment are reflected in the Company’s Consolidated Statements of Assets and Liabilities as investments. Those assets are owned by special purpose entities, including 2019‑1 Entities, that are consolidated in the Company’s consolidated financial statements. The creditors of the special purpose entities have received security interests in such assets and such assets are not intended to be available to the creditors of the Company (or any affiliate of the Company).
Use of Estimates, Policy [Policy Text Block]	*Use of estimates* In preparing the consolidated financial statements in accordance with GAAP, management is required to make estimates and assumptions that affect the reported amounts of assets and liabilities, and disclosures of contingent assets and liabilities, as of the date of the balance sheet and income and expenses for the period. Actual results could differ from those estimates. Material estimates that are particularly susceptible to significant change in the near term relate to the valuation of investments.
Fair Value Measurement, Policy [Policy Text Block]	*Fair value* The Company records all of its investments at fair value in accordance with relevant GAAP, which establishes a framework used to measure fair value and requires disclosures for fair value measurements. The Company has categorized its investments carried at fair value, based on the priority of the valuation technique, into a three-level fair value hierarchy as more fully described in Note 6. Fair value is a market-based measure considered from the perspective of the market participant who holds the financial instrument rather than an entity specific measure. Therefore, when market assumptions are not readily available, the Company’s own assumptions are set to reflect those that management believes market participants would use in pricing the financial instrument at the measurement date. The availability of observable inputs can vary depending on the financial instrument and is affected by a wide variety of factors, including, for example, the type of product, whether the product is new, whether the product is traded on an active exchange or in the secondary market and the current market conditions. To the extent that the valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. Accordingly, the degree of judgment exercised by the Company in determining fair value is greatest for financial instruments classified as Level 3. See Note 6 for additional information regarding fair value.
Segment Reporting, Policy [Policy Text Block]	*Segments* The Company has determined that it has a single reporting segment and operating unit structure. The Company lends to and invests in portfolio companies in various technology, life science, healthcare information and services and sustainability industries. The Company separately evaluates the performance of each of its lending and investment relationships. However, because each of these debt investments and investment relationships has similar business and economic characteristics, they have been aggregated into a single lending and investment segment.
Investment, Policy [Policy Text Block]	*Investments* Investments are recorded at fair value. Pursuant to the amended SEC Rule 2a-5 of the 1940 Act, on July 29, 2022, the Board designated the Advisor as the Company’s “valuation designee.” The valuation designee determines the fair value of the Company’s portfolio investments and the Company's board of directors (the “Board”) oversees the valuation designee. The Company has the intent to hold its debt investments for the foreseeable future or until maturity or payoff. Interest on debt investments is accrued and included in income based on contractual rates applied to principal amounts outstanding. Interest income is determined using a method that results in a level rate of return on principal amounts outstanding. Generally, when a debt investment becomes 90 days or more past due, or if the Company otherwise does not expect to receive interest and principal repayments, the debt investment is placed on non-accrual status and the recognition of interest income may be discontinued. Interest payments received on non-accrual debt investments may be recognized as income, on a cash basis, or applied to principal depending upon management’s judgment at the time the debt investment is placed on non-accrual status. As of September 30, 2022, there were no investments on nonaccrual status. As of December 31, 2021, there was one investment on non-accrual status with a cost of $11.5 million and a fair value of $6.9 million. For the three and nine months ended September 30, 2022, the Company did not recognize any interest income from debt investments on non-accrual status. For the three months ended September 30, 2021, the Company did not recognize any interest income from debt investments on non-accrual status. For the nine months ended September 30, 2021, the Company recognized, as interest income, payments of $1.3 million received from one portfolio company whose debt investment was on non-accrual status. The Company receives a variety of fees from borrowers in the ordinary course of conducting its business, including advisory fees, commitment fees, amendment fees, non-utilization fees, success fees and prepayment fees. In a limited number of cases, the Company may also receive a non-refundable deposit earned upon the termination of a transaction. Debt investment origination fees, net of certain direct origination costs, are deferred and, along with unearned income, are amortized as a level-yield adjustment over the respective term of the debt investment. All other income is recognized when earned. Fees for counterparty debt investment commitments with multiple debt investments are allocated to each debt investment based upon each debt investment’s relative fair value. When a debt investment is placed on non-accrual status, the amortization of the related fees and unearned income is discontinued until the debt investment is returned to accrual status. Certain debt investment agreements also require the borrower to make an ETP, that is accrued into interest receivable and taken into income over the life of the debt investment to the extent such amounts are expected to be collected. The Company will generally cease accruing the income if there is insufficient value to support the accrual or the Company does not expect the borrower to be able to pay the ETP when due. The proportion of the Company’s total investment income that resulted from the portion of ETPs not received in cash for the three months ended September 30, 2022 and 2021 was 7.0% and 5.2%, respectively. The proportion of the Company’s total investment income that resulted from the portion of ETPs not received in cash for the nine months ended September 30, 2022 and 2021 was 7.5% and 6.7%, respectively. In connection with substantially all lending arrangements, the Company receives warrants to purchase shares of stock from the borrower. The warrants are recorded as assets at estimated fair value on the grant date using the Black-Scholes valuation model. The warrants are considered loan fees and are recorded as unearned income on the grant date. The unearned income is recognized as interest income over the contractual life of the related debt investment in accordance with the Company’s income recognition policy. Subsequent to debt investment origination, the fair value of the warrants is determined using the Black-Scholes valuation model. Any adjustment to fair value is recorded through earnings as net unrealized appreciation or depreciation on investments. Gains and losses from the disposition of the warrants or stock acquired from the exercise of warrants are recognized as realized gains and losses on investments. Realized gains or losses on the sale of investments, or upon the determination that an investment balance, or portion thereof, is not recoverable, are calculated using the specific identification method. The Company measures realized gains or losses by calculating the difference between the net proceeds from the repayment or sale and the amortized cost basis of the investment. Net change in unrealized appreciation or depreciation reflects the change in the fair values of the Company’s portfolio investments during the reporting period, including any reversal of previously recorded unrealized appreciation or depreciation when gains or losses are realized.
Deferred Charges, Policy [Policy Text Block]	*Debt issuance costs* Debt issuance costs are fees and other direct incremental costs incurred by the Company in obtaining debt financing from its lenders and issuing debt securities. The unamortized balance of debt issuance costs as of September 30, 2022 and December 31, 2021 was $5.6 million and $4.3 million, respectively. These amounts are amortized and included in interest expense in the consolidated statements of operations over the life of the borrowings. The accumulated amortization balances as of September 30, 2022 and December 31, 2021 were $4.4 million and $3.2 million, respectively. The amortization expense for the three months ended September 30, 2022 and 2021 was $0.4 million and $0.2 million, respectively. The amortization expense for the nine months ended September 30, 2022 and 2021 was $1.1 million and $0.7 million, respectively.
Income Tax, Policy [Policy Text Block]	*Income taxes* As a BDC, the Company has elected to be treated as a RIC under Subchapter M of the Code and operates in a manner so as to qualify for the tax treatment applicable to RICs. In order to qualify as a RIC and to avoid the imposition of corporate-level income tax on the portion of its taxable income distributed to stockholders, among other things, the Company is required to meet certain source of income and asset diversification requirements and to timely distribute dividends out of assets legally available for distribution to its stockholders of an amount generally at least equal to 90% of its investment company taxable income, as defined by the Code and determined without regard to any deduction for dividends paid, for each tax year. The Company, among other things, has made and intends to continue to make the requisite distributions to its stockholders, which generally relieves the Company from corporate-level U.S. federal income taxes. Accordingly, no provision for federal income tax has been recorded in the financial statements. Differences between taxable income and net increase in net assets resulting from operations either can be temporary, meaning they will reverse in the future, or permanent. In accordance with ASC Topic 946, Financial Services—Investment Companies, as amended, of the Financial Accounting Standards Board (“FASB”), permanent tax differences, such as non-deductible excise taxes paid, are reclassified from distributions in excess of net investment income and net realized loss on investments to paid-in-capital at the end of each fiscal year. These permanent book-to-tax differences are reclassified on the consolidated statements of changes in net assets to reflect their tax character but have no impact on total net assets. For the year ended December 31, 2021, the Company reclassified $0.4 million to paid-in capital from distributions in excess of net investment income, which related to excise taxes payable. Depending on the level of taxable income earned in a tax year, the Company may choose to carry forward taxable income in excess of current year distributions into the next tax year and incur a 4% U.S. federal excise tax on such income, as required. To the extent that the Company determines that its estimated current year annual taxable income will be in excess of estimated current year distributions, the Company accrues excise tax, if any, on estimated excess taxable income as taxable income is earned. For the three and nine months ended September 30, 2022, $0.1 million and $0.3 million, respectively, was accrued for U.S. federal excise tax. For the three and nine months ended September 30, 2021, $0.1 million and $0.2 million, respectively, was recorded for U.S. federal excise tax. The Company evaluates tax positions taken in the course of preparing the Company’s tax returns to determine whether the tax positions are “more-likely-than-not” to be sustained by the applicable tax authority in accordance with ASC Topic 740, Income Taxes, as modified by ASC Topic 946. Tax benefits of positions not deemed to meet the more-likely-than-not threshold, or uncertain tax positions, would be recorded as a tax expense in the current year. It is the Company’s policy to recognize accrued interest and penalties related to uncertain tax benefits in income tax expense. The Company had no material uncertain tax positions at September 30, 2022 and December 31, 2021. The Company’s income tax returns for the 2021, 2020 and 2019 tax years remain subject to examination by U.S. federal and state tax authorities.
Distributions [Policy Text Block]	*Distributions* Distributions to common stockholders are recorded on the declaration date. The amount to be paid out as distributions is determined by the Board. Net realized capital gains, if any, may be distributed, although the Company may decide to retain such net realized gains for investment. The Company has adopted a dividend reinvestment plan that provides for reinvestment of cash distributions on behalf of its stockholders, unless a stockholder elects to receive cash. As a result, if the Board declares a cash distribution, then stockholders who have not “opted out” of the dividend reinvestment plan will have their cash distributions automatically reinvested in additional shares of the Company’s common stock, rather than receiving the cash distribution. The Company may issue new shares or purchase shares in the open market to fulfill its obligations under the plan.
Stockholders' Equity, Policy [Policy Text Block]	*Stockholders’ Equity* On July 30, 2020, the Company entered into an At-The-Market (“ATM”) sales agreement (the “2020 Equity Distribution Agreement”), with Goldman Sachs & Co. LLC and B. Riley FBR, Inc. (each a “Sales Agent” and, collectively, the “Sales Agents”). The 2020 Equity Distribution Agreement provided that the Company may offer and sell its shares from time to time through the Sales Agents up to $100.0 million worth of its common stock, in amounts and at times to be determined by the Company. On August 2, 2021, the Company terminated the 2020 Equity Distribution Agreement and entered into a new ATM sales agreement (the “2021 Equity Distribution Agreement”), with the Sales Agents. The remaining shares available under the 2020 Equity Distribution Agreement are no longer available for issuance. The 2021 Equity Distribution Agreement provides that the Company may offer and sell its shares from time to time through the Sales Agents up to $100.0 million worth of its common stock, in amounts and at times to be determined by the Company. Sales of the Company’s common stock, if any, may be made in negotiated transactions or transactions that are deemed to be “at-the-market,” as defined in Rule 415 under the Securities Act, including sales made directly on the NASDAQ or similar securities exchange or sales made to or through a market maker other than on an exchange, at prices related to the prevailing market prices or at negotiated prices. During the three months ended September 30, 2022, the Company sold 1,523,519 shares of common stock under the 2021 Equity Distribution Agreement. For the same period, the Company received total accumulated net proceeds of approximately $19.0 million, including $0.4 million of offering expenses, from these sales. During the three months ended September 30, 2021, the Company sold 395,068 shares of common stock under the 2020 Equity Distribution Agreement and the 2021 Equity Distribution Agreement. For the same period, the Company received total accumulated net proceeds of approximately $6.6 million, including $0.2 million of offering expenses, from these sales. During the nine months ended September 30, 2022, the Company sold 2,641,920 shares of common stock under the 2021 Equity Distribution Agreement. For the same period, the Company received total accumulated net proceeds of approximately $33.2 million, including $0.6 million of offering expenses, from these sales. During the nine months ended September 30, 2021, the Company sold 1,122,516 shares of common stock under the 2020 Equity Distribution Agreement and the 2021 Equity Distribution Agreement. For the same period, the Company received total accumulated net proceeds of approximately $17.3 million, including $0.5 million of offering expenses, from these sales. The Company generally uses net proceeds from these offerings to make investments, to pay down liabilities and for general corporate purposes. As of September 30, 2022, shares representing approximately $48.9 million of its common stock remain available for issuance and sale under the Equity Distribution Agreement.
Stock Repurchase Program [Policy Text Block]	*Stock Repurchase Program* On April 29, 2022, the Board extended a previously authorized stock repurchase program which allows the Company to repurchase up to $5.0 million of its common stock at prices below the Company’s net asset value per share as reported in its most recent consolidated financial statements. Under the repurchase program, the Company may, but is not obligated to, repurchase shares of its outstanding common stock in the open market or in privately negotiated transactions from time to time. Any repurchases by the Company will comply with the requirements of Rule 10b‑18 under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and any applicable requirements of the 1940 Act. Unless extended by the Board, the repurchase program will terminate on the earlier of June 30, 2023 or the repurchase of $5.0 million of the Company’s common stock. During the three and nine months ended September 30, 2022 and 2021, the Company did not make any repurchases of its common stock. From the inception of the stock repurchase program through September 30, 2022, the Company repurchased 167,465 shares of its common stock at an average price of $11.22 on the open market at a total cost of $1.9 million.
Transfers and Servicing of Financial Assets, Policy [Policy Text Block]	*Transfers of financial assets* Assets related to transactions that do not meet the requirements under ASC Topic 860, Transfers and Servicing for sale treatment under GAAP are reflected in the Company’s consolidated statements of assets and liabilities as investments. Those assets are owned by special purpose entities that are consolidated in the Company’s financial statements. The creditors of the special purpose entities have received security interests in such assets and such assets are not intended to be available to the creditors of the Company (or any other affiliate of the Company). Transfers of financial assets are accounted for as sales when control over the assets has been surrendered. Control over transferred assets is deemed to be surrendered when (1) the assets have been isolated from the Company — put presumptively beyond the reach of the transferor and its creditors, even in bankruptcy or other receivership, (2) the transferee obtains the right (free of conditions that constrain it from taking advantage of that right) to pledge or exchange the transferred assets and (3) the transferor does not maintain effective control over the transferred assets through either (a) an agreement that both entitles and obligates the transferor to repurchase or redeem the assets before maturity or (b) the ability to unilaterally cause the holder to return specific assets, other than through a cleanup call.
New Accounting Pronouncements, Policy [Policy Text Block]	*Recently issued accounting pronouncements* In March 2020, the FASB issued Accounting Standards Update No. 2020-04, Reference Rate Reform (Topic 848): Facilitation of the Effects of Reference Rate Reform on Financial Reporting (“ASU 2020-04”). ASU 2020-04 provides optional expedients and exceptions for applying GAAP to contract modifications and hedging relationships, subject to meeting certain criteria, that reference LIBOR or another rate that is expected to be discontinued. The amendments in ASU 2020-04 are effective for all entities as of March 12, 2020 through December 31, 2022. The Company is currently assessing the impact of ASU 2020-04 and the LIBOR transition on its consolidated financial statements. In June 2022, the FASB issues Accounting Standards Update No. 2022-03, Fair Value Measurement of Equity Securities Subject to Contractual Sale Restrictions (“ASU 2022-03”). ASU 2022-03 clarifies the guidance when measuring the fair value of an equity security subject to contractual restrictions that prohibit the sale of the security. The amendments in ASU 2022-03 are effective for public companies for fiscal years beginning after December 15, 2023, and interim periods within those fiscal years. The Company is currently assessing the impact of ASU 2022-03 on its consolidated financial statements.

Consolidated Schedule of Investments (Unaudited) (Tables)

9 Months Ended

Sep. 30, 2022

Notes Tables

Investment [Table Text Block]


Portfolio Company (1)(3)	*Sector*	*Type of Investment (7)*	*Cash Rate (4)*			*Index*	*Margin*			*Floor*			*Ceiling*			*ETP (10)*			*Maturity Date*	*Principal Amount*		*Cost of Investments (6)(9)*		*Fair Value (9)*
Non-Affiliate Investments — 206.2% (8)
Non-Affiliate Debt Investments — 197.9% (8)
Non-Affiliate Debt Investments — Life Science — 83.0% (8)
Avalo Therapeutics, Inc. (2)(5)(12)	Biotechnology	Term Loan		12.50	%	Prime		6.25	%		9.50	%		-			3.00	%	January 1, 2025	$	2,885	$	2,817	$	2,765
		Term Loan		12.50	%	Prime		6.25	%		9.50	%		-			3.00	%	January 1, 2025		2,885		2,817		2,765
		Term Loan		12.50	%	Prime		6.25	%		9.50	%		-			3.00	%	January 1, 2025		1,442		1,435		1,410
		Term Loan		12.50	%	Prime		6.25	%		9.50	%		-			3.00	%	February 1, 2025		2,885		2,813		2,763
		Term Loan		12.50	%	Prime		6.25	%		9.50	%		-			3.00	%	February 1, 2025		2,885		2,813		2,763
		Term Loan		12.50	%	Prime		6.25	%		9.50	%		-			3.00	%	April 1, 2025		1,442		1,404		1,379
		Term Loan		12.50	%	Prime		6.25	%		9.50	%		-			3.00	%	April 1, 2025		1,442		1,404		1,379
Castle Creek Biosciences, Inc. (2)(12)	Biotechnology	Term Loan		11.55	%	Prime		6.05	%		9.55	%		13.50	%		5.50	%	May 1, 2026		5,000		4,887		4,887
		Term Loan		11.55	%	Prime		6.05	%		9.55	%		13.50	%		5.50	%	May 1, 2026		5,000		4,959		4,959
		Term Loan		11.55	%	Prime		6.05	%		9.55	%		13.50	%		5.50	%	May 1, 2026		3,000		2,976		2,976
		Term Loan		11.55	%	Prime		6.05	%		9.55	%		13.50	%		5.50	%	May 1, 2026		5,000		4,959		4,959
		Term Loan		11.55	%	Prime		6.05	%		9.55	%		13.50	%		5.50	%	May 1, 2026		5,000		4,959		4,959
		Term Loan		11.55	%	Prime		6.05	%		9.55	%		13.50	%		5.50	%	May 1, 2026		3,000		2,975		2,975
Emalex Biosciences, Inc. (2)(12)	Biotechnology	Term Loan		10.45	%	Libor		7.90	%		9.75	%		-			5.00	%	June 1, 2024		2,188		2,168		2,168
		Term Loan		10.45	%	Libor		7.90	%		9.75	%		-			5.00	%	June 1, 2024		2,188		2,169		2,169
		Term Loan		10.45	%	Libor		7.90	%		9.75	%		-			5.00	%	November 1, 2025		5,000		4,916		4,916
		Term Loan		10.45	%	Libor		7.90	%		9.75	%		-			5.00	%	May 1, 2026		5,000		4,902		4,902
F-Star Therapeutics, Inc. (2)(5)(12)	Biotechnology	Term Loan		11.75	%	Prime		6.25	%		9.50	%		-			4.00	%	April 1, 2025		2,500		2,473		2,473
		Term Loan		11.75	%	Prime		6.25	%		9.50	%		-			4.00	%	July 1, 2025		2,500		2,471		2,471
Greenlight Biosciences, Inc. (2)(5)(12)	Biotechnology	Term Loan		12.00	%	Prime		5.75	%		9.00	%		-			3.00	%	July 1, 2025		5,000		4,843		4,843
		Term Loan		12.00	%	Prime		5.75	%		9.00	%		-			3.00	%	July 1, 2025		2,500		2,423		2,423
IMV Inc. (2)(5)(12)	Biotechnology	Term Loan		12.00	%	Prime		5.75	%		9.00	%		-			5.00	%	July 1, 2025		5,000		4,942		4,942
		Term Loan		12.00	%	Prime		5.75	%		9.00	%		-			5.00	%	July 1, 2025		2,500		2,470		2,470
		Term Loan		12.00	%	Prime		5.75	%		9.00	%		-			5.00	%	January 1, 2026		5,000		4,942		4,942
		Term Loan		12.00	%	Prime		5.75	%		9.00	%		-			5.00	%	January 1, 2026		5,000		4,941		4,941
KSQ Therapeutics, Inc. (2) (12)	Biotechnology	Term Loan		11.00	%	Prime		4.75	%		8.50	%		-			5.50	%	May 1, 2027		6,250		6,071		6,071
		Term Loan		11.00	%	Prime		4.75	%		8.50	%		-			5.50	%	May 1, 2027		6,250		6,172		6,172
LogicBio, Inc. (2)(5)(12)	Biotechnology	Term Loan		8.80	%	Libor		6.25	%		8.75	%		-			4.50	%	June 1, 2024		2,778		2,766		2,766
Native Microbials, Inc (2) (12)	Biotechnology	Term Loan		11.50	%	Prime		5.25	%		8.50	%		-			5.00	%	November 1, 2026		3,750		3,633		3,633
PDS Biotechnology Corporation (2)(5)(12)	Biotechnology	Term Loan		12.00	%	Prime		5.75	%		9.75	%		-			3.75	%	September 1, 2026		10,000		9,688		9,688
		Term Loan		12.00	%	Prime		5.75	%		9.75	%		-			3.75	%	September 1, 2026		3,750		3,692		3,692
		Term Loan		12.00	%	Prime		5.75	%		9.75	%		-			3.75	%	September 1, 2026		3,750		3,692		3,692
Provivi, Inc. (2)(12)	Biotechnology	Term Loan		11.05	%	Libor		8.50	%		9.50	%		-			5.50	%	December 1, 2024		4,666		4,618		4,618
		Term Loan		11.05	%	Libor		8.50	%		9.50	%		-			5.50	%	December 1, 2024		4,666		4,618		4,618
		Term Loan		11.05	%	Libor		8.50	%		9.50	%		-			5.50	%	December 1, 2024		2,333		2,288		2,288
		Term Loan		11.05	%	Libor		8.50	%		9.50	%		-			5.50	%	December 1, 2024		2,333		2,288		2,288
		Term Loan		11.05	%	Libor		8.50	%		9.50	%		-			5.50	%	December 1, 2024		2,333		2,281		2,281
		Term Loan		11.05	%	Libor		8.50	%		9.50	%		-			5.50	%	December 1, 2024		2,333		2,281		2,281


Portfolio Company (1)(3)	*Sector*	*Type of Investment (7)*	*Cash Rate (4)*			*Index*	*Margin*			*Floor*			*Ceiling*		*ETP (10)*			*Maturity Date*	*Principal Amount*		*Cost of Investments (6)(9)*		*Fair Value (9)*
Stealth Biotherapeutics Inc. (2)(5)(12)	Biotechnology	Term Loan		11.75	%	Prime		5.50	%		8.75	%		-		6.00	%	October 1, 2025		5,000		4,906		4,906
		Term Loan		11.75	%	Prime		5.50	%		8.75	%		-		6.00	%	October 1, 2025		2,500		2,453		2,453
Aerobiotix, LLC (2)(12)	Medical Device	Term Loan		12.50	%	Prime		6.25	%		9.50	%		-		6.00	%	April 1, 2026		2,500		2,462		2,366
		Term Loan		12.50	%	Prime		6.25	%		9.50	%		-		6.00	%	April 1, 2026		2,500		2,462		2,365
Canary Medical Inc. (2)(12)	Medical Device	Term Loan		11.25	%	Prime		5.75	%		9.00	%		-		7.00	%	November 1, 2024		2,500		2,438		2,438
		Term Loan		11.25	%	Prime		5.75	%		9.00	%		-		7.00	%	November 1, 2024		2,500		2,486		2,486
		Term Loan		11.25	%	Prime		5.75	%		9.00	%		-		7.00	%	November 1, 2024		2,500		2,466		2,466
Ceribell, Inc. (2)(12)	Medical Device	Term Loan		9.00	%	Prime		3.75	%		8.25	%		-		5.50	%	October 1, 2024		5,000		4,965		4,965
		Term Loan		9.00	%	Prime		3.75	%		8.25	%		-		5.50	%	October 1, 2024		5,000		4,969		4,969
		Term Loan		9.00	%	Prime		3.75	%		8.25	%		-		5.50	%	October 1, 2024		2,500		2,475		2,475
		Term Loan		9.00	%	Prime		3.75	%		8.25	%		-		5.50	%	October 1, 2024		2,500		2,475		2,475
Cognoa, Inc. (2)(12)	Medical Device	Term Loan		11.75	%	Prime		5.50	%		8.75	%		-		6.00	%	August 1, 2026		5,000		4,924		4,924
		Term Loan		11.75	%	Prime		5.50	%		8.75	%		-		6.00	%	August 1, 2026		2,500		2,462		2,462
Conventus Orthopaedics, Inc. (2)(12)	Medical Device	Term Loan		10.55	%	Libor		8.00	%		9.25	%		-		10.36	%	July 1, 2025		3,960		3,892		3,892
		Term Loan		10.55	%	Libor		8.00	%		9.25	%		-		10.36	%	July 1, 2025		3,960		3,892		3,892
Corinth Medtech, Inc. (2)(12)	Medical Device	Term Loan		10.75	%	Prime		5.25	%		8.50	%		-		20.00	%	September 15, 2022		2,500		2,500		2,500
		Term Loan		10.75	%	Prime		5.25	%		8.50	%		-		20.00	%	September 15, 2022		2,500		2,500		2,500
CSA Medical, Inc. (2)(12)	Medical Device	Term Loan		10.75	%	Libor		8.20	%		10.00	%		-		5.00	%	January 1, 2024		2,000		1,981		1,981
		Term Loan		10.75	%	Libor		8.20	%		10.00	%		-		5.00	%	January 1, 2024		133		132		132
		Term Loan		10.75	%	Libor		8.20	%		10.00	%		-		5.00	%	March 1, 2024		2,400		2,379		2,379
Embody, Inc. (2)(12)	Medical Device	Term Loan		12.75	%	Prime		6.50	%		9.75	%		-		28.00	%	August 1, 2026		2,500		2,461		2,461
InfoBionic, Inc. (2)(12)	Medical Device	Term Loan		11.75	%	Prime		6.25	%		9.50	%		-		4.00	%	October 1, 2024		3,500		3,425		3,425
		Term Loan		11.75	%	Prime		6.25	%		9.50	%		-		4.00	%	June 1, 2025		1,000		971		971
Magnolia Medical Technologies, Inc. (2)(12)	Medical Device	Term Loan		10.50	%	Prime		5.00	%		9.75	%		-		4.00	%	March 1, 2025		5,000		4,810		4,810
		Term Loan		10.50	%	Prime		5.00	%		9.75	%		-		4.00	%	March 1, 2025		5,000		4,932		4,932
		Term Loan		10.50	%	Prime		5.00	%		9.75	%		-		4.00	%	March 1, 2025		5,000		4,925		4,925
		Term Loan		10.50	%	Prime		5.00	%		9.75	%		-		4.00	%	March 1, 2025		5,000		4,926		4,926
Scientia Vascular, Inc. (2)(12)	Medical Device	Term Loan		10.25	%	Prime		4.75	%		8.50	%		-		5.00	%	January 1, 2027		3,750		3,593		3,593
		Term Loan		10.25	%	Prime		4.75	%		8.50	%		-		5.00	%	January 1, 2027		3,750		3,702		3,702
Sonex Health, Inc. (2)(12)	Medical Device	Term Loan		12.00	%	Prime		6.50	%		9.75	%		-		5.00	%	June 1, 2025		2,500		2,428		2,428
		Term Loan		12.00	%	Prime		6.50	%		9.75	%		-		5.00	%	June 1, 2025		2,500		2,473		2,473
		Term Loan		12.00	%	Prime		6.50	%		9.75	%		-		5.00	%	June 1, 2025		2,500		2,473		2,473
		Term Loan		12.00	%	Prime		6.50	%		9.75	%		-		8.00	%	April 1, 2026		2,500		2,455		2,455
Spineology, Inc. (2)(12)	Medical Device	Term Loan		13.25	%	Prime		7.00	%		10.25	%		-		1.00	%	October 1, 2025		5,000		4,963		4,963
		Term Loan		13.25	%	Prime		7.00	%		10.25	%		-		1.00	%	April 1, 2026		2,500		2,479		2,479


Portfolio Company (1)(3)	*Sector*	*Type of Investment (7)*	*Cash Rate (4)*			*Index*	*Margin*			*Floor*			*Ceiling*		*ETP (10)*			*Maturity Date*	*Principal Amount*		*Cost of Investments (6)(9)*		*Fair Value (9)*
Swift Health Systems Inc. (2)(12)	Medical Device	Term Loan		10.75	%	Prime		5.25	%		9.00	%		-		5.00	%	July 1, 2027		3,500		3,345		3,345
		Term Loan		10.75	%	Prime		5.25	%		9.00	%		-		5.00	%	July 1, 2027		3,500		3,451		3,451
Total Non-Affiliate Debt Investments — Life Science																						255,997		255,525
Non-Affiliate Debt Investments — Sustainability — 24.7% (8)
Dream Holdings, Inc. (2)(12)	Other Sustainability	Term Loan		13.00	%	Prime		6.75	%		10.00	%		-		3.00	%	April 1, 2026		3,750		3,692		3,692
		Term Loan		13.00	%	Prime		6.75	%		10.00	%		-		3.00	%	April 1, 2026		3,750		3,692		3,692
Nexii Building Solutions, Inc. (2)(12)	Other Sustainability	Term Loan		13.25	%	Prime		7.00	%		10.25	%		-		2.50	%	September 1, 2025		7,500		7,359		7,359
		Term Loan		13.25	%	Prime		7.00	%		10.25	%		-		2.50	%	September 1, 2025		7,500		7,359		7,359
		Term Loan		13.25	%	Prime		7.00	%		10.25	%		-		2.50	%	September 1, 2025		7,500		7,359		7,359
		Term Loan		13.25	%	Prime		7.00	%		10.25	%		-		2.50	%	July 1, 2026		5,000		4,893		4,893
		Term Loan		13.25	%	Prime		7.00	%		10.25	%		-		2.50	%	July 1, 2026		5,000		4,893		4,893
Soli Organic, Inc. (2)(12)	Other Sustainability	Term Loan		13.00	%	Prime		6.75	%		10.00	%		-		2.75	%	April 1, 2026		5,000		4,919		4,919
		Term Loan		13.00	%	Prime		6.75	%		10.00	%		-		2.75	%	April 1, 2026		2,500		2,313		2,313
		Term Loan		13.00	%	Prime		6.75	%		10.00	%		-		2.75	%	May 1, 2026		5,000		4,916		4,916
		Term Loan		13.00	%	Prime		6.75	%		10.00	%		-		2.75	%	May 1, 2026		2,500		2,458		2,458
Temperpack Technologies, Inc. (2)(12)	Other Sustainability	Term Loan		13.00	%	Prime		6.75	%		10.00	%		-		2.50	%	June 1, 2025		3,750		3,694		3,694
		Term Loan		13.00	%	Prime		6.75	%		10.00	%		-		2.50	%	June 1, 2025		3,750		3,713		3,713
		Term Loan		13.00	%	Prime		6.75	%		10.00	%		-		2.50	%	October 1, 2025		7,500		7,417		7,417
		Term Loan		13.00	%	Prime		6.75	%		10.00	%		-		2.50	%	October 1, 2025		3,750		3,709		3,709
		Term Loan		13.00	%	Prime		6.75	%		10.00	%		-		2.50	%	October 1, 2025		3,750		3,709		3,709
Total Non-Affiliate Debt Investments — Sustainability																						76,095		76,095
Non-Affiliate Debt Investments — Technology — 80.2% (8)
Axiom Space, Inc. (2)(12)	Communications	Term Loan		11.50	%	Prime		6.00	%		9.25	%		-		2.50	%	June 1, 2026		7,500		7,452		7,452
		Term Loan		11.50	%	Prime		6.00	%		9.25	%		-		2.50	%	June 1, 2026		7,500		7,452		7,452
		Term Loan		11.50	%	Prime		6.00	%		9.25	%		-		2.50	%	June 1, 2026		7,500		7,452		7,452
		Convertible Note		3.00	%													July 1, 2023		250		250		250
Alula Holdings, Inc. (2)(12)	Consumer-related Technologies	Term Loan		12.25	%	Prime		6.75	%		10.00	%		-		3.00	%	January 1, 2025		5,000		4,961		4,961
		Term Loan		12.25	%	Prime		6.75	%		10.00	%		-		3.00	%	January 1, 2025		5,000		4,961		4,961
		Term Loan		12.25	%	Prime		6.75	%		10.00	%		-		3.00	%	January 1, 2025		3,000		2,977		2,977
		Term Loan		12.25	%	Prime		6.75	%		10.00	%		-		3.00	%	December 1, 2025		1,000		974		974
		Term Loan		12.25	%	Prime		6.75	%		10.00	%		-		3.00	%	February 1, 2026		1,000		974		974
Better Place Forests Co. (2)(12)	Consumer-related Technologies	Term Loan		12.50	%	Prime		6.25	%		9.50	%		-		1.85	%	July 1, 2025		5,000		4,944		4,944
		Term Loan		12.50	%	Prime		6.25	%		9.50	%		-		1.85	%	October 1, 2025		2,500		2,474		2,474
CAMP NYC, Inc. (2)(12)	Consumer-related Technologies	Term Loan		13.50	%	Prime		7.25	%		10.50	%		-		3.00	%	May 1, 2026		3,500		3,458		3,458
Clara Foods Co. (2)(12)	Consumer-related Technologies	Term Loan		11.25	%	Prime		5.75	%		9.00	%		-		5.50	%	August 1, 2025		2,500		2,481		2,481
		Term Loan		11.25	%	Prime		5.75	%		9.00	%		-		5.50	%	August 1, 2025		2,500		2,481		2,481


Portfolio Company (1)(3)	*Sector*	*Type of Investment (7)*	*Cash Rate (4)*			*Index*	*Margin*			*Floor*			*Ceiling*			*ETP (10)*			*Maturity Date*	*Principal Amount*		*Cost of Investments (6)(9)*		*Fair Value (9)*
Divergent Technologies, Inc. (2)(12)	Consumer-related Technologies	Term Loan		11.25	%	Prime		6.00	%		9.50	%		11.25	%		3.00	%	July 1, 2027		3,750		3,397		3,397
		Term Loan		11.25	%	Prime		6.00	%		9.50	%		11.25	%		3.00	%	July 1, 2027		1,250		1,237		1,237
		Term Loan		11.25	%	Prime		6.00	%		9.50	%		11.25	%		3.00	%	July 1, 2027		3,750		3,712		3,712
		Term Loan		11.25	%	Prime		6.00	%		9.50	%		11.25	%		3.00	%	July 1, 2027		1,250		1,237		1,237
		Term Loan		11.25	%	Prime		6.00	%		9.50	%		11.25	%		3.00	%	July 1, 2027		3,750		3,712		3,712
		Term Loan		11.25	%	Prime		6.00	%		9.50	%		11.25	%		3.00	%	July 1, 2027		1,250		1,237		1,237
Interior Define, Inc. (2)(12)	Consumer-related Technologies	Term Loan		12.75	%	Prime		6.50	%		9.75	%		-			4.00	%	January 1, 2026		6,500		6,417		5,215
		Term Loan		12.75	%	Prime		6.50	%		9.75	%		-			4.00	%	January 1, 2026		6,000		5,858		4,760
Lyrical Foods, Inc. (2)(12)	Consumer-related Technologies	Term Loan		13.00	%	Prime		6.75	%		10.00	%		-			9.75	%	January 1, 2024		2,500		2,585		2,219
MyForest Foods Co. (2)(12)	Consumer-related Technologies	Term Loan		13.00	%	Prime		6.75	%		10.00	%		-			3.00	%	October 1, 2025		5,000		4,947		4,947
		Term Loan		13.00	%	Prime		6.75	%		10.00	%		-			3.00	%	October 1, 2025		2,500		2,474		2,474
NextCar Holding Company, Inc. (2)(12)	Consumer-related Technologies	Term Loan		11.25	%	Prime		5.75	%		9.00	%		-			2.00	%	January 1, 2026		5,000		4,947		4,947
		Term Loan		11.25	%	Prime		5.75	%		9.00	%		-			2.00	%	January 1, 2026		2,000		1,979		1,979
		Term Loan		11.25	%	Prime		5.75	%		9.00	%		-			2.00	%	January 1, 2026		2,500		2,474		2,474
		Term Loan		11.25	%	Prime		5.75	%		9.00	%		-			2.00	%	January 1, 2026		3,000		2,968		2,968
		Term Loan		11.25	%	Prime		5.75	%		9.00	%		-			2.00	%	January 1, 2026		2,500		2,453		2,453
		Term Loan		11.25	%	Prime		5.75	%		9.00	%		-			2.00	%	January 1, 2026		2,500		2,453		2,453
		Term Loan		11.25	%	Prime		5.75	%		9.00	%		-			2.00	%	January 1, 2026		5,000		4,904		4,904
		Term Loan		11.25	%	Prime		5.75	%		9.00	%		-			2.00	%	January 1, 2026		2,500		2,450		2,450
Optoro, Inc. (2)(12)	Consumer-related Technologies	Term Loan		11.75	%	Prime		6.25	%		9.50	%		-			4.00	%	August 1, 2027		2,500		2,339		2,339
Primary Kids, Inc. (2)(12)	Consumer-related Technologies	Term Loan		12.75	%	Prime		7.25	%		10.50	%		-			3.00	%	March 1, 2025		2,900		2,870		2,870
		Term Loan		12.75	%	Prime		7.25	%		10.50	%		-			3.00	%	March 1, 2025		2,900		2,870		2,870
		Term Loan		12.75	%	Prime		7.25	%		10.50	%		-			3.00	%	September 1, 2025		3,000		2,964		2,964
Unagi, Inc. (2)(12)	Consumer-related Technologies	Term Loan		14.00	%	Prime		7.25	%		11.00	%		-			-		July 1, 2025		2,500		2,471		2,317
		Term Loan		14.00	%	Prime		7.25	%		11.00	%		-			-		July 1, 2025		1,250		1,235		1,158
		Term Loan		14.00	%	Prime		7.25	%		11.00	%		-			-		July 1, 2025		1,250		1,234		1,157
Liqid, Inc. (2)(12)	Networking	Term Loan		11.75	%	Prime		6.25	%		9.50	%		-			4.00	%	September 1, 2024		3,833		3,779		3,779
		Term Loan		11.75	%	Prime		6.25	%		9.50	%		-			4.00	%	September 1, 2024		3,833		3,779		3,779
		Term Loan		11.75	%	Prime		6.25	%		9.50	%		-			4.00	%	September 1, 2024		1,917		1,887		1,887
		Term Loan		11.75	%	Prime		6.25	%		9.50	%		-			4.00	%	September 1, 2024		1,917		1,887		1,887
		Term Loan		11.75	%	Prime		6.25	%		9.50	%		-			4.00	%	September 1, 2024		1,917		1,855		1,855
BriteCore Holdings, Inc. (2)(12)	Software	Term Loan		12.25	%	Prime		6.75	%		10.00	%		-			4.00	%	October 1, 2024		2,500		2,420		2,420
		Term Loan		12.25	%	Prime		6.75	%		10.00	%		-			4.00	%	October 1, 2024		2,500		2,486		2,486
Decisyon, Inc. (12)	Software	Term Loan		15.68	%	Prime		9.43	%		12.68	%		-			50.43	%	December 31, 2022		3,313		3,313		3,313


Portfolio Company (1)(3)	*Sector*	*Type of Investment (7)*	*Cash Rate (4)*			*Index*	*Margin*			*Floor*			*Ceiling*		*ETP (10)*			*Maturity Date*	*Principal Amount*		*Cost of Investments (6)(9)*		*Fair Value (9)*
Dropoff, Inc. (2)(12)	Software	Term Loan		12.75	%	Prime		6.50	%		9.75	%		-		3.50	%	April 1, 2026		6,500		6,147		6,147
		Term Loan		12.75	%	Prime		6.50	%		9.75	%		-		3.50	%	April 1, 2026		6,000		5,847		5,847
		Term Loan		12.75	%	Prime		6.50	%		9.75	%		-		3.50	%	August 1, 2026		2,500		2,431		2,431
Engage3, LLC (2)(12)	Software	Term Loan		12.75	%	Prime		6.25	%		9.75	%		-		4.50	%	July 1, 2027		3,750		3,675		3,675
		Term Loan		11.75	%	Prime		6.25	%		9.75	%		-		4.50	%	July 1, 2027		3,750		3,715		3,715
Kodiak Robotics, Inc. (2)(12)	Software	Term Loan		11.75	%	Prime		5.50	%		10.25	%		-		4.00	%	April 1, 2026		10,000		9,809		9,809
		Term Loan		11.75	%	Prime		5.50	%		10.25	%		-		4.00	%	April 1, 2026		10,000		9,809		9,809
		Term Loan		11.75	%	Prime		5.50	%		10.25	%		-		4.00	%	April 1, 2026		5,000		4,904		4,904
		Term Loan		11.75	%	Prime		5.50	%		10.25	%		-		4.00	%	April 1, 2026		5,000		4,904		4,904
Lemongrass Holdings, Inc. (2)(12)	Software	Term Loan		12.75	%	Prime		6.50	%		9.75	%		-		2.50	%	March 1, 2026		5,000		4,941		4,941
		Term Loan		12.75	%	Prime		6.50	%		9.75	%		-		2.50	%	March 1, 2026		2,500		2,471		2,471
Lytics, Inc. (2)(12)	Software	Term Loan		11.50	%	Prime		6.00	%		9.25	%		-		3.00	%	July 1, 2025		2,500		2,472		2,472
Reputation Institute, Inc. (2)(12)	Software	Term Loan		12.75	%	Prime		7.25	%		10.50	%		-		3.00	%	August 1, 2025		5,000		4,926		4,926
Slingshot Aerospace, Inc. (2)(12)	Software	Term Loan		12.00	%	Prime		5.75	%		9.75	%		-		5.00	%	August 1, 2026		5,000		4,927		4,927
		Term Loan		12.00	%	Prime		5.75	%		9.75	%		-		5.00	%	August 1, 2026		5,000		4,927		4,927
		Term Loan		12.00	%	Prime		5.75	%		9.75	%		-		5.00	%	August 1, 2026		5,000		4,863		4,863
		Term Loan		12.00	%	Prime		5.75	%		9.75	%		-		5.00	%	August 1, 2026		5,000		4,927		4,927
Supply Network Visiblity Holdings LLC (2)(12)	Software	Term Loan		12.00	%	Prime		6.50	%		9.75	%		-		4.00	%	February 1, 2025		3,500		3,469		3,469
		Term Loan		12.00	%	Prime		6.50	%		9.75	%		-		4.00	%	February 1, 2025		3,500		3,469		3,469
		Term Loan		12.00	%	Prime		6.50	%		9.75	%		-		4.00	%	December 1, 2025		2,500		2,470		2,470
		Term Loan		12.00	%	Prime		6.50	%		9.75	%		-		4.00	%	December 1, 2025		2,500		2,470		2,470
Total Non-Affiliate Debt Investments — Technology																						249,694		246,720
Non-Affiliate Debt Investments — Healthcare information and services — 10.0% (8)
Hound Labs inc. (2) (12)	Diagnostics	Term Loan		12.25	%	Prime		6.00	%		9.25	%		-		3.50	%	June 1, 2026		2,500		2,383		2,383
		Term Loan		12.25	%	Prime		6.00	%		9.25	%		-		3.50	%	June 1, 2026		2,500		2,470		2,470
		Term Loan		12.25	%	Prime		6.00	%		9.25	%		-		3.50	%	June 1, 2026		5,000		4,940		4,940
Secure Transfusion Services, Inc. (2)(12)	Other Healthcare	Term Loan		12.00	%	Prime		5.75	%		9.00	%		-		4.00	%	October 1, 2025		5,000		4,934		4,934
		Term Loan		12.00	%	Prime		5.75	%		9.00	%		-		4.00	%	December 31, 2025		2,500		2,463		2,463
BrightInsight, Inc. (2)(12)	Software	Term Loan		11.00	%	Prime		5.50	%		9.50	%		-		3.00	%	August 1, 2027		7,000		6,612		6,612
		Term Loan		11.00	%	Prime		5.50	%		9.50	%		-		3.00	%	August 1, 2027		3,500		3,445		3,445
		Term Loan		11.00	%	Prime		5.50	%		9.50	%		-		3.00	%	August 1, 2027		3,500		3,445		3,445
Total Non-Affiliate Debt Investments — Healthcare information and services																						30,692		30,692
*Total Non- Affiliate Debt Investments*																						612,478		609,032

					*Cost of*		*Fair*
Portfolio Company (1)(3)	*Sector*	*Type of Investment (7)*	*Number of Shares*		*Investments (6)(9)*		*Value (9)*
Non-Affiliate Warrant Investments — 7.2% (8)
Non-Affiliate Warrants — Life Science — 1.8% (8)
Avalo Therapeutics, Inc. (2)(5)(12)	Biotechnology	Common Stock Warrant		26,442		311		—
Castle Creek Biosciences, Inc. (2)(12)	Biotechnology	Preferred Stock Warrant		5,372		214		104
Corvium, Inc. (2)(12)	Biotechnology	Preferred Stock Warrant		661,956		52		—
Emalex Biosciences, Inc. (2)(12)	Biotechnology	Preferred Stock Warrant		110,402		176		244
F-Star Therapeutics, Inc. (2)(5)(12)	Biotechnology	Common Stock Warrant		21,120		35		—
Greenlight Biosciences, Inc. (2)(5)(12)	Biotechnology	Common Stock Warrant		71,292		366		5
Imunon, Inc. (2)(5)(12)	Biotechnology	Common Stock Warrant		16,502		65		—
IMV Inc. (2)(5)(12)	Biotechnology	Common Stock Warrant		397,726		67		4
KSQ Therapeutics, Inc. (2) (12)	Biotechnology	Preferred Stock Warrant		48,077		50		54
LogicBio, Inc. (2)(5)(12)	Biotechnology	Common Stock Warrant		7,843		8		—
Mustang Bio, Inc. (2)(5)(12)	Biotechnology	Common Stock Warrant		252,161		146		—
Native Microbials, Inc (2) (12)	Biotechnology	Preferred Stock Warrant		94,253		52		59
PDS Biotechnology Corporation (2)(5)(12)	Biotechnology	Common Stock Warrant		299,848		160		160
Provivi, Inc. (2)(12)	Biotechnology	Preferred Stock Warrant		164,608		278		513
Rocket Pharmaceuticals Corporation (5)(12)	Biotechnology	Common Stock Warrant		7,051		17		1
Stealth Biotherapeutics Inc. (2)(5)(12)	Biotechnology	Common Stock Warrant		795,455		264		—
vTv Therapeutics Inc. (2)(5)(12)	Biotechnology	Common Stock Warrant		95,293		44		—
Xeris Pharmaceuticals, Inc. (2)(5)(12)	Biotechnology	Common Stock Warrant		126,000		72		2
AccuVein Inc. (2)(12)	Medical Device	Common Stock Warrant		1,175		23		—
Aerin Medical, Inc. (2)(12)	Medical Device	Preferred Stock Warrant		1,818,183		64		1,187
Aerobiotix, LLC (2)(12)	Medical Device	Preferred Stock Warrant		27,330		46		52
Canary Medical Inc. (2)(12)	Medical Device	Preferred Stock Warrant		12,153		85		1,865
Ceribell, Inc. (2)(12)	Medical Device	Preferred Stock Warrant		145,483		69		204
Cognoa, Inc. (2)(12)	Medical Device	Preferred Stock Warrant		775,000		148		167
Conventus Orthopaedics, Inc. (2)(12)	Medical Device	Preferred Stock Warrant		7,972,222		221		209
CSA Medical, Inc. (2)(12)	Medical Device	Preferred Stock Warrant		1,375,727		153		134
CVRx, Inc. (2)(5)(12)	Medical Device	Common Stock Warrant		47,410		76		47
Infobionic, Inc. (2)(12)	Medical Device	Preferred Stock Warrant		317,647		124		111

					*Cost of*		*Fair*
Portfolio Company (1)(3)	*Sector*	*Type of Investment (7)*	*Number of Shares*		*Investments (6)(9)*		*Value (9)*
Magnolia Medical Technologies, Inc. (2)(12)	Medical Device	Preferred Stock Warrant		699,485		141		135
Meditrina, Inc. (2)(12)	Medical Device	Preferred Stock Warrant		221,510		82		142
Scientia Vascular, Inc (2)(12)	Medical Device	Preferred Stock Warrant		19,662		39		43
Sonex Health, Inc. (2)(12)	Medical Device	Preferred Stock Warrant		605,313		97		113
VERO Biotech LLC (2)(12)	Medical Device	Preferred Stock Warrant		408		53		—
Swift Health Systems Inc. (2)(12)	Medical Device	Preferred Stock Warrant		135,484		71		79
Total Non-Affiliate Warrants — Life Science						3,869		5,634
Non-Affiliate Warrants — Sustainability — 0.5% (8)
Dream Holdings, Inc. (2)(12)	Other Sustainability	Preferred Stock Warrant		70,539		61		68
LiquiGlide, Inc. (2)(12)	Other Sustainability	Common Stock Warrant		61,539		39		45
Nexii Building Solutions, Inc. (2)(12)	Other Sustainability	Common Stock Warrant		209,669		489		888
Soli Organic, Inc. (2)(12)	Other Sustainability	Preferred Stock Warrant		681		214		345
Temperpack Technologies, Inc. (2)(12)	Other Sustainability	Preferred Stock Warrant		35,906		126		259
Total Non-Affiliate Warrants — Sustainability						929		1,605
Non-Affiliate Warrants — Technology — 4.2% (8)
Axiom Space, Inc. (2)(12)	Communications	Common Stock Warrant		1,991		47		52
Intelepeer Holdings, Inc. (2)(12)	Communications	Preferred Stock Warrant		2,936,535		138		3,219
PebblePost, Inc. (2)(12)	Communications	Preferred Stock Warrant		598,850		92		193
Alula Holdings, Inc. (2)(12)	Consumer-related Technologies	Preferred Stock Warrant		20,000		93		57
Aterian, Inc. (2)(5)(12)	Consumer-related Technologies	Common Stock Warrant		76,923		195		—
Better Place Forests Co. (2)(12)	Consumer-related Technologies	Preferred Stock Warrant		10,690		27		32
Caastle, Inc. (2)(12)	Consumer-related Technologies	Preferred Stock Warrant		268,591		68		1,068
CAMP NYC, Inc. (2)(12)	Consumer-related Technologies	Preferred Stock Warrant		17,605		24		61
Clara Foods Co. (2)(12)	Consumer-related Technologies	Preferred Stock Warrant		46,745		31		378
Divergent Technologies, Inc. (2)(12)	Consumer-related Technologies	Preferred Stock Warrant		25,758		30		35
Getaround, Inc. (2)(12)	Consumer-related Technologies	Preferred Stock Warrant		651,040		450		199
Interior Define, Inc. (2)(12)	Consumer-related Technologies	Preferred Stock Warrant		553,710		103		—
MyForest Foods Co. (2)(12)	Consumer-related Technologies	Preferred Stock Warrant		143		29		33
NextCar Holding Company, Inc. (2)(12)	Consumer-related Technologies	Preferred Stock Warrant		630,626		188		116
Optoro, Inc. (2)(12)	Consumer-related Technologies	Preferred Stock Warrant		6,600		104		104
Primary Kids, Inc. (2)(12)	Consumer-related Technologies	Preferred Stock Warrant		553,778		57		425
Quip NYC Inc. (2)(12)	Consumer-related Technologies	Preferred Stock Warrant		6,191		324		525
Unagi, Inc. (2)(12)	Consumer-related Technologies	Preferred Stock Warrant		171,081		32		38
Updater, Inc.(2)(12)	Consumer-related Technologies	Common Stock Warrant		108,333		34		12
CPG Beyond, Inc. (2)(12)	Data Storage	Preferred Stock Warrant		500,000		242		895
Silk, Inc. (2)(12)	Data Storage	Preferred Stock Warrant		442,110		234		316
Global Worldwide LLC (2)(12)	Internet and Media	Preferred Stock Warrant		245,810		75		—
Rocket Lawyer Incorporated (2)(12)	Internet and Media	Preferred Stock Warrant		261,721		92		500
Skillshare, Inc. (2)(12)	Internet and Media	Preferred Stock Warrant		139,074		162		799
Liqid, Inc. (2)(12)	Networking	Preferred Stock Warrant		344,102		364		226
Halio, Inc. (2)(12)	Power Management	Preferred Stock Warrant		5,002,574		1,585		2,254
Avalanche Technology, Inc. (2)(12)	Semiconductors	Preferred and Common Stock Warrants		6,081		56		—
BriteCore Holdings, Inc. (2)(12)	Software	Preferred Stock Warrant		77,828		21		64
Decisyon, Inc. (12)	Software	Common Stock Warrant		82,967		46		—
Dropoff, Inc. (2)(12)	Software	Common Stock Warrant		516,732		455		187
E La Carte, Inc. (2)(5)(12)	Software	Common Stock Warrant		152,908		60		1
Kodiak Robotics, Inc. (2)(12)	Software	Preferred Stock Warrant		639,918		273		273
Lemongrass Holdings, Inc. (2)(12)	Software	Preferred Stock Warrant		101,308		34		38
Lotame Solutions, Inc. (2)(12)	Software	Preferred Stock Warrant		288,115		22		306
Lytics, Inc. (2)(12)	Software	Preferred Stock Warrant		26,733		11		14
Reputation Institute, Inc. (2)(12)	Software	Preferred Stock Warrant		3,731		56		35
Revinate Holdings, Inc. (2)(12)	Software	Preferred Stock Warrant		498,241		47		81
Riv Data Corp. (2)(12)	Software	Preferred Stock Warrant		321,428		12		296
SIGNiX, Inc. (12)	Software	Preferred Stock Warrant		186,235		225		—
Skyword, Inc. (12)	Software	Preferred and Common Stock Warrants		301,055		48		9
Slingshot Aerospace, Inc. (2)(12)	Software	Preferred Stock Warrant		309,208		123		123
Supply Network Visiblity Holdings LLC (2)(12)	Software	Preferred Stock Warrant		682		64		74
Topia Mobility, Inc. (2)(12)	Software	Preferred Stock Warrant		3,049,607		135		—
xAd, Inc. (2)(12)	Software	Preferred Stock Warrant		4,343,348		177		2
Total Non-Affiliate Warrants — Technology						6,685		13,040

					*Cost of*		*Fair*
Portfolio Company (1)(3)	*Sector*	*Type of Investment (7)*	*Number of Shares*		*Investments (6)(9)*		*Value (9)*
Non-Affiliate Warrants — Healthcare information and services — 0.6% (8)
Hound Labs, Inc (2) (12)	Diagnostics	Preferred Stock Warrant		159,893		47		51
Kate Farms, Inc. (2)(12)	Other Healthcare	Preferred Stock Warrant		82,965		103		1,217
Watermark Medical, Inc. (2)(12)	Other Healthcare	Preferred Stock Warrant		27,373		73		—
Secure Transfusion Services, Inc. (2)(12)	Other Healthcare	Preferred Stock Warrant		77,690		48		68
BrightInsight, Inc. (2)(12)	Software	Preferred Stock Warrant		80,544		157		157
Medsphere Systems Corporation (2)(12)	Software	Preferred Stock Warrant		7,097,792		60		341
Total Non-Affiliate Warrants — Healthcare information and services						488		1,834
*Total Non-Affiliate Warrants*						11,971		22,113
Non-Affiliate Other Investments — 0.4% (8)
Lumithera, Inc. (2)	Medical Device	Royalty Agreement				1,200		1,100
ZetrOZ, Inc. (12)	Medical Device	Royalty Agreement				—		200
*Total Non-Affiliate Other Investments*						1,200		1,300
Non-Affiliate Equity — 0.7% (8)
Castle Creek Biosciences, Inc. (12)	Biotechnology	Common Stock		1,162		250		250
SnagAJob.com, Inc. (12)	Consumer-related Technologies	Common Stock		829,674		8		83
Lumithera, Inc. (2)	Medical Device	Common Stock		392,651		2,000		1,700
Branded Online, Inc. (5)(12)	Software	Common Stock		108,004		1,079		146
Decisyon, Inc. (12)	Software	Preferred and Common Stock		72,638,663		230		—
*Total Non-Affiliate Equity*						3,567		2,179
*Total Non-Affiliate Portfolio Investment Assets*					$	629,216	$	634,624
*Total Portfolio Investment Assets — 206.3% (8)*					$	629,216	$	634,624

Short Term Investments — Unrestricted Investments — 2.5% (8)
US Bank Money Market Deposit Account					$	7,732	$	7,732
*Total Short Term Investments — Unrestricted Investments*					$	7,732	$	7,732

Short Term Investments — Restricted Investments — 0.5% (8)
US Bank Money Market Deposit Account					$	1,617	$	1,617
*Total Short Term Investments — Restricted Investments*					$	1,617	$	1,617


Portfolio Company (1)(3)	*Sector*	*Type of Investment (7)*	*Cash Rate (4)*			*Index*	*Margin*			*Floor*			*Ceiling*		*ETP (10)*			*Maturity Date*	*Principal Amount*		*Cost of Investments (6)(9)*		*Fair Value (9)*
Non-Affiliate Investments — 186.7% (8)
Non-Affiliate Debt Investments — 178.3% (8)
Non-Affiliate Debt Investments — Life Science — 77.3% (8)
Castle Creek Pharmaceuticals Holdings, Inc. (2)(12)	Biotechnology	Term Loan		9.30	%	Libor		7.50	%		9.30	%		-		5.00	%	March 1, 2024	$	5,000	$	4,957	$	4,957
		Term Loan		9.30	%	Libor		7.50	%		9.30	%		-		5.00	%	March 1, 2024		5,000		4,957		4,957
		Term Loan		9.30	%	Libor		7.50	%		9.30	%		-		5.00	%	March 1, 2024		5,000		4,957		4,957
		Term Loan		9.30	%	Libor		7.50	%		9.30	%		-		5.00	%	March 1, 2024		5,000		4,957		4,957
Avalo Therapeutics, Inc. (2)(5)(12)	Biotechnology	Term Loan		9.50	%	Prime		6.25	%		9.50	%		-		3.00	%	January 1, 2025		5,000		4,909		4,909
		Term Loan		9.50	%	Prime		6.25	%		9.50	%		-		3.00	%	January 1, 2025		5,000		4,909		4,909
		Term Loan		9.50	%	Prime		6.25	%		9.50	%		-		3.00	%	January 1, 2025		2,500		2,454		2,454
		Term Loan		9.50	%	Prime		6.25	%		9.50	%		-		3.00	%	February 1, 2025		5,000		4,906		4,906
		Term Loan		9.50	%	Prime		6.25	%		9.50	%		-		3.00	%	February 1, 2025		5,000		4,906		4,906
		Term Loan		9.50	%	Prime		6.25	%		9.50	%		-		3.00	%	April 1, 2025		2,500		2,451		2,451
		Term Loan		9.50	%	Prime		6.25	%		9.50	%		-		3.00	%	April 1, 2025		2,500		2,451		2,451
Emalex Biosciences, Inc. (2)(12)	Biotechnology	Term Loan		9.75	%	Libor		7.90	%		9.75	%		-		5.00	%	June 1, 2024		2,500		2,420		2,420
		Term Loan		9.75	%	Libor		7.90	%		9.75	%		-		5.00	%	June 1, 2024		2,500		2,472		2,472
		Term Loan		9.75	%	Libor		7.90	%		9.75	%		-		5.00	%	November 1, 2025		5,000		4,896		4,896
F-Star Therapeutics, Inc. (2)(5)(12)	Biotechnology	Term Loan		9.50	%	Prime		6.25	%		9.50	%		-		4.00	%	April 1, 2025		2,500		2,465		2,465
		Term Loan		9.50	%	Prime		6.25	%		9.50	%		-		4.00	%	July 1, 2025		2,500		2,463		2,463
Greenlight Biosciences, Inc. (2)(12)	Biotechnology	Term Loan		9.50	%	Prime		6.25	%		9.50	%		-		4.00	%	July 1, 2025		5,000		4,850		4,850
		Term Loan		9.50	%	Prime		6.25	%		9.50	%		-		4.00	%	July 1, 2025		2,500		2,475		2,475
IMV Inc. (2)(5)(12)	Biotechnology	Term Loan		9.00	%	Prime		6.25	%		9.00	%		-		5.00	%	July 1, 2025		5,000		4,799		4,799
		Term Loan		9.00	%	Prime		6.25	%		9.00	%		-		5.00	%	July 1, 2025		2,500		2,462		2,462
LogicBio, Inc. (2)(5)(12)	Biotechnology	Term Loan		8.75	%	Libor		6.25	%		8.75	%		-		4.50	%	June 1, 2024		4,028		4,011		4,011
Provivi, Inc. (2)(12)	Biotechnology	Term Loan		9.50	%	Libor		8.50	%		9.50	%		-		5.50	%	December 1, 2024		5,000		4,935		4,935
		Term Loan		9.50	%	Libor		8.50	%		9.50	%		-		5.50	%	December 1, 2024		5,000		4,935		4,935
		Term Loan		9.50	%	Libor		8.50	%		9.50	%		-		5.50	%	December 1, 2024		2,500		2,440		2,440
		Term Loan		9.50	%	Libor		8.50	%		9.50	%		-		5.50	%	December 1, 2024		2,500		2,440		2,440
		Term Loan		9.50	%	Libor		8.50	%		9.50	%		-		5.50	%	December 1, 2024		2,500		2,430		2,430
		Term Loan		9.50	%	Libor		8.50	%		9.50	%		-		5.50	%	December 1, 2024		2,500		2,430		2,430
Stealth Biotherapeutics Inc. (2)(5)(12)	Biotechnology	Term Loan		8.75	%	Prime		5.50	%		8.75	%		-		6.00	%	October 1, 2025		5,000		4,631		4,631
		Term Loan		8.75	%	Prime		5.50	%		8.75	%		-		6.00	%	October 1, 2025		2,500		2,441		2,441
Canary Medical Inc. (2)(12)	Medical Device	Term Loan		9.00	%	Prime		5.75	%		9.00	%		-		7.00	%	November 1, 2024		2,500		2,394		2,394
Ceribell, Inc. (2)(12)	Medical Device	Term Loan		8.25	%	Libor		6.70	%		8.25	%		-		5.50	%	October 1, 2024		5,000		4,926		4,926
		Term Loan		8.25	%	Libor		6.70	%		8.25	%		-		5.50	%	October 1, 2024		5,000		4,957		4,957
		Term Loan		8.25	%	Libor		6.70	%		8.25	%		-		5.50	%	October 1, 2024		2,500		2,466		2,466
		Term Loan		8.25	%	Libor		6.70	%		8.25	%		-		5.50	%	October 1, 2024		2,500		2,466		2,466
Conventus Orthopaedics, Inc. (2)(12)	Medical Device	Term Loan		9.25	%	Libor		8.00	%		9.25	%		-		10.36	%	July 1, 2025		4,056		4,009		4,009
		Term Loan		9.25	%	Libor		8.00	%		9.25	%		-		10.36	%	July 1, 2025		4,056		4,009		4,009
Corinth Medtech, Inc. (2)(12)	Medical Device	Term Loan		8.50	%	Prime		5.25	%		8.50	%		-		20.00	%	April 1, 2022		2,500		2,495		2,495
		Term Loan		8.50	%	Prime		5.25	%		8.50	%		-		20.00	%	April 1, 2022		2,500		2,495		2,495
CSA Medical, Inc. (2)(12)	Medical Device	Term Loan		10.00	%	Libor		8.20	%		10.00	%		-		5.00	%	January 1, 2024		3,125		3,095		3,095
		Term Loan		10.00	%	Libor		8.20	%		10.00	%		-		5.00	%	January 1, 2024		208		206		206
		Term Loan		10.00	%	Libor		8.20	%		10.00	%		-		5.00	%	March 1, 2024		3,600		3,569		3,569


Portfolio Company (1)(3)	*Sector*	*Type of Investment (7)*	*Cash Rate (4)*			*Index*	*Margin*			*Floor*			*Ceiling*		*ETP (10)*			*Maturity Date*	*Principal Amount*		*Cost of Investments (6)(9)*		*Fair Value (9)*
Embody, Inc. (2)(12)	Medical Device	Term Loan		9.75	%	Prime		6.50	%		9.75	%		-		28.00	%	August 1, 2026		2,500		2,457		2,457
InfoBionic, Inc. (2)(12)	Medical Device	Term Loan		9.50	%	Prime		6.25	%		9.50	%		-		4.00	%	October 1, 2024		3,500		3,397		3,397
		Term Loan		9.50	%	Prime		6.25	%		9.50	%		-		4.00	%	June 1, 2025		1,000		963		963
MacuLogix, Inc. (2)(12)(14)	Medical Device	Term Loan		10.08	%	Libor		7.68	%		10.08	%		-		6.00	%	September 1, 2023		7,500		7,447		4,481
		Term Loan		10.08	%	Libor		7.68	%		10.08	%		-		6.00	%	September 1, 2023		4,050		4,022		2,420
Magnolia Medical Technologies, Inc. (2)(12)	Medical Device	Term Loan		9.75	%	Prime		5.00	%		9.75	%		-		4.00	%	March 1, 2025		5,000		4,952		4,952
		Term Loan		9.75	%	Prime		5.00	%		9.75	%		-		4.00	%	March 1, 2025		5,000		4,952		4,952
		Term Loan		9.75	%	Prime		5.00	%		9.75	%		-		4.00	%	March 1, 2025		5,000		4,944		4,944
		Term Loan		9.75	%	Prime		5.00	%		9.75	%		-		4.00	%	March 1, 2025		5,000		4,944		4,944
Sonex Health, Inc. (2)(12)	Medical Device	Term Loan		9.25	%	Prime		6.00	%		9.25	%		-		5.00	%	June 1, 2024		2,500		2,391		2,391
		Term Loan		9.25	%	Prime		6.00	%		9.25	%		-		5.00	%	June 1, 2024		2,500		2,472		2,472
		Term Loan		9.25	%	Prime		6.00	%		9.25	%		-		5.00	%	June 1, 2024		2,500		2,472		2,472
Spineology, Inc. (2)(12)	Medical Device	Term Loan		10.25	%	Prime		7.00	%		10.25	%		-		1.00	%	October 1, 2025		5,000		4,928		4,928
Total Non-Affiliate Debt Investments — Life Science																						194,237		189,669
Non-Affiliate Debt Investments — Sustainability — 18.8% (8)
LiquiGlide, Inc. (2)(12)	Other Sustainability	Term Loan		9.50	%	Prime		6.25	%		9.50	%		-		5.00	%	January 1, 2025		2,000		1,928		1,928
Nexii Building Solutions, Inc. (2)(12)	Other Sustainability	Term Loan		10.25	%	Prime		7.00	%		10.25	%		-		2.50	%	September 1, 2025		7,500		7,322		7,322
		Term Loan		10.25	%	Prime		7.00	%		10.25	%		-		2.50	%	September 1, 2025		7,500		7,322		7,322
		Term Loan		10.25	%	Prime		7.00	%		10.25	%		-		2.50	%	September 1, 2025		7,500		7,322		7,322
Temperpack Technologies, Inc. (2)(12)	Other Sustainability	Term Loan		10.00	%	Prime		6.75	%		10.00	%		-		2.50	%	June 1, 2025		3,750		3,703		3,703
		Term Loan		10.00	%	Prime		6.75	%		10.00	%		-		2.50	%	June 1, 2025		3,750		3,703		3,703
		Term Loan		10.00	%	Prime		6.75	%		10.00	%		-		2.50	%	October 1, 2025		7,500		7,396		7,396
		Term Loan		10.00	%	Prime		6.75	%		10.00	%		-		2.50	%	October 1, 2025		3,750		3,698		3,698
		Term Loan		10.00	%	Prime		6.75	%		10.00	%		-		2.50	%	October 1, 2025		3,750		3,698		3,698
Total Non-Affiliate Debt Investments — Sustainability																						46,092		46,092
Non-Affiliate Debt Investments — Technology — 77.2% (8)
Axiom Space, Inc. (2)(12)	Communications	Term Loan		9.25	%	Prime		6.00	%		9.25	%		-		2.50	%	June 1, 2026		7,500		7,442		7,442
		Term Loan		9.25	%	Prime		6.00	%		9.25	%		-		2.50	%	June 1, 2026		7,500		7,442		7,442
		Term Loan		9.25	%	Prime		6.00	%		9.25	%		-		2.50	%	June 1, 2026		7,500		7,442		7,442
		Convertible Note		3.00	%													July 1, 2023		250		250		250
Alula Holdings, Inc. (2)(12)	Consumer-related Technologies	Term Loan		10.00	%	Prime		6.75	%		10.00	%		-		3.00	%	January 1, 2025		5,000		4,935		4,935
		Term Loan		10.00	%	Prime		6.75	%		10.00	%		-		3.00	%	January 1, 2025		5,000		4,949		4,949
		Term Loan		10.00	%	Prime		6.75	%		10.00	%		-		3.00	%	January 1, 2025		3,000		2,969		2,969
		Term Loan		10.00	%	Prime		6.75	%		10.00	%		-		3.00	%	December 1, 2025		1,000		968		968
Better Place Forests Co. (2)(12)	Consumer-related Technologies	Term Loan		9.50	%	Prime		6.25	%		9.50	%		-		1.85	%	July 1, 2025		5,000		4,928		4,928
CAMP NYC, Inc. (2)(12)	Consumer-related Technologies	Term Loan		10.50	%	Prime		7.25	%		10.50	%		-		3.00	%	May 1, 2026		3,500		3,430		3,430
Clara Foods Co. (2)(12)	Consumer-related Technologies	Term Loan		9.00	%	Prime		5.75	%		9.00	%		-		5.50	%	August 1, 2025		2,500		2,476		2,476
		Term Loan		9.00	%	Prime		5.75	%		9.00	%		-		5.50	%	August 1, 2025		2,500		2,476		2,476
Interior Define, Inc. (2)(12)	Consumer-related Technologies	Term Loan		9.75	%	Prime		6.50	%		9.75	%		-		4.00	%	January 1, 2026		6,500		6,397		6,397


Portfolio Company (1)(3)	*Sector*	*Type of Investment (7)*	*Cash Rate (4)*			*Index*	*Margin*			*Floor*			*Ceiling*			*ETP (10)*			*Maturity Date*	*Principal Amount*		*Cost of Investments (6)(9)*		*Fair Value (9)*
		Term Loan		9.75	%	Prime		6.50	%		9.75	%		-			4.00	%	January 1, 2026		6,000		5,775		5,775
Lyrical Foods, Inc. (2)(12)	Consumer-related Technologies	Term Loan		10.00	%	Prime		6.75	%		10.00	%		-			9.75	%	January 1, 2024		2,500		2,480		2,480
NextCar Holding Company, Inc. (2)(12)	Consumer-related Technologies	Term Loan		9.00	%	Prime		5.75	%		9.00	%		-			10.10	%	January 1, 2026		5,000		4,935		4,935
		Term Loan		9.00	%	Prime		5.75	%		9.00	%		-			10.10	%	January 1, 2026		2,000		1,920		1,920
Primary Kids, Inc. (2)(12)	Consumer-related Technologies	Term Loan		10.50	%	Prime		7.25	%		10.50	%		-			3.00	%	March 1, 2025		3,000		2,961		2,961
		Term Loan		10.50	%	Prime		7.25	%		10.50	%		-			3.00	%	March 1, 2025		3,000		2,961		2,961
		Term Loan		10.50	%	Prime		7.25	%		10.50	%		-			3.00	%	September 1, 2025		3,000		2,955		2,955
Quip NYC Inc. (2)(12)	Consumer-related Technologies	Term Loan		11.25	%	Prime		8.00	%		11.25	%		-			3.00	%	April 1, 2026		10,000		9,639		9,639
Unagi, Inc. (2)(12)	Consumer-related Technologies	Term Loan		11.00	%	Prime		7.75	%		11.00	%		-			-		July 1, 2025		2,500		2,446		2,446
		Term Loan		11.00	%	Prime		7.75	%		11.00	%		-			-		July 1, 2025		1,250		1,234		1,234
Updater, Inc. (2)(12)	Consumer-related Technologies	Term Loan		12.00	%	Prime		5.75	%		12.00	%		14.00	%		0.56	%	December 20, 2024		5,000		4,961		4,961
		Term Loan		12.00	%	Prime		5.75	%		12.00	%		14.00	%		0.56	%	December 20, 2024		5,000		4,961		4,961
		Term Loan		12.00	%	Prime		5.75	%		12.00	%		14.00	%		0.56	%	December 20, 2024		10,000		9,922		9,922
Liqid, Inc. (2)(12)	Networking	Term Loan		9.50	%	Prime		6.25	%		9.50	%		-			4.00	%	September 1, 2024		5,000		4,770		4,770
		Term Loan		9.50	%	Prime		6.25	%		9.50	%		-			4.00	%	September 1, 2024		5,000		4,924		4,924
		Term Loan		9.50	%	Prime		6.25	%		9.50	%		-			4.00	%	September 1, 2024		2,500		2,459		2,459
		Term Loan		9.50	%	Prime		6.25	%		9.50	%		-			4.00	%	September 1, 2024		2,500		2,459		2,459
		Term Loan		9.50	%	Prime		6.25	%		9.50	%		-			4.00	%	September 1, 2024		2,500		2,414		2,414
Branded Online, Inc. (2)(12)	Software	Term Loan		9.50	%	Prime		6.25	%		9.50	%		-			6.00	%	September 1, 2026		5,000		4,719		4,719
		Term Loan		9.50	%	Prime		6.25	%		9.50	%		-			6.00	%	November 1, 2026		2,500		2,355		2,355
		Term Loan		9.50	%	Prime		6.25	%		9.50	%		-			-		July 1, 2023		5,000		5,000		5,000
BriteCore Holdings, Inc. (2)(12)	Software	Term Loan		10.50	%	Prime		7.25	%		10.50	%		-			4.00	%	October 1, 2024		2,500		2,481		2,481
		Term Loan		10.50	%	Prime		7.25	%		10.50	%		-			4.00	%	October 1, 2024		2,500		2,481		2,481
Decisyon, Inc. (12)	Software	Term Loan		12.68	%	Prime		9.23	%		12.68	%		-			50.43	%	January 1, 2023		3,470		3,470		3,470
Dropoff, Inc. (2)(12)	Software	Term Loan		9.75	%	Prime		6.50	%		9.75	%		-			3.50	%	April 1, 2026		6,500		6,087		6,087
		Term Loan		9.75	%	Prime		6.50	%		9.75	%		-			3.50	%	April 1, 2026		6,000		5,816		5,816
E La Carte, Inc. (2)(12)	Software	Term Loan		9.75	%	Prime		6.50	%		9.75	%		-			4.00	%	October 1, 2025		3,000		2,937		2,937
		Term Loan		9.75	%	Prime		6.50	%		9.75	%		-			4.00	%	October 1, 2025		3,000		2,958		2,958
		Term Loan		9.75	%	Prime		6.50	%		9.75	%		-			4.00	%	October 1, 2025		1,500		1,479		1,479
Lytics, Inc. (2)(12)	Software	Term Loan		9.25	%	Prime		6.00	%		9.25	%		-			4.00	%	July 1, 2025		2,500		2,464		2,464
Reputation Institute, Inc. (2)(12)	Software	Term Loan		10.50	%	Prime		7.25	%		10.50	%		-			3.00	%	August 1, 2025		5,000		4,905		4,905
Supply Network Visiblity Holdings LLC (2)(12)	Software	Term Loan		9.75	%	Prime		6.50	%		9.75	%		-			4.00	%	February 1, 2025		3,500		3,458		3,458
		Term Loan		9.75	%	Prime		6.50	%		9.75	%		-			4.00	%	February 1, 2025		3,500		3,458		3,458
		Term Loan		9.75	%	Prime		6.50	%		9.75	%		-			4.00	%	December 1, 2025		2,500		2,463		2,463
		Term Loan		9.75	%	Prime		6.50	%		9.75	%		-			4.00	%	December 1, 2025		2,500		2,463		2,463
Total Non-Affiliate Debt Investments — Technology																							189,274		189,274
Non-Affiliate Debt Investments — Healthcare information and services — 5.0% (8)
IDbyDNA, Inc. (2)(12)	Diagnostics	Term Loan		9.00	%	Prime		5.75	%		9.00	%		-			5.50	%	January 1, 2025		5,000		4,902		4,902
		Term Loan		9.00	%	Prime		5.75	%		9.00	%		-			5.50	%	January 1, 2025		5,000		4,936		4,936
		Term Loan		9.00	%	Prime		5.75	%		9.00	%		-			5.50	%	January 1, 2026		2,500		2,444		2,444
Total Non-Affiliate Debt Investments — Healthcare information and services																							12,282		12,282
*Total Non- Affiliate Debt Investments*																							441,885		437,317

					Cost of		Fair
Portfolio Company (1)(3)	Sector	Type of Investment (7)	Number of Shares		Investments (6)(9)		Value (9)
Non-Affiliate Warrant Investments — 8.2% (8)
Non-Affiliate Warrants — Life Science — 1.0% (8)
Avalo Therapeutics, Inc. (2)(5)(12)	Biotechnology	Common Stock Warrant		317,306		311		27
Castle Creek Pharmaceuticals, Inc. (2)(12)	Biotechnology	Preferred Stock Warrant		2,428		142		148
Celsion Corporation (2)(5)(12)	Biotechnology	Common Stock Warrant		295,053		65		1
Corvium, Inc. (2)(12)	Biotechnology	Preferred Stock Warrant		661,956		54		—
Emalex Biosciences, Inc. (2)(12)	Biotechnology	Preferred Stock Warrant		92,002		139		162
F-Star Therapeutics, Inc. (2)(5)(12)	Biotechnology	Common Stock Warrant		21,120		36		3
IMV Inc. (2)(5)(12)	Biotechnology	Common Stock Warrant		284,090		64		64
LogicBio, Inc. (2)(5)(12)	Biotechnology	Common Stock Warrant		7,843		8		—
Mustang Bio, Inc. (2)(5)(12)	Biotechnology	Common Stock Warrant		252,161		146		5
Provivi, Inc. (2)(12)	Biotechnology	Preferred Stock Warrant		164,608		278		519
Rocket Pharmaceuticals Corporation (5)(12)	Biotechnology	Common Stock Warrant		7,051		17		9
Stealth Biotherapeutics Inc. (2)(5)(12)	Biotechnology	Common Stock Warrant		795,455		264		45
Strongbridge U.S. Inc. (2)(5)(12)	Biotechnology	Common Stock Warrant		160,714		72		110
vTv Therapeutics Inc. (2)(5)(12)	Biotechnology	Common Stock Warrant		95,293		44		—
AccuVein Inc. (2)(12)	Medical Device	Common Stock Warrant		1,175		24		—
Aerin Medical, Inc. (2)(12)	Medical Device	Preferred Stock Warrant		1,818,183		66		463
Canary Medical Inc. (2)(12)	Medical Device	Preferred Stock Warrant		7,292		53		45
Ceribell, Inc. (2)(12)	Medical Device	Preferred Stock Warrant		134,299		61		172
Conventus Orthopaedics, Inc. (2)(12)	Medical Device	Preferred Stock Warrant		6,361,111		149		169
CSA Medical, Inc. (2)(12)	Medical Device	Preferred Stock Warrant		1,375,727		154		108
CVRx, Inc. (2)(5)(12)	Medical Device	Common Stock Warrant		47,410		80		90
Infobionic, Inc. (2)(12)	Medical Device	Preferred Stock Warrant		317,647		124		121
MacuLogix, Inc. (2)(12)	Medical Device	Preferred Stock Warrant		454,460		238		—
Magnolia Medical Technologies, Inc. (2)(12)	Medical Device	Preferred Stock Warrant		441,780		91		112
Meditrina, Inc. (2)(12)	Medical Device	Preferred Stock Warrant		221,510		83		122
Sonex Health, Inc. (2)(12)	Medical Device	Preferred Stock Warrant		484,250		77		75
VERO Biotech LLC (2)(12)	Medical Device	Preferred Stock Warrant		408		53		30
Total Non-Affiliate Warrants — Life Science						2,893		2,600
Non-Affiliate Warrants — Sustainability — 0.4% (8)
LiquiGlide, Inc. (2)(12)	Other Sustainability	Common Stock Warrant		61,359		39		36
Nexii Building Solutions, Inc. (2)(12)	Other Sustainability	Common Stock Warrant		142,405		356		331
Temperpack Technologies, Inc. (2)(12)	Other Sustainability	Preferred Stock Warrant		48,756		107		552
Total Non-Affiliate Warrants — Sustainability						502		919

					Cost of		Fair
Portfolio Company (1)(3)	Sector	Type of Investment (7)	Number of Shares		Investments (6)(9)		Value (9)
Non-Affiliate Warrants — Technology — 6.2% (8)
Axiom Space, Inc. (2)(12)	Communications	Common Stock Warrant		1,991		45		42
Intelepeer Holdings, Inc. (2)(12)	Communications	Preferred Stock Warrant		2,936,535		140		3,141
PebblePost, Inc. (2)(12)	Communications	Preferred Stock Warrant		598,850		92		161
Alula Holdings, Inc. (2)(12)	Consumer-related Technologies	Preferred Stock Warrant		20,000		93		70
Aterian, Inc. (2)(5)(12)	Consumer-related Technologies	Common Stock Warrant		76,923		195		1
Better Place Forests Co. (2)(12)	Consumer-related Technologies	Preferred Stock Warrant		9,353		23		23
Caastle, Inc. (2)(12)	Consumer-related Technologies	Preferred Stock Warrant		268,591		68		823
CAMP NYC, Inc. (2)(12)	Consumer-related Technologies	Preferred Stock Warrant		17,605		22		22
Clara Foods Co. (2)(12)	Consumer-related Technologies	Preferred Stock Warrant		46,745		30		368
Getaround, Inc. (2)(12)	Consumer-related Technologies	Preferred Stock Warrant		651,040		450		367
Interior Define, Inc. (2)(12)	Consumer-related Technologies	Preferred Stock Warrant		553,710		103		103
NextCar Holding Company, Inc. (2)(12)	Consumer-related Technologies	Preferred Stock Warrant		310,463		47		47
Primary Kids, Inc. (2)(12)	Consumer-related Technologies	Preferred Stock Warrant		553,778		57		51
Quip NYC Inc. (2)(12)	Consumer-related Technologies	Preferred Stock Warrant		6,191		324		503
Unagi, Inc. (2)(12)	Consumer-related Technologies	Preferred Stock Warrant		134,421		25		24
Updater, Inc. (2)(12)	Consumer-related Technologies	Common Stock Warrant		108,333		34		31
CPG Beyond, Inc. (2)(12)	Data Storage	Preferred Stock Warrant		500,000		242		859
Silk, Inc. (2)(12)	Data Storage	Preferred and Common Stock Warrant		44,211,003		234		188
Global Worldwide LLC (2)(12)	Internet and Media	Preferred Stock Warrant		245,810		75		6
Rocket Lawyer Incorporated (2)(12)	Internet and Media	Preferred Stock Warrant		261,721		92		741
Skillshare, Inc. (2)(12)	Internet and Media	Preferred Stock Warrant		139,074		162		2,403
Liqid, Inc. (2)(12)	Networking	Preferred Stock Warrant		344,102		364		938
Kinestral, Inc. (2)(12)	Power Management	Preferred Stock Warrant		5,002,574		1,585		2,609
Avalanche Technology, Inc. (2)(12)	Semiconductors	Preferred and Common Stock Warrant		6,753		101		—
Branded Online, Inc. (2)(12)	Software	Common Stock Warrant		16,678		370		443
BriteCore Holdings, Inc. (2)(12)	Software	Preferred Stock Warrant		55,591		5		37
Decisyon, Inc. (12)	Software	Common Stock Warrant		82,967		46		—
Dropoff, Inc. (2)(12)	Software	Common Stock Warrant		482,283		397		395
E La Carte, Inc. (2)(12)	Software	Preferred Stock Warrant		181,947		61		53
Lotame Solutions, Inc. (2)(12)	Software	Preferred Stock Warrant		288,115		23		276
Lytics, Inc. (2)(12)	Software	Preferred Stock Warrant		26,733		12		12
Reputation Institute, Inc. (2)(12)	Software	Preferred Stock Warrant		3,731		54		52
Revinate Holdings, Inc. (2)(12)	Software	Preferred Stock Warrant		615,475		44		66
Riv Data Corp. (2)(12)	Software	Preferred Stock Warrant		321,428		12		292
SIGNiX, Inc. (12)	Software	Preferred Stock Warrant		186,235		224		—
Skyword, Inc. (12)	Software	Preferred and Common Stock Warrant		301,055		49		4
Supply Network Visiblity Holdings LLC (2)(12)	Software	Preferred Stock Warrant		682		64		62
Topia Mobility, Inc. (2)(12)	Software	Preferred Stock Warrant		3,049,607		138		—
xAd, Inc. (2)(12)	Software	Preferred Stock Warrant		4,343,348		179		1
Total Non-Affiliate Warrants — Technology						6,281		15,214
Non-Affiliate Warrants — Healthcare information and services — 0.6% (8)
IDbyDNA, Inc. (2)(12)	Diagnostics	Preferred Stock Warrant		472,006		112		95
Kate Farms, Inc. (2)(12)	Other Healthcare	Preferred Stock Warrant		82,965		101		1,177
Watermark Medical, Inc. (2)(12)	Other Healthcare	Preferred Stock Warrant		27,373		74		—
Medsphere Systems Corporation (2)(12)	Software	Preferred Stock Warrant		7,097,792		60		195
Total Non-Affiliate Warrants — Healthcare information and services						347		1,467
*Total Non-Affiliate Warrants*						10,023		20,200
Non-Affiliate Other Investments — 0.1% (8)
ZetrOZ, Inc. (12)	Medical Device	Royalty Agreement				—		200
*Total Non-Affiliate Other Investments*						—		200
Non-Affiliate Equity — 0.1% (8)
SnagAJob.com, Inc. (12)	Consumer-related Technologies	Common Stock		82,974		9		83
Zeta Global Holdings Corp. (2)(5)(12)	Internet and Media	Common Stock		18,405		240		155
Decisyon, Inc. (12)	Software	Preferred and Common Stock		72,638,663		230		120
*Total Non-Affiliate Equity*						479		358
*Total Non-Affiliate Portfolio Investment Assets*					$	452,387	$	458,075
Controlled Affiliate Investments — 0.0% (8)
Controlled Affiliate Other Investments — Biotechnology — 0.0% (8)
HESP LLC (12)(13)	Biotechnology	Other Investment			$	1,450	$	—
*Total Controlled Affiliate Other Investments*						1,450		—
*Total Controlled Affiliate Portfolio Investment Assets*					$	1,450	$	—
Total Portfolio Investment Assets — 186.7% (8)					$	453,837	$	458,075

Short Term Investments — Unrestricted Investments — 3.2% (8)
US Bank Money Market Deposit Account					$	7,868	$	7,868
Total Short Term Investments — Unrestricted Investments					$	7,868	$	7,868

Short Term Investments — Restricted Investments — 0.6% (8)
US Bank Money Market Deposit Account					$	1,359	$	1,359
Total Short Term Investments — Restricted Investments					$	1,359	$	1,359

Note 4 - Investments (Tables)

9 Months Ended

Sep. 30, 2022

Notes Tables

Investment Holdings, Schedule of Investments [Table Text Block]

	*September 30, 2022*				*December 31, 2021*
	*Cost*		*Fair Value*		*Cost*		*Fair Value*
	(In thousands)
Investments
Debt	$	612,478	$	609,032	$	441,885	$	437,317
Warrants		11,971		22,113		10,023		20,200
Other		1,200		1,300		1,450		200
Equity		3,567		2,179		479		358
Total investments	$	629,216	$	634,624	$	453,837	$	458,075

	*September 30, 2022*				*December 31, 2021*
	*Cost*		*Fair Value*		*Cost*		*Fair Value*
	(In thousands)
Life Science
Biotechnology	$	148,952	$	147,442	$	109,899	$	107,902
Medical Device		114,364		116,967		88,681		84,567
Technology
Communications		22,883		26,070		22,853		25,920
Consumer-Related		109,906		108,301		92,158		93,194
Data Storage		476		1,211		476		1,047
Internet and Media		329		1,299		569		3,305
Networking		13,551		13,413		17,390		17,964
Power Management		1,585		2,254		1,585		2,609
Semiconductors		56		—		101		—
Software		108,910		107,441		60,902		60,807
Sustainability
Other Sustainability		77,024		77,700		46,595		47,011
Healthcare Information and Services
Diagnostics		9,840		9,844		12,393		12,377
Other		7,621		8,682		175		1,177
Software		13,719		14,000		60		195
Total investments	$	629,216	$	634,624	$	453,837	$	458,075

Note 5 - Transactions With Affiliated Companies (Tables)

9 Months Ended

Sep. 30, 2022

Notes Tables

Investments in and Advances to Affiliates [Table Text Block]

					Year ended December 31, 2021
	*Fair value at*							*Transfers*					*Net*						*Fair value at*
Portfolio	*December 31,*				*Principal*			*in/(out) at*			*Discount*		*unrealized*			*Net realized*			*December 31,*		*Interest*
Company	*2020*		*Purchases*		*Payments*			*fair value*			*accretion*		*gain/(loss)*			*gain/(loss)*			*2021*		*income*
	(In thousands)
Decisyon, Inc. (1)	$	1,181	$	—	$	—		$	(1,181	)	$	—	$	—		$	—		$	—	$	41
		626		—		—			(638	)		12		—			—			—		21
		227		—		—			(227	)		—		—			—			—		7
		228		—		—			(228	)		—		—			—			—		7
		685		—		—			(685	)		—		—			—			—		22
		276		—		—			(276	)		—		—			—			—		9
		183		—		—			(183	)		—		—			—			—		6
		120		—		—			(120	)		—		—			—			—		—
MVI (ABC) LLC fka StereoVision, Inc.		2,382		—		(2,783	)		—			—		—			401			—		139
		—		250		(250	)		—			—		—			—			—		—
		—		70		(70	)		—			—		—			—			—		—
		—		330		(330	)		—			—		—						—		—
		—		150		(150	)		—			—		—			—			—		—
		1,639		—		—			—			—		(848	)		(791	)		—		—
Total non-controlled affiliates	$	7,547	$	800	$	(3,583	)	$	(3,538	)	$	12	$	(848	)	$	(390	)	$	—	$	252

					*Nine months ended September 30, 2022*

	*Fair value at*							*Transfers*				*Net*					*Fair value at*
Portfolio	*December 31,*							*in/(out) at*		*Dividends*		*unrealized*		*Net realized*			*September 30,*		*Dividend*
Company	*2021*		*Purchases*		*Sales*			*fair value*		*declared*		*gain/(loss)*		*gain/(loss)*			*2021*		*income*
	(In thousands)
HESP LLC		—		—		(300	)		—		—		1,450		(1,150	)		—		—
Total controlled affiliates	$	—	$	—	$	(300	)	$	—	$	—	$	1,450	$	(1,150	)	$	—	$	—

					Year ended December 31, 2021

	*Fair value at*							*Transfers*				*Net*					*Fair value at*
Portfolio	*December 31,*							*in/(out) at*		*Dividends*		*unrealized*			*Net realized*		*December 31,*		*Dividend*
Company	*2020*		*Purchases*		*Sales*			*fair value*		*declared*		*gain/(loss)*			*gain/(loss)*		*2021*		*income*
	(In thousands)
HESP LLC		1,500		—		(50	)		—		—		(1,450	)		—		—		—
Total controlled affiliates	$	1,500	$	—	$	(50	)	$	—	$	—	$	(1,450	)	$	—	$	—	$	—

Note 6 - Fair Value (Tables)

9 Months Ended

Sep. 30, 2022

Notes Tables

Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]

*September 30, 2022*
	*Fair*		*Valuation Techniques/*	*Unobservable*		*Weighted*
Investment Type	*Value*		*Methodologies*	*Input*	*Range*	*Average(1)*
			(Dollars in thousands, except per share data)
Debt investments	$	605,719	Discounted Expected Future Cash Flows	Hypothetical Market Yield	3% – 25%		14	%

		3,313	Multiple Probability Weighted Cash Flow Model	Probability Weighting	25%		25	%

Warrant investments		21,894	Black-Scholes Valuation Model	Price Per Share	0.000 –1,89999	$	64.53
				Average Industry Volatility	25%		25	%
				Marketability Discount	20%		20	%
				Estimated Time to Exit (in years)	1 to 4		2

Other investments		1,300	Multiple Probability Weighted Cash Flow Model	Discount Rate	25%		25	%
				Probability Weighting	100%		100	%

Equity investments		2,033	Last Equity Financing	Price Per Share	1.000 –215.0303	$	30.09

Total Level 3 investments	$	634,259

December 31, 2021
	Fair		Valuation Techniques/	Unobservable		Weighted
Investment Type	Value		Methodologies	Input	Range	Average⁽¹⁾
			(Dollars in thousands, except per share data)
Debt investments	$	430,417	Discounted Expected Future Cash Flows	Hypothetical Market Yield	3% –23%		12	%

		6,900	Multiple Probability Weighted Cash Flow Model	Probability Weighting	20% - 50%		33	%

Warrant investments		19,837	Black-Scholes Valuation Model	Price Per Share	0.000 –980.0000	$	20.35
				Average Industry Volatility	25%		25	%
				Marketability Discount	20%		20	%
				Estimated Time to Exit (in years)	1 to 4		2

Other investments		200	Multiple Probability Weighted Cash Flow Model	Discount Rate	25%		25	%
				Probability Weighting	0% –100%		100	%

Equity investments		203	Last Equity Financing	Price Per Share	0.000 –1.0000	$	0.41

Total Level 3 investments	$	457,557

Fair Value, Assets Measured on Recurring Basis [Table Text Block]

	*September 30, 2022*
	*Level 1*		*Level 2*		*Level 3*		*Total*
	(In thousands)
Investments in money market funds	$	—	$	7,732	$	—	$	7,732
Restricted investments in money market funds	$	—	$	1,617	$	—	$	1,617
Debt investments	$	—	$	—	$	609,032	$	609,032
Warrant investments		—		219		21,894		22,113
Other investments		—		—		1,300		1,300
Equity investments		146		—		2,033		2,179
Total investments	$	146	$	219	$	634,259	$	634,624

	December 31, 2021
	Level 1		Level 2		Level 3		Total
	(In thousands)
Investments in money market funds	$	—	$	7,868	$	—	$	7,868
Restricted investments in money market funds	$	—	$	1,359	$	—	$	1,359
Debt investments	$	—	$	—	$	437,317	$	437,317
Warrant investments		—		363		19,837		20,200
Other investments		—		—		200		200
Equity investments		155		—		203		358
Total investments	$	155	$	363	$	457,557	$	458,075

Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]

	*Three months ended September 30, 2022*
	*Debt*			*Warrant*			*Equity*			*Other*
	*Investments*			*Investments*			*Investments*			*Investments*			*Total*
	(In thousands)
Level 3 assets, beginning of period	$	551,560		$	25,167		$	453		$	200		$	577,380
Purchase of investments		94,627			—			—			—			94,627
Warrants and equity received and classified as Level 3		—			964			—			—			964
Principal payments received on investments		(26,929	)		—			—			(31	)		(26,960	)
Proceeds from sale of investments		(6,088	)		(38	)		—			—			(6,126	)
Net realized (loss) gain on investments		(8,492	)		266			—			31			(8,195	)
Unrealized appreciation (depreciation) included in earnings		8,095			(3,348	)		(420	)		(100	)		4,227
Transfer out of Level 3		—			(1,117	)		—						(1,117	)
Transfer out of debt investments		(3,200	)		—			2,000			1,200			—
Other		(541	)		—			—			—			(541	)
Level 3 assets, end of period	$	609,032		$	21,894		$	2,033		$	1,300		$	634,259

	*Three months ended September 30, 2021*
	*Debt*			*Warrant*			*Equity*		*Other*
	*Investments*			*Investments*			*Investments*		*Investments*			*Total*
	(In thousands)
Level 3 assets, beginning of period	$	385,814		$	15,102		$	237	$	1,700		$	402,853
Purchase of investments		98,592			—			—		—			98,592
Warrants and equity received and classified as Level 3		—			1,394			—		—			1,394
Principal payments received on investments		(53,588	)		—			—		—			(53,588	)
Proceeds from sale of investments		(34	)		(1,519	)		—		—			(1,553	)
Net realized (loss) gain on investments		(40	)		1,384			—		—			1,344
Unrealized appreciation (depreciation) included in earnings		798			3,353			149		(375	)		3,925
Other		(1,606	)		—			—		—			(1,606	)
Level 3 assets, end of period	$	429,936		$	19,714		$	386	$	1,325		$	451,361

	*Nine months ended September 30, 2022*
	*Debt*			*Warrant*			*Equity*			*Other*
	*Investments*			*Investments*			*Investments*			*Investments*			*Total*
	(In thousands)
Level 3 assets, beginning of period	$	437,317		$	19,837		$	203		$	200		$	457,557
Purchase of investments		348,097			—			250			—			348,347
Warrants and equity received and classified as Level 3		—			2,441			—			—			2,441
Principal payments received on investments		(114,120	)		—			—			(313	)		(114,433	)
Proceeds from sale of investments		(49,088	)		(464	)		—			—			(49,552	)
Net realized (loss) gain on investments		(8,492	)		535			—			(1,137	)		(9,094	)
Unrealized appreciation (depreciation) included in earnings		1,128			662			(420	)		1,350			2,720
Transfer out of Level 3		—			(1,117	)		—						(1,117	)
Transfer out of debt investments		(3,200	)		—			2,000			1,200			—
Other		(2,610	)		—			—			—			(2,610	)
Level 3 assets, end of period	$	609,032		$	21,894		$	2,033		$	1,300		$	634,259

	*Nine months ended September 30, 2021*
	*Debt*			*Warrant*			*Equity*			*Other*
	*Investments*			*Investments*			*Investments*			*Investments*			*Total*
	(In thousands)
Level 3 assets, beginning of period	$	333,495		$	12,736		$	2,117		$	1,700		$	350,048
Purchase of investments		217,252			—			—			—			217,252
Warrants and equity received and classified as Level 3		—			2,313			—			—			2,313
Principal payments received on investments		(119,260	)		—			—			—			(119,260	)
Proceeds from sale of investments		(135	)		(3,159	)		—			(13	)		(3,307	)
Net realized (loss) gain on investments		(5,035	)		2,566			—			—			(2,469	)
Unrealized appreciation (depreciation) included in earnings		5,609			5,329			(1,682	)		(362	)		8,894
Transfer out of Level 3		—			(71	)		(49	)		—			(120	)
Other		(1,990	)		—			—			—			(1,990	)
Level 3 assets, end of period	$	429,936		$	19,714		$	386		$	1,325		$	451,361

Note 7 - Borrowings (Tables)

9 Months Ended

Sep. 30, 2022

Notes Tables

Schedule of Debt [Table Text Block]

	*September 30, 2022*							*December 31, 2021*
	*Total*		*Balance*			*Unused*		*Total*		*Balance*			*Unused*
	*Commitment*		*Outstanding*			*Commitment*		*Commitment*		*Outstanding*			*Commitment*
	(In thousands)
Key Facility	$	125,000	$	67,500		$	57,500	$	125,000	$	53,500		$	71,500
NYL Facility		200,000		136,750			63,250		100,000		78,750			21,250
Asset-Backed Notes		43,461		43,461			—		70,500		70,500			—
2027 Notes		57,500		57,500			—		—		—			—
2026 Notes		57,500		57,500			—		57,500		57,500			—
Total before debt issuance costs		483,461		362,711			120,750		353,000		260,250			92,750
Unamortized debt issuance costs attributable to term borrowings		—		(3,700	)		—		—		(2,637	)		—
Total borrowings outstanding, net	$	483,461	$	359,011		$	120,750	$	353,000	$	257,613		$	92,750

Note 8 - Financial Instruments With Off-balance-sheet Risk (Tables)

9 Months Ended

Sep. 30, 2022

Notes Tables

Schedule of Fair Value, off-Balance-Sheet Risks [Table Text Block]

	September 30, 2022
			Fair Value of
			Unfunded
	*Principal*		*Commitment*
	*Balance*		*Liability*
	(In thousands)
Better Place Forests Co.	$	5,000	$	6
BrightInsight, Inc.		21,000		278
Britecore Holdings, Inc.		5,000		66
Canary Medical Inc.		2,500		34
Castle Creek Biosciences		4,000		72
Ceribell, Inc.		2,500		4
Divergent Technologies, Inc.		30,000		315
DropOff, Inc.		7,500		188
Embody, Inc.		2,000		20
Engage3, LLC		8,000		40
Hound Labs, Inc.		7,500		87
Interior Define, Inc.		5,000		65
KSQ Therapeutics, Inc.		10,000		100
Lytics, Inc.		1,250		—
Magnolia Medical Technologies, Inc.		10,000		122
Native Microbials, Inc.		8,750		64
Optoro, Inc.		15,000		38
PDS Biotechnology Corporation		10,000		158
Scientia Vascular, Inc.		10,000		110
Slingshot Aerospace, Inc.		5,000		64
Soli, Inc.		7,500		147
Sonex Health, Inc.		2,500		45
Swift Health Systems Inc.		25,500		105
Temperpack Technologies, Inc.		9,000		19
Total	$	214,500	$	2,147

Note 10 - Distributions (Tables)

9 Months Ended

Sep. 30, 2022

Notes Tables

Dividends Declared [Table Text Block]

							*DRIP*		*DRIP*
Date			*Amount*		*Cash*		*Shares*		*Share*
Declared	*Record Date*	*Payment Date*	*Per Share*		*Distribution*		*Issued*		*Value*
			(In thousands, except share and per share data)
Nine Months Ended September 30, 2022
7/29/2022	11/17/22	12/15/22	$	0.10	$	—		—	$	—
7/29/2022	10/18/22	11/15/22		0.10		—		—		—
7/29/2022	9/19/22	10/14/22		0.10		2,558		7,703		81
4/29/2022	8/18/22	9/15/22		0.10		2,528		4,925		60
4/29/2022	7/19/22	8/16/22		0.10		2,484		3,939		55
4/29/2022	6/17/22	7/15/22		0.10		2,434		4,286		51
2/25/2022	5/18/22	6/15/22		0.10		2,378		4,428		50
2/25/2022	4/19/22	5/16/22		0.10		2,349		4,088		49
2/25/2022	3/18/22	4/14/22		0.10		2,352		3,221		46
			$	0.90	$	17,083		32,590	$	392
Year Ended December 31, 2021
10/22/21	2/18/22	3/16/22	$	0.10	$	2,100		3,409	$	46
10/22/21	1/19/22	2/16/22		0.10		2,096		2,680		43
10/22/21	12/17/21	1/14/22		0.10		2,031		3,417		56
10/22/21	11/18/21	12/15/21		0.05		1,013		1,197		20
7/23/21	11/18/21	12/15/21		0.10		2,027		2,395		38
7/23/21	10/19/21	11/16/21		0.10		2,010		1,907		34
7/23/21	9/17/21	10/15/21		0.10		2,008		2,068		36
4/23/21	8/18/21	9/15/21		0.10		1,996		2,041		34
4/23/21	7/20/21	8/16/21		0.10		1,983		1,937		34
4/23/21	6/17/21	7/16/21		0.10		1,964		1,888		33
2/26/21	5/18/21	6/15/21		0.10		1,964		1,671		29
2/26/21	4/20/21	5/14/21		0.10		1,937		1,794		29
2/26/21	3/18/21	4/16/21		0.10		1,938		1,653		28
			$	1.25	$	25,067		28,057	$	460

Ex-Dividend Date	*Record Date*	*Payment Date*	*Distributions Declared*
December 16, 2022	December 19, 2022	January 13, 2023	$	0.11
January 17, 2023	January 18, 2023	February 15, 2023	$	0.11
February 16, 2023	February 17, 2023	March 15, 2023	$	0.11

Ex-Dividend Date	Record Date	Payment Date		Distributions Declared
November 16, 2022	November 17, 2022	December 15, 2022		$	0.05

Note 11 - Financial Highlights (Tables)

9 Months Ended

Sep. 30, 2022

Notes Tables

Investment Company, Financial Highlights [Table Text Block]

	Nine months ended September 30,
	2022			2021
	(In thousands, except share and per share data)
Per share data:
Net asset value at beginning of period	$	11.56		$	11.02
Net investment income		1.06			1.02
Realized loss		(0.40	)		(0.14	)
Unrealized appreciation on investments		0.05			0.41
Net increase in net assets resulting from operations		0.71			1.29
Distributions declared ⁽¹⁾		(0.90	)		(0.90	)
From net investment income		(0.90	)		(0.90	)
From net realized gain on investments		—			—
Return of capital		—			—
Other ⁽²⁾		0.29			0.22
Net asset value at end of period	$	11.66		$	11.63
Per share market value, beginning of period	$	15.92		$	13.24
Per share market value, end of period	$	10.01		$	16.26
Total return based on a market value ⁽³⁾		(31.5	)%		29.6	%
Shares outstanding at end of period		26,393,773			20,425,175
Ratios to average net assets:
Expenses without incentive value ⁽⁴⁾		11.4	%		10.6	%
Incentive fees ⁽⁴⁾		3.0	%		3.0	%
Net expenses ⁽⁴⁾		14.4	%		13.6	%
Net investment income with incentive fees ⁽⁴⁾		12.1	%		12.1	%
Net assets at the end of the period	$	307,687		$	237,590
Average net asset value	$	280,904		$	223,031
Average debt per share	$	13.32		$	11.07
Portfolio turnover ratio ⁽⁵⁾		14.9	%		29.0	%

Consolidated Schedule of Investments (Unaudited) (Details Textual) - USD ($) $ in Thousands	Oct. 22, 2022	Sep. 30, 2022	Dec. 31, 2021	Aug. 13, 2019
Debt Instrument, Face Amount		$ 483,461	$ 353,000
Percentage of Nonqualifying Assets on a Cost Basis		7.40%	5.80%
Percentage of Nonqualifying Assets on a Fair Value Basis		7.30%	5.80%
Assets of Espero [Member]
Asset Acquisition, Consideration Transferred, Total	$ 7,000
Asset-Backed Notes [Member]
Debt Instrument, Face Amount		$ 43,461	$ 70,500	$ 160,000
Asset-Backed Notes [Member] \| Affiliated Entity [Member]
Debt Instrument, Face Amount				$ 100,000

Consolidated Schedule of Investments (Unaudited) - Investments (Details) - USD ($) $ in Thousands	9 Months Ended	12 Months Ended
	Sep. 30, 2022	Dec. 31, 2021
Investments at cost	$ 629,216	$ 453,837
Investments at fair value	634,624	458,075
Non-affiliate [Member]
Investments at cost	629,216	452,387
Investments at fair value	634,624	458,075
Controlled Affiliate [Member]
Investments at cost		1,450
Investments at fair value		0
Debt Securities [Member] \| Non-affiliate [Member]
Investments at cost	612,478
Investments at fair value	609,032
Warrant [Member] \| Non-affiliate [Member]
Investments at cost	11,971	10,023
Investments at fair value	22,113	20,200
Other Long-Term Investments [Member] \| Non-affiliate [Member]
Investments at cost	1,200	0
Investments at fair value	1,300	200
Other Long-Term Investments [Member] \| Controlled Affiliate [Member]
Investments at cost		1,450
Investments at fair value		0
Debt Investments [Member] \| Non-affiliate [Member]
Investments at cost		441,885
Investments at fair value		437,317
Preferred and Common Stock [Member] \| Non-affiliate [Member]
Investments at cost		479
Investments at fair value		358
Equity Securities [Member] \| Non-affiliate [Member]
Investments at cost	3,567
Investments at fair value	2,179
Money Market Funds, Unrestricted Investment [Member]
Investments at cost	7,732	7,868
Investments at fair value	7,732	7,868
Unrestricted Short Term Investments [Member]
Investments at cost	7,732	7,868
Investments at fair value	7,732	7,868
Money Market Funds, Restricted Investments [Member]
Investments at cost	1,617	1,359
Investments at fair value	1,617	1,359
Restricted Short Term Investments [Member]
Investments at cost	1,617	1,359
Investments at fair value	1,617	1,359
Biotechnology Sector [Member]
Investments at cost	148,952	109,899
Investments at fair value	147,442	107,902
Biotechnology Sector [Member] \| Common Stock Warrants [Member] \| Avalo Therapeutics, Inc. [Member]
Investments at cost	311	311
Investments at fair value	$ 0	$ 27
Number of Shares (in shares)	26,442	317,306
Biotechnology Sector [Member] \| Common Stock Warrants [Member] \| Stealth BioTherapeutics Inc. [Member]
Investments at cost	$ 264	$ 264
Investments at fair value	$ 0	$ 45
Number of Shares (in shares)	795,455	795,455
Biotechnology Sector [Member] \| Common Stock Warrants [Member] \| Celsion Corporation [Member]
Investments at cost		$ 65
Investments at fair value		$ 1
Number of Shares (in shares)		295,053
Biotechnology Sector [Member] \| Common Stock Warrants [Member] \| F-Star Therapeutics, Inc [Member]
Investments at cost	$ 35	$ 36
Investments at fair value	$ 0	$ 3
Number of Shares (in shares)	21,120	21,120
Biotechnology Sector [Member] \| Common Stock Warrants [Member] \| IMV Inc [Member]
Investments at cost	$ 67	$ 64
Investments at fair value	$ 4	$ 64
Number of Shares (in shares)	397,726	284,090
Biotechnology Sector [Member] \| Common Stock Warrants [Member] \| Greenlight Biosciences, Inc [Member]
Investments at cost	$ 366
Investments at fair value	$ 5
Number of Shares (in shares)	71,292
Biotechnology Sector [Member] \| Common Stock Warrants [Member] \| LogicBio, Inc [Member]
Investments at cost	$ 8	$ 8
Investments at fair value	$ 0	$ 0
Number of Shares (in shares)	7,843	7,843
Biotechnology Sector [Member] \| Common Stock Warrants [Member] \| Imunon, Inc [Member]
Investments at cost	$ 65
Investments at fair value	$ 0
Number of Shares (in shares)	16,502
Biotechnology Sector [Member] \| Common Stock Warrants [Member] \| Mustang Bio, Inc [Member]
Investments at cost	$ 146	$ 146
Investments at fair value	$ 0	$ 5
Number of Shares (in shares)	252,161	252,161
Biotechnology Sector [Member] \| Common Stock Warrants [Member] \| Rocket Pharmaceuticals Corporation [Member]
Investments at cost	$ 17	$ 17
Investments at fair value	$ 1	$ 9
Number of Shares (in shares)	7,051	7,051
Biotechnology Sector [Member] \| Common Stock Warrants [Member] \| Strongbridge U.S. Inc [Member]
Investments at cost		$ 72
Investments at fair value		$ 110
Number of Shares (in shares)		160,714
Biotechnology Sector [Member] \| Common Stock Warrants [Member] \| vTv Therapeutics Inc [Member]
Investments at cost	$ 44	$ 44
Investments at fair value	$ 0	$ 0
Number of Shares (in shares)	95,293	95,293
Biotechnology Sector [Member] \| Common Stock Warrants [Member] \| PDS Biotechnology Corporation [Member]
Investments at cost	$ 160
Investments at fair value	$ 160
Number of Shares (in shares)	299,848
Biotechnology Sector [Member] \| Common Stock Warrants [Member] \| Xeris Pharmaceuticals, Inc [Member]
Investments at cost	$ 72
Investments at fair value	$ 2
Number of Shares (in shares)	126,000
Biotechnology Sector [Member] \| Term Loan (12.50% cash (Prime + 6.25%; Floor 9.50%), 3.0% ETP, Due 1/1/25) One [Member] \| Avalo Therapeutics, Inc. [Member]
Cash Rate	12.50%
Margin	6.25%
Floor	9.50%
Ceiling Rate	0.00%
ETP	3.00%
Maturity Date	Jan. 01, 2025
Principal Amount	$ 2,885
Investments at cost	2,817
Investments at fair value	$ 2,765
Biotechnology Sector [Member] \| Term Loan (11.75% cash (Prime + 5.50%; Floor 8.75%), 6.0% ETP, Due 10/1/25) One [Member] \| Stealth BioTherapeutics Inc. [Member]
Cash Rate	11.75%
Margin	5.50%
Floor	8.75%
Ceiling Rate	0.00%
ETP	6.00%
Maturity Date	Oct. 01, 2025
Principal Amount	$ 5,000
Investments at cost	4,906
Investments at fair value	4,906
Biotechnology Sector [Member] \| Term Loan (9.30% cash (Libor + 7.50%; Floor 9.30%), 5.00% ETP, Due 3/1/24) One [Member] \| Castle Creek Pharmaceuticals Holdings, Inc. [Member]
Cash Rate		9.30%
Margin		7.50%
Floor		9.30%
Ceiling Rate		0.00%
ETP		5.00%
Maturity Date		Mar. 01, 2024
Principal Amount		$ 5,000
Investments at cost		4,957
Investments at fair value		4,957
Biotechnology Sector [Member] \| Preferred Stock Warrants [Member] \| Castle Creek Biosciences, Inc [Member]
Investments at cost	214	142
Investments at fair value	$ 104	$ 148
Number of Shares (in shares)	5,372	2,428
Biotechnology Sector [Member] \| Preferred Stock Warrants [Member] \| Corvium, Inc [Member]
Investments at cost	$ 52	$ 54
Investments at fair value	$ 0	$ 0
Number of Shares (in shares)	661,956	661,956
Biotechnology Sector [Member] \| Preferred Stock Warrants [Member] \| Emalex Biosciences, Inc. [Member]
Investments at cost	$ 176	$ 139
Investments at fair value	$ 244	$ 162
Number of Shares (in shares)	110,402	92,002
Biotechnology Sector [Member] \| Preferred Stock Warrants [Member] \| Provivi, Inc. [Member]
Investments at cost	$ 278	$ 278
Investments at fair value	$ 513	$ 519
Number of Shares (in shares)	164,608	164,608
Biotechnology Sector [Member] \| Preferred Stock Warrants [Member] \| KSQ Therapeutics, Inc. [Member]
Investments at cost	$ 50
Investments at fair value	$ 54
Number of Shares (in shares)	48,077
Biotechnology Sector [Member] \| Preferred Stock Warrants [Member] \| Native Microbials, Inc. [Member]
Investments at cost	$ 52
Investments at fair value	$ 59
Number of Shares (in shares)	94,253
Biotechnology Sector [Member] \| Term Loan (11.00% cash (Prime + 6.25%; Floor 9.50%), 3.0% ETP, Due 1/1/25), Two [Member] \| Avalo Therapeutics, Inc. [Member]
Cash Rate	12.50%
Margin	6.25%
Floor	9.50%
Ceiling Rate	0.00%
ETP	3.00%
Maturity Date	Jan. 01, 2025
Principal Amount	$ 2,885
Investments at cost	2,817
Investments at fair value	$ 2,765
Biotechnology Sector [Member] \| Term Loan (10.25% cash (Prime + 5.50%; Floor 8.75%), 6.0% ETP, Due 10/1/25) Two [Member] \| Stealth BioTherapeutics Inc. [Member]
Cash Rate	11.75%
Margin	5.50%
Floor	8.75%
Ceiling Rate	0.00%
ETP	6.00%
Maturity Date	Oct. 01, 2025
Principal Amount	$ 2,500
Investments at cost	2,453
Investments at fair value	$ 2,453
Biotechnology Sector [Member] \| Term Loan (9.30% cash (Libor + 7.50%; Floor 9.30%), 5.00% ETP, Due 3/1/24) Two [Member] \| Castle Creek Pharmaceuticals Holdings, Inc. [Member]
Cash Rate		9.30%
Margin		7.50%
Floor		9.30%
Ceiling Rate		0.00%
ETP		5.00%
Maturity Date		Mar. 01, 2024
Principal Amount		$ 5,000
Investments at cost		4,957
Investments at fair value		$ 4,957
Biotechnology Sector [Member] \| Term Loan (12.50% cash (Prime + 6.25%; Floor 9.50%), 3.0% ETP, Due 1/1/25) Three [Member] \| Avalo Therapeutics, Inc. [Member]
Cash Rate	12.50%
Margin	6.25%
Floor	9.50%
Ceiling Rate	0.00%
ETP	3.00%
Maturity Date	Jan. 01, 2025
Principal Amount	$ 1,442
Investments at cost	1,435
Investments at fair value	$ 1,410
Biotechnology Sector [Member] \| Term Loan (9.30% cash (Libor + 7.50%; Floor 9.30%), 5.00% ETP, Due 3/1/24) Three [Member] \| Castle Creek Pharmaceuticals Holdings, Inc. [Member]
Cash Rate		9.30%
Margin		7.50%
Floor		9.30%
Ceiling Rate		0.00%
ETP		5.00%
Maturity Date		Mar. 01, 2024
Principal Amount		$ 5,000
Investments at cost		4,957
Investments at fair value		$ 4,957
Biotechnology Sector [Member] \| Term Loan (12.50% cash (Prime + 6.25%; Floor 9.50%), 3.0% ETP, Due 2/1/25) One [Member] \| Avalo Therapeutics, Inc. [Member]
Cash Rate	12.50%
Floor	9.50%
Ceiling Rate	0.00%
ETP	3.00%
Maturity Date	Feb. 01, 2025
Principal Amount	$ 2,885
Investments at cost	2,813
Investments at fair value	$ 2,763
Biotechnology Sector [Member] \| Term Loan (9.30% cash (Libor + 7.50%; Floor 9.30%), 5.00% ETP, Due 3/1/24) Four [Member] \| Castle Creek Pharmaceuticals Holdings, Inc. [Member]
Cash Rate		9.30%
Margin		7.50%
Floor		9.30%
Ceiling Rate		0.00%
ETP		5.00%
Maturity Date		Mar. 01, 2024
Principal Amount		$ 5,000
Investments at cost		4,957
Investments at fair value		$ 4,957
Biotechnology Sector [Member] \| Term Loan (12.50% cash (Prime + 6.25%; Floor 9.50%), 3.0% ETP, Due 2/1/25) Two [Member] \| Avalo Therapeutics, Inc. [Member]
Cash Rate	12.50%
Margin	6.25%
Floor	9.50%
Ceiling Rate	0.00%
ETP	3.00%
Maturity Date	Feb. 01, 2025
Principal Amount	$ 2,885
Investments at cost	2,813
Investments at fair value	$ 2,763
Biotechnology Sector [Member] \| Term Loan (9.50% cash (Prime + 6.25%; Floor 9.50%), 3.0% ETP, Due 1/1/25) One [Member] \| Avalo Therapeutics, Inc. [Member]
Cash Rate		9.50%
Margin		6.25%
Floor		9.50%
Ceiling Rate		0.00%
ETP		3.00%
Maturity Date		Jan. 01, 2025
Principal Amount		$ 5,000
Investments at cost		4,909
Investments at fair value		$ 4,909
Biotechnology Sector [Member] \| Term Loan (12.50% cash (Prime + 6.25%; Floor 9.50%), 3.0% ETP, Due 4/1/25) One [Member] \| Avalo Therapeutics, Inc. [Member]
Cash Rate	12.50%
Margin	6.25%
Floor	9.50%
Ceiling Rate	0.00%
ETP	3.00%
Maturity Date	Apr. 01, 2025
Principal Amount	$ 1,442
Investments at cost	1,404
Investments at fair value	$ 1,379
Biotechnology Sector [Member] \| Term Loan (9.50% cash (Prime + 6.25%; Floor 9.50%), 3.0% ETP, Due 1/1/25) Two [Member] \| Avalo Therapeutics, Inc. [Member]
Cash Rate		9.50%
Margin		6.25%
Floor		9.50%
Ceiling Rate		0.00%
ETP		3.00%
Maturity Date		Jan. 01, 2025
Principal Amount		$ 5,000
Investments at cost		4,909
Investments at fair value		$ 4,909
Biotechnology Sector [Member] \| Term Loan (12.50% cash (Prime + 6.25%; Floor 9.50%), 3.0% ETP, Due 4/1/25) Two [Member] \| Avalo Therapeutics, Inc. [Member]
Cash Rate	12.50%
Margin	6.25%
Floor	9.50%
Ceiling Rate	0.00%
ETP	3.00%
Maturity Date	Apr. 01, 2025
Principal Amount	$ 1,442
Investments at cost	1,404
Investments at fair value	$ 1,379
Biotechnology Sector [Member] \| Term Loan (9.50% cash (Prime + 6.25%; Floor 9.50%), 3.0% ETP, Due 1/1/25) Three [Member] \| Avalo Therapeutics, Inc. [Member]
Cash Rate		9.50%
Margin		6.25%
Floor		9.50%
Ceiling Rate		0.00%
ETP		3.00%
Maturity Date		Jan. 01, 2025
Principal Amount		$ 2,500
Investments at cost		2,454
Investments at fair value		$ 2,454
Biotechnology Sector [Member] \| Term Loan (11.55% cash (Prime + 6.05%; Floor 9.55%), 5.50% ETP, Due 5/1/26) One [Member] \| Castle Creek Biosciences, Inc [Member]
Cash Rate	11.55%
Margin	6.05%
Floor	9.55%
Ceiling Rate	13.50%
ETP	5.50%
Maturity Date	May 01, 2026
Principal Amount	$ 5,000
Investments at cost	4,887
Investments at fair value	$ 4,887
Biotechnology Sector [Member] \| Term Loan (9.50% cash (Prime + 6.25%; Floor 9.50%), 3.0% ETP, Due 2/1/25) Four [Member] \| Avalo Therapeutics, Inc. [Member]
Cash Rate		9.50%
Margin		6.25%
Floor		9.50%
Ceiling Rate		0.00%
ETP		3.00%
Maturity Date		Feb. 01, 2025
Principal Amount		$ 5,000
Investments at cost		4,906
Investments at fair value		$ 4,906
Biotechnology Sector [Member] \| Term Loan (11.55% cash (Prime + 6.05%; Floor 9.55%), 5.50% ETP, Due 5/1/26) Two [Member] \| Castle Creek Biosciences, Inc [Member]
Cash Rate	11.55%
Margin	6.05%
Floor	9.55%
Ceiling Rate	13.50%
ETP	5.50%
Maturity Date	May 01, 2026
Principal Amount	$ 5,000
Investments at cost	4,959
Investments at fair value	$ 4,959
Biotechnology Sector [Member] \| Term Loan (9.50% cash (Prime + 6.25%; Floor 9.50%), 3.0% ETP, Due 2/1/25) Five [Member] \| Avalo Therapeutics, Inc. [Member]
Cash Rate		9.50%
Margin		6.25%
Floor		9.50%
Ceiling Rate		0.00%
ETP		3.00%
Maturity Date		Feb. 01, 2025
Principal Amount		$ 5,000
Investments at cost		4,906
Investments at fair value		$ 4,906
Biotechnology Sector [Member] \| Term Loan (11.55% cash (Prime + 6.05%; Floor 9.55%), 5.50% ETP, Due 5/1/26) Three [Member] \| Castle Creek Biosciences, Inc [Member]
Cash Rate	11.55%
Margin	6.05%
Floor	9.55%
Ceiling Rate	13.50%
ETP	5.50%
Maturity Date	May 01, 2026
Principal Amount	$ 3,000
Investments at cost	2,976
Investments at fair value	$ 2,976
Biotechnology Sector [Member] \| Term Loan (9.50% cash (Prime + 6.25%; Floor 9.50%), 3.0% ETP, Due 4/1/25) Six [Member] \| Avalo Therapeutics, Inc. [Member]
Cash Rate		9.50%
Margin		6.25%
Floor		9.50%
Ceiling Rate		0.00%
ETP		3.00%
Maturity Date		Apr. 01, 2025
Principal Amount		$ 2,500
Investments at cost		2,451
Investments at fair value		$ 2,451
Biotechnology Sector [Member] \| Term Loan (11.55% cash (Prime + 6.05%; Floor 9.55%), 5.50% ETP, Due 5/1/26) Four [Member] \| Castle Creek Biosciences, Inc [Member]
Cash Rate	11.55%
Margin	6.05%
Floor	9.55%
Ceiling Rate	13.50%
ETP	5.50%
Maturity Date	May 01, 2026
Principal Amount	$ 5,000
Investments at cost	4,959
Investments at fair value	$ 4,959
Biotechnology Sector [Member] \| Term Loan (9.50% cash (Prime + 6.25%; Floor 9.50%), 3.0% ETP, Due 4/1/25) Seven [Member] \| Avalo Therapeutics, Inc. [Member]
Cash Rate		9.50%
Margin		6.25%
Floor		9.50%
Ceiling Rate		0.00%
ETP		3.00%
Maturity Date		Apr. 01, 2025
Principal Amount		$ 2,500
Investments at cost		2,451
Investments at fair value		2,451
Biotechnology Sector [Member] \| Term Loan (11.55% cash (Prime + 6.05%; Floor 9.55%), 5.50% ETP, Due 5/1/26) Five [Member] \| Castle Creek Biosciences, Inc [Member]
Cash Rate	11.55%
Margin	6.05%
Floor	9.55%
Ceiling Rate	13.50%
ETP	5.50%
Maturity Date	May 01, 2026
Principal Amount	$ 5,000
Investments at cost	4,959
Investments at fair value	$ 4,959
Biotechnology Sector [Member] \| Other Long-Term Investments [Member] \| HESP LLC [Member]
Investments at cost		1,450
Investments at fair value		$ 0
Biotechnology Sector [Member] \| Term Loan (9.75% cash (Libor + 7.90%; Floor 9.75%), 5.00% ETP, Due 6/1/24), One [Member] \| Emalex Biosciences, Inc. [Member]
Cash Rate		9.75%
Margin		7.90%
Floor		9.75%
Ceiling Rate		0.00%
ETP		5.00%
Maturity Date		Jun. 01, 2024
Principal Amount		$ 2,500
Investments at cost		2,420
Investments at fair value		$ 2,420
Biotechnology Sector [Member] \| Term Loan (11.55% cash (Prime + 6.05%; Floor 9.55%), 5.50% ETP, Due 5/1/26) Six [Member] \| Castle Creek Biosciences, Inc [Member]
Cash Rate	11.55%
Margin	6.05%
Floor	9.55%
Ceiling Rate	13.50%
ETP	5.50%
Maturity Date	May 01, 2026
Principal Amount	$ 3,000
Investments at cost	2,975
Investments at fair value	2,975
Biotechnology Sector [Member] \| Preferred Stock [Member] \| Castle Creek Biosciences, Inc [Member]
Investments at cost	250
Investments at fair value	$ 250
Number of Shares (in shares)	1,162
Biotechnology Sector [Member] \| Term Loan (9.75% cash (Libor + 7.90%; Floor 9.75%), 5.00% ETP, Due 6/1/24), Two [Member] \| Emalex Biosciences, Inc. [Member]
Cash Rate		9.75%
Margin		7.90%
Floor		9.75%
Ceiling Rate		0.00%
ETP		5.00%
Maturity Date		Jun. 01, 2024
Principal Amount		$ 2,500
Investments at cost		2,472
Investments at fair value		$ 2,472
Biotechnology Sector [Member] \| Term Loan (10.45% cash (Libor + 7.90%; Floor 9.75%), 5.00% ETP, Due 6/1/24) One [Member] \| Emalex Biosciences, Inc. [Member]
Cash Rate	10.45%
Margin	7.90%
Floor	9.75%
Ceiling Rate	0.00%
ETP	5.00%
Maturity Date	Jun. 01, 2024
Principal Amount	$ 2,188
Investments at cost	2,168
Investments at fair value	$ 2,168
Biotechnology Sector [Member] \| Term Loan (9.75% cash (Libor + 7.90%; Floor 9.75%), 5.00% ETP, Due 11/1/25) One [Member] \| Emalex Biosciences, Inc. [Member]
Cash Rate		9.75%
Margin		7.90%
Floor		9.75%
Ceiling Rate		0.00%
ETP		5.00%
Maturity Date		Nov. 01, 2025
Principal Amount		$ 5,000
Investments at cost		4,896
Investments at fair value		$ 4,896
Biotechnology Sector [Member] \| Term Loan (10.45% cash (Libor + 7.90%; Floor 9.75%), 5.00% ETP, Due 6/1/24) Two [Member] \| Emalex Biosciences, Inc. [Member]
Cash Rate	10.45%
Margin	7.90%
Floor	9.75%
Ceiling Rate	0.00%
ETP	5.00%
Maturity Date	Jun. 01, 2024
Principal Amount	$ 2,188
Investments at cost	2,169
Investments at fair value	$ 2,169
Biotechnology Sector [Member] \| Term Loan (9.50% cash (Prime + 6.25%; Floor 9.50%), 4.00% ETP, Due 4/1/25) One [Member] \| F-Star Therapeutics, Inc [Member]
Cash Rate		9.50%
Margin		6.25%
Floor		9.50%
Ceiling Rate		0.00%
ETP		4.00%
Maturity Date		Apr. 01, 2025
Principal Amount		$ 2,500
Investments at cost		2,465
Investments at fair value		$ 2,465
Biotechnology Sector [Member] \| Term Loan (10.45% cash (Libor + 7.90%; Floor 9.75%), 5.00% ETP, Due 11/1/25) [Member] \| Emalex Biosciences, Inc. [Member]
Cash Rate	10.45%
Margin	7.90%
Floor	9.75%
Ceiling Rate	0.00%
ETP	5.00%
Maturity Date	Nov. 01, 2025
Principal Amount	$ 5,000
Investments at cost	4,916
Investments at fair value	$ 4,916
Biotechnology Sector [Member] \| Term Loan (9.50% cash (Prime + 6.25%; Floor 9.50%), 4.00% ETP, Due 7/1/25) Two [Member] \| F-Star Therapeutics, Inc [Member]
Cash Rate		9.50%
Margin		6.25%
Floor		9.50%
Ceiling Rate		0.00%
ETP		4.00%
Maturity Date		Jul. 01, 2025
Principal Amount		$ 2,500
Investments at cost		2,463
Investments at fair value		$ 2,463
Biotechnology Sector [Member] \| Term Loan (9.50% cash (Prime + 6.25%; Floor 9.50%), 4.00% ETP, Due 7/1/25) Two [Member] \| Greenlight Biosciences, Inc [Member]
Cash Rate		9.50%
Margin		6.25%
Floor		9.50%
Ceiling Rate		0.00%
ETP		4.00%
Maturity Date		Jul. 01, 2025
Principal Amount		$ 2,500
Investments at cost		2,475
Investments at fair value		$ 2,475
Biotechnology Sector [Member] \| Term Loan (10.45% cash (Libor + 7.90%; Floor 9.75%), 5.00% ETP, Due 5/1/26) [Member] \| Emalex Biosciences, Inc. [Member]
Cash Rate	10.45%
Margin	7.90%
Floor	9.75%
Ceiling Rate	0.00%
ETP	5.00%
Maturity Date	May 01, 2026
Principal Amount	$ 5,000
Investments at cost	4,902
Investments at fair value	$ 4,902
Biotechnology Sector [Member] \| Term Loan (9.50% cash (Prime + 6.25%; Floor 9.50%), 4.00% ETP, Due 7/1/25) One [Member] \| Greenlight Biosciences, Inc [Member]
Cash Rate		9.50%
Margin		6.25%
Floor		9.50%
Ceiling Rate		0.00%
ETP		4.00%
Maturity Date		Jul. 01, 2025
Principal Amount		$ 5,000
Investments at cost		4,850
Investments at fair value		$ 4,850
Biotechnology Sector [Member] \| Term Loan (11.75% cash (Prime + 6.25%; Floor 9.50%), 4.00% ETP, Due 4/1/25) [Member] \| F-Star Therapeutics, Inc [Member]
Cash Rate	11.75%
Margin	6.25%
Floor	9.50%
Ceiling Rate	0.00%
ETP	4.00%
Maturity Date	Apr. 01, 2025
Principal Amount	$ 2,500
Investments at cost	2,473
Investments at fair value	$ 2,473
Biotechnology Sector [Member] \| Term Loan (11.75% cash (Prime + 6.25%; Floor 9.50%), 4.00% ETP, Due 7/1/25) [Member] \| F-Star Therapeutics, Inc [Member]
Cash Rate	11.75%
Margin	6.25%
Floor	9.50%
Ceiling Rate	0.00%
ETP	4.00%
Maturity Date	Jul. 01, 2025
Principal Amount	$ 2,500
Investments at cost	2,471
Investments at fair value	$ 2,471
Biotechnology Sector [Member] \| Term Loan (9.00% cash (Prime + 6.25%; Floor 9.00%), 5.00% ETP, Due 7/1/25) One [Member] \| IMV Inc [Member]
Cash Rate		9.00%
Margin		6.25%
Floor		9.00%
Ceiling Rate		0.00%
ETP		5.00%
Maturity Date		Jul. 01, 2025
Principal Amount		$ 5,000
Investments at cost		4,799
Investments at fair value		$ 4,799
Biotechnology Sector [Member] \| Term Loan (12.00% cash (Prime + 5.75%; Floor 9.00%), 3.00% ETP, Due 7/1/25) One [Member] \| Greenlight Biosciences, Inc [Member]
Cash Rate	12.00%
Margin	5.75%
Floor	9.00%
Ceiling Rate	0.00%
ETP	3.00%
Maturity Date	Jul. 01, 2025
Principal Amount	$ 5,000
Investments at cost	4,843
Investments at fair value	$ 4,843
Biotechnology Sector [Member] \| Term Loan (9.00% cash (Prime + 6.25%; Floor 9.00%), 5.00% ETP, Due 7/1/25) Two [Member] \| IMV Inc [Member]
Cash Rate		9.00%
Margin		6.25%
Floor		9.00%
Ceiling Rate		0.00%
ETP		5.00%
Maturity Date		Jul. 01, 2025
Principal Amount		$ 2,500
Investments at cost		2,462
Investments at fair value		$ 2,462
Biotechnology Sector [Member] \| Term Loan (12.00% cash (Prime + 5.75%; Floor 9.00%), 3.00% ETP, Due 7/1/25) Two [Member] \| Greenlight Biosciences, Inc [Member]
Cash Rate	12.00%
Margin	5.75%
Floor	9.00%
Ceiling Rate	0.00%
ETP	3.00%
Maturity Date	Jul. 01, 2025
Principal Amount	$ 2,500
Investments at cost	2,423
Investments at fair value	$ 2,423
Biotechnology Sector [Member] \| Term Loan (8.75% cash (Libor + 6.25%; Floor 8.75%), 4.50% ETP, Due 6/1/24) One [Member] \| LogicBio, Inc [Member]
Cash Rate		8.75%
Margin		6.25%
Floor		8.75%
Ceiling Rate		0.00%
ETP		4.50%
Maturity Date		Jun. 01, 2024
Principal Amount		$ 4,028
Investments at cost		4,011
Investments at fair value		$ 4,011
Biotechnology Sector [Member] \| Term Loan (12.00% cash (Prime + 5.75%; Floor 9.00%), 5.00% ETP, Due 7/1/25) One [Member] \| IMV Inc [Member]
Cash Rate	12.00%
Margin	5.75%
Floor	9.00%
Ceiling Rate	0.00%
ETP	5.00%
Maturity Date	Jul. 01, 2025
Principal Amount	$ 5,000
Investments at cost	4,942
Investments at fair value	$ 4,942
Biotechnology Sector [Member] \| Term Loan (9.50% cash (Libor + 8.50%; Floor 9.50%), 5.50% ETP, Due 12/1/24), One [Member] \| Provivi, Inc. [Member]
Cash Rate		9.50%
Margin		8.50%
Floor		9.50%
Ceiling Rate		0.00%
ETP		5.50%
Maturity Date		Dec. 01, 2024
Principal Amount		$ 5,000
Investments at cost		4,935
Investments at fair value		$ 4,935
Biotechnology Sector [Member] \| Term Loan (12.00% cash (Prime + 5.75%; Floor 9.00%), 5.00% ETP, Due 7/1/25) Two [Member] \| IMV Inc [Member]
Cash Rate	12.00%
Margin	5.75%
Floor	9.00%
Ceiling Rate	0.00%
ETP	5.00%
Maturity Date	Jul. 01, 2025
Principal Amount	$ 2,500
Investments at cost	2,470
Investments at fair value	$ 2,470
Biotechnology Sector [Member] \| Term Loan (9.50% cash (Libor + 8.50%; Floor 9.50%), 5.50% ETP, Due 12/1/24), Two [Member] \| Provivi, Inc. [Member]
Cash Rate		9.50%
Margin		8.50%
Floor		9.50%
Ceiling Rate		0.00%
ETP		5.50%
Maturity Date		Dec. 01, 2024
Principal Amount		$ 5,000
Investments at cost		4,935
Investments at fair value		$ 4,935
Biotechnology Sector [Member] \| Term Loan (12.00% cash (Prime + 5.75%; Floor 9.00%), 5.00% ETP, Due 1/1/26) One [Member] \| IMV Inc [Member]
Cash Rate	12.00%
Margin	5.75%
Floor	9.00%
Ceiling Rate	0.00%
ETP	5.00%
Maturity Date	Jan. 01, 2026
Principal Amount	$ 5,000
Investments at cost	4,942
Investments at fair value	$ 4,942
Biotechnology Sector [Member] \| Term Loan (9.50% cash (Libor + 8.50%; Floor 9.50%), 5.50% ETP, Due 12/1/24), Three [Member] \| Provivi, Inc. [Member]
Cash Rate		9.50%
Margin		8.50%
Floor		9.50%
Ceiling Rate		0.00%
ETP		5.50%
Maturity Date		Dec. 01, 2024
Principal Amount		$ 2,500
Investments at cost		2,440
Investments at fair value		$ 2,440
Biotechnology Sector [Member] \| Term Loan (12.00% cash (Prime + 5.75%; Floor 9.00%), 5.00% ETP, Due 1/1/26) Two [Member] \| IMV Inc [Member]
Cash Rate	12.00%
Margin	5.75%
Floor	9.00%
Ceiling Rate	0.00%
ETP	5.00%
Maturity Date	Jan. 01, 2026
Principal Amount	$ 5,000
Investments at cost	4,941
Investments at fair value	$ 4,941
Biotechnology Sector [Member] \| Term Loan (9.50% cash (Libor + 8.50%; Floor 9.50%), 5.50% ETP, Due 12/1/24), Four [Member] \| Provivi, Inc. [Member]
Cash Rate		9.50%
Margin		8.50%
Floor		9.50%
Ceiling Rate		0.00%
ETP		5.50%
Maturity Date		Dec. 01, 2024
Principal Amount		$ 2,500
Investments at cost		2,440
Investments at fair value		$ 2,440
Biotechnology Sector [Member] \| Term Loan (11.00% cash (Prime + 4.75%; Floor 8.50%), 5.50% ETP, Due 5/1/27) One [Member] \| KSQ Therapeutics, Inc. [Member]
Cash Rate	11.00%
Margin	4.75%
Floor	8.50%
Ceiling Rate	0.00%
ETP	5.50%
Maturity Date	May 01, 2027
Principal Amount	$ 6,250
Investments at cost	6,071
Investments at fair value	$ 6,071
Biotechnology Sector [Member] \| Term Loan (9.50% cash (Libor + 8.50%; Floor 9.50%), 5.50% ETP, Due 12/1/24), Five [Member] \| Provivi, Inc. [Member]
Cash Rate		9.50%
Margin		8.50%
Floor		9.50%
Ceiling Rate		0.00%
ETP		5.50%
Maturity Date		Dec. 01, 2024
Principal Amount		$ 2,500
Investments at cost		2,430
Investments at fair value		$ 2,430
Biotechnology Sector [Member] \| Term Loan (11.00% cash (Prime + 4.75%; Floor 8.50%), 5.50% ETP, Due 5/1/27) Two [Member] \| KSQ Therapeutics, Inc. [Member]
Cash Rate	11.00%
Margin	4.75%
Floor	8.50%
Ceiling Rate	0.00%
ETP	5.50%
Maturity Date	May 01, 2027
Principal Amount	$ 6,250
Investments at cost	6,172
Investments at fair value	$ 6,172
Biotechnology Sector [Member] \| Term Loan (9.50% cash (Libor + 8.50%; Floor 9.50%), 5.50% ETP, Due 12/1/24), Six [Member] \| Provivi, Inc. [Member]
Cash Rate		9.50%
Margin		8.50%
Floor		9.50%
Ceiling Rate		0.00%
ETP		5.50%
Maturity Date		Dec. 01, 2024
Principal Amount		$ 2,500
Investments at cost		2,430
Investments at fair value		$ 2,430
Biotechnology Sector [Member] \| Term Loan (8.80% cash (Libor + 6.25%; Floor 8.75%), 4.50% ETP, Due 6/1/24) [Member] \| LogicBio, Inc [Member]
Cash Rate	8.80%
Margin	6.25%
Floor	8.75%
Ceiling Rate	0.00%
ETP	4.50%
Maturity Date	Jun. 01, 2024
Principal Amount	$ 2,778
Investments at cost	2,766
Investments at fair value	$ 2,766
Biotechnology Sector [Member] \| Term Loan (8.75% cash (Prime + 5.50%; Floor 8.75%), 6.0% ETP, Due 10/1/25) One [Member] \| Stealth BioTherapeutics Inc. [Member]
Cash Rate		8.75%
Margin		5.50%
Floor		8.75%
Ceiling Rate		0.00%
ETP		6.00%
Maturity Date		Oct. 01, 2025
Principal Amount		$ 5,000
Investments at cost		4,631
Investments at fair value		$ 4,631
Biotechnology Sector [Member] \| Term Loan (11.50% cash (Prime + 5.25%; Floor 8.50%), 5.00% ETP, Due 11/1/26) [Member] \| Native Microbials, Inc. [Member]
Cash Rate	11.50%
Margin	5.25%
Floor	8.50%
Ceiling Rate	0.00%
ETP	5.00%
Maturity Date	Nov. 01, 2026
Principal Amount	$ 3,750
Investments at cost	3,633
Investments at fair value	$ 3,633
Biotechnology Sector [Member] \| Term Loan (8.75% cash (Prime + 5.50%; Floor 8.75%), 6.0% ETP, Due 10/1/25) Two [Member] \| Stealth BioTherapeutics Inc. [Member]
Cash Rate		8.75%
Margin		5.50%
Floor		8.75%
Ceiling Rate		0.00%
ETP		6.00%
Maturity Date		Oct. 01, 2025
Principal Amount		$ 2,500
Investments at cost		2,441
Investments at fair value		2,441
Biotechnology Sector [Member] \| Term Loan (12.00% cash (Prime + 5.75%; Floor 9.75%), 3.75% ETP, Due 9/1/26) One [Member] \| PDS Biotechnology Corporation [Member]
Cash Rate	12.00%
Margin	5.75%
Floor	9.75%
Ceiling Rate	0.00%
ETP	3.75%
Maturity Date	Sep. 01, 2026
Principal Amount	$ 10,000
Investments at cost	9,688
Investments at fair value	$ 9,688
Biotechnology Sector [Member] \| Term Loan (12.00% cash (Prime + 5.75%; Floor 9.75%), 3.75% ETP, Due 9/1/26) Two [Member] \| PDS Biotechnology Corporation [Member]
Cash Rate	12.00%
Margin	5.75%
Floor	9.75%
Ceiling Rate	0.00%
ETP	3.75%
Maturity Date	Sep. 01, 2026
Principal Amount	$ 3,750
Investments at cost	3,692
Investments at fair value	$ 3,692
Biotechnology Sector [Member] \| Term Loan (12.00% cash (Prime + 5.75%; Floor 9.75%), 3.75% ETP, Due 9/1/26) Three [Member] \| PDS Biotechnology Corporation [Member]
Cash Rate	12.00%
Margin	5.75%
Floor	9.75%
Ceiling Rate	0.00%
ETP	3.75%
Maturity Date	Sep. 01, 2026
Principal Amount	$ 3,750
Investments at cost	3,692
Investments at fair value	$ 3,692
Biotechnology Sector [Member] \| Term Loan (11.05% cash (Libor + 8.50%; Floor 9.50%), 5.50% ETP, Due 12/1/24) One [Member] \| Provivi, Inc. [Member]
Cash Rate	11.05%
Margin	8.50%
Floor	9.50%
Ceiling Rate	0.00%
ETP	5.50%
Maturity Date	Dec. 01, 2024
Principal Amount	$ 4,666
Investments at cost	4,618
Investments at fair value	$ 4,618
Biotechnology Sector [Member] \| Term Loan (11.05% cash (Libor + 8.50%; Floor 9.50%), 5.50% ETP, Due 12/1/24) Two [Member] \| Provivi, Inc. [Member]
Cash Rate	11.05%
Margin	8.50%
Floor	9.50%
Ceiling Rate	0.00%
ETP	5.50%
Maturity Date	Dec. 01, 2024
Principal Amount	$ 4,666
Investments at cost	4,618
Investments at fair value	$ 4,618
Biotechnology Sector [Member] \| Term Loan (11.05% cash (Libor + 8.50%; Floor 9.50%), 5.50% ETP, Due 12/1/24) Three [Member] \| Provivi, Inc. [Member]
Cash Rate	11.05%
Margin	8.50%
Floor	9.50%
Ceiling Rate	0.00%
ETP	5.50%
Maturity Date	Dec. 01, 2024
Principal Amount	$ 2,333
Investments at cost	2,288
Investments at fair value	$ 2,288
Biotechnology Sector [Member] \| Term Loan (11.05% cash (Libor + 8.50%; Floor 9.50%), 5.50% ETP, Due 12/1/24) Four [Member] \| Provivi, Inc. [Member]
Cash Rate	11.05%
Margin	8.50%
Floor	9.50%
Ceiling Rate	0.00%
ETP	5.50%
Maturity Date	Dec. 01, 2024
Principal Amount	$ 2,333
Investments at cost	2,288
Investments at fair value	$ 2,288
Biotechnology Sector [Member] \| Term Loan (11.05% cash (Libor + 8.50%; Floor 9.50%), 5.50% ETP, Due 12/1/24) Five [Member] \| Provivi, Inc. [Member]
Cash Rate	11.05%
Margin	8.50%
Floor	9.50%
Ceiling Rate	0.00%
ETP	5.50%
Maturity Date	Dec. 01, 2024
Principal Amount	$ 2,333
Investments at cost	2,281
Investments at fair value	$ 2,281
Biotechnology Sector [Member] \| Term Loan (11.05% cash (Libor + 8.50%; Floor 9.50%), 5.50% ETP, Due 12/1/24) Six [Member] \| Provivi, Inc. [Member]
Cash Rate	11.05%
Margin	8.50%
Floor	9.50%
Ceiling Rate	0.00%
ETP	5.50%
Maturity Date	Dec. 01, 2024
Principal Amount	$ 2,333
Investments at cost	2,281
Investments at fair value	2,281
Communications Sector [Member]
Investments at cost	22,883	22,853
Investments at fair value	26,070	25,920
Communications Sector [Member] \| Common Stock Warrants [Member] \| Axiom Space, Inc [Member]
Investments at cost	47	45
Investments at fair value	$ 52	$ 42
Number of Shares (in shares)	1,991	1,991
Communications Sector [Member] \| Preferred Stock Warrants [Member] \| Intelepeer Holdings, Inc [Member]
Investments at cost	$ 138	$ 140
Investments at fair value	$ 3,219	$ 3,141
Number of Shares (in shares)	2,936,535	2,936,535
Communications Sector [Member] \| Preferred Stock Warrants [Member] \| PebblePost, Inc [Member]
Investments at cost	$ 92	$ 92
Investments at fair value	$ 193	$ 161
Number of Shares (in shares)	598,850	598,850
Communications Sector [Member] \| Term Loan (11.50% cash (Prime + 6.00%; Floor 9.25%), 2.50% ETP, Due 6/1/26) One [Member] \| Axiom Space, Inc [Member]
Cash Rate	11.50%
Margin	6.00%
Floor	9.25%
Ceiling Rate	0.00%
ETP	2.50%
Maturity Date	Jun. 01, 2026
Principal Amount	$ 7,500
Investments at cost	7,452
Investments at fair value	$ 7,452
Communications Sector [Member] \| Term Loan (11.50% cash (Prime + 6.00%; Floor 9.25%), 2.50% ETP, Due 6/1/26) Two [Member] \| Axiom Space, Inc [Member]
Cash Rate	11.50%
Margin	6.00%
Floor	9.25%
Ceiling Rate	0.00%
ETP	2.50%
Maturity Date	Jun. 01, 2026
Principal Amount	$ 7,500
Investments at cost	7,452
Investments at fair value	$ 7,452
Communications Sector [Member] \| Term Loan (11.50% cash (Prime + 6.00%; Floor 9.25%), 2.50% ETP, Due 6/1/26) Three [Member] \| Axiom Space, Inc [Member]
Cash Rate	11.50%
Margin	6.00%
Floor	9.25%
Ceiling Rate	0.00%
ETP	2.50%
Maturity Date	Jun. 01, 2026
Principal Amount	$ 7,500
Investments at cost	7,452
Investments at fair value	$ 7,452
Communications Sector [Member] \| Convertible Note (3.00%, Due 7/1/23) [Member] \| Axiom Space, Inc [Member]
Cash Rate	3.00%	3.00%
Maturity Date	Jul. 01, 2023	Jul. 01, 2023
Principal Amount	$ 250	$ 250
Investments at cost	250	250
Investments at fair value	250	$ 250
Communications Sector [Member] \| Term Loan (9.25% cash (Prime + 6.00%; Floor 9.25%), 2.50% ETP, Due 6/1/26), One [Member] \| Axiom Space, Inc [Member]
Cash Rate		9.25%
Margin		6.00%
Floor		9.25%
Ceiling Rate		0.00%
ETP		2.50%
Maturity Date		Jun. 01, 2026
Principal Amount		$ 7,500
Investments at cost		7,442
Investments at fair value		$ 7,442
Communications Sector [Member] \| Term Loan (9.25% cash (Prime + 6.00%; Floor 9.25%), 2.50% ETP, Due 6/1/26), Two [Member] \| Axiom Space, Inc [Member]
Cash Rate		9.25%
Margin		6.00%
Floor		9.25%
Ceiling Rate		0.00%
ETP		2.50%
Maturity Date		Jun. 01, 2026
Principal Amount		$ 7,500
Investments at cost		7,442
Investments at fair value		$ 7,442
Communications Sector [Member] \| Term Loan (9.25% cash (Prime + 6.00%; Floor 9.25%), 2.50% ETP, Due 6/1/26), Three [Member] \| Axiom Space, Inc [Member]
Cash Rate		9.25%
Margin		6.00%
Floor		9.25%
Ceiling Rate		0.00%
ETP		2.50%
Maturity Date		Jun. 01, 2026
Principal Amount		$ 7,500
Investments at cost		7,442
Investments at fair value		7,442
Medical Device Sector [Member]
Investments at cost	114,364	88,681
Investments at fair value	116,967	84,567
Medical Device Sector [Member] \| Common Stock Warrants [Member] \| AccuVein Inc [Member]
Investments at cost	23	24
Investments at fair value	$ 0	$ 0
Number of Shares (in shares)	1,175	1,175
Medical Device Sector [Member] \| Common Stock Warrants [Member] \| CVRx, Inc [Member]
Investments at cost	$ 76	$ 80
Investments at fair value	$ 47	$ 90
Number of Shares (in shares)	47,410	47,410
Medical Device Sector [Member] \| Term Loan (10.75% cash (Prime + 5.25%; Floor 9.00%), 5.00% ETP, Due 7/1/27) One [Member] \| Swift Health Systems Inc. [Member]
Cash Rate	10.75%
Margin	5.25%
Floor	9.00%
Ceiling Rate	0.00%
ETP	5.00%
Maturity Date	Jul. 01, 2027
Principal Amount	$ 3,500
Investments at cost	3,345
Investments at fair value	3,345
Medical Device Sector [Member] \| Term Loan (9.30% cash (Libor + 7.50%; Floor 9.30%), 5.00% ETP, Due 3/1/24) One [Member] \| CSA Medical, Inc [Member]
Cash Rate		10.00%
Margin		8.20%
Floor		10.00%
Ceiling Rate		0.00%
ETP		5.00%
Maturity Date		Mar. 01, 2024
Principal Amount		$ 3,600
Investments at cost		3,569
Investments at fair value		$ 3,569
Medical Device Sector [Member] \| Term Loan (9.75% cash (Prime + 6.50%; Floor 9.75%), 28.00% ETP, Due 8/1/26) One [Member] \| Embody, Inc. [Member]
Cash Rate		9.75%
Margin		6.50%
Floor		9.75%
Ceiling Rate		0.00%
ETP		28.00%
Maturity Date		Aug. 01, 2026
Principal Amount		$ 2,500
Investments at cost		2,457
Investments at fair value		2,457
Medical Device Sector [Member] \| Preferred Stock Warrants [Member] \| Swift Health Systems Inc. [Member]
Investments at cost	71
Investments at fair value	$ 79
Number of Shares (in shares)	135,484
Medical Device Sector [Member] \| Preferred Stock Warrants [Member] \| Magnolia Medical Technologies, Inc [Member]
Investments at cost	$ 141	91
Investments at fair value	$ 135	$ 112
Number of Shares (in shares)	699,485	441,780
Medical Device Sector [Member] \| Preferred Stock Warrants [Member] \| InfoBionic, Inc [Member]
Investments at cost	$ 124	$ 124
Investments at fair value	$ 111	$ 121
Number of Shares (in shares)	317,647	317,647
Medical Device Sector [Member] \| Preferred Stock Warrants [Member] \| Aerobiotix, LLC [Member]
Investments at cost	$ 46
Investments at fair value	$ 52
Number of Shares (in shares)	27,330
Medical Device Sector [Member] \| Preferred Stock Warrants [Member] \| Meditrina, Inc [Member]
Investments at cost	$ 82	$ 83
Investments at fair value	$ 142	$ 122
Number of Shares (in shares)	221,510	221,510
Medical Device Sector [Member] \| Preferred Stock Warrants [Member] \| Scientia Vascular, Inc. [Member]
Investments at cost	$ 39
Investments at fair value	$ 43
Number of Shares (in shares)	19,662
Medical Device Sector [Member] \| Preferred Stock Warrants [Member] \| MacuLogix, Inc [Member]
Investments at cost		$ 238
Investments at fair value		$ 0
Number of Shares (in shares)		454,460
Medical Device Sector [Member] \| Preferred Stock Warrants [Member] \| Canary Medical Inc. [Member]
Investments at cost	$ 85	$ 53
Investments at fair value	$ 1,865	$ 45
Number of Shares (in shares)	12,153	7,292
Medical Device Sector [Member] \| Preferred Stock Warrants [Member] \| Sonex Health, Inc. [Member]
Investments at cost	$ 97	$ 77
Investments at fair value	$ 113	$ 75
Number of Shares (in shares)	605,313	484,250
Medical Device Sector [Member] \| Preferred Stock Warrants [Member] \| VERO Biotech LLC [Member]
Investments at cost	$ 53	$ 53
Investments at fair value	$ 0	$ 30
Number of Shares (in shares)	408	408
Medical Device Sector [Member] \| Preferred Stock Warrants [Member] \| Ceribell, Inc. [Member]
Investments at cost	$ 69	$ 61
Investments at fair value	$ 204	$ 172
Number of Shares (in shares)	145,483	134,299
Medical Device Sector [Member] \| Preferred Stock Warrants [Member] \| Cognoa, Inc. [Member]
Investments at cost	$ 148
Investments at fair value	$ 167
Number of Shares (in shares)	775,000
Medical Device Sector [Member] \| Preferred Stock Warrants [Member] \| Conventus Orthopaedics, Inc [Member]
Investments at cost	$ 221	$ 149
Investments at fair value	$ 209	$ 169
Number of Shares (in shares)	7,972,222	6,361,111
Medical Device Sector [Member] \| Preferred Stock Warrants [Member] \| Aerin Medical, Inc [Member]
Investments at cost	$ 64	$ 66
Investments at fair value	$ 1,187	$ 463
Number of Shares (in shares)	1,818,183	1,818,183
Medical Device Sector [Member] \| Preferred Stock Warrants [Member] \| CSA Medical, Inc [Member]
Investments at cost	$ 153	$ 154
Investments at fair value	$ 134	$ 108
Number of Shares (in shares)	1,375,727	1,375,727
Medical Device Sector [Member] \| Term Loan (10.00% cash (Prime + 5.25%; Floor 9.00%), 5.00% ETP, Due 7/1/27), Two [Member] \| Swift Health Systems Inc. [Member]
Cash Rate	10.75%
Margin	5.25%
Floor	9.00%
Ceiling Rate	0.00%
ETP	5.00%
Maturity Date	Jul. 01, 2027
Principal Amount	$ 3,500
Investments at cost	3,451
Investments at fair value	$ 3,451
Medical Device Sector [Member] \| Term Loan (9.50% cash (Prime + 6.25%; Floor 9.50%), 4.00% ETP, Due 10/1/24) One [Member] \| InfoBionic, Inc [Member]
Cash Rate		9.50%
Margin		6.25%
Floor		9.50%
Ceiling Rate		0.00%
ETP		4.00%
Maturity Date		Oct. 01, 2024
Principal Amount		$ 3,500
Investments at cost		3,397
Investments at fair value		$ 3,397
Medical Device Sector [Member] \| Term Loan (12.50% cash (Prime + 6.25%; Floor 9.50%), 6.0% ETP, Due 4/1/26) One [Member] \| Aerobiotix, LLC [Member]
Cash Rate	12.50%
Margin	6.25%
Floor	9.50%
Ceiling Rate	0.00%
ETP	6.00%
Maturity Date	Apr. 01, 2026
Principal Amount	$ 2,500
Investments at cost	2,462
Investments at fair value	$ 2,366
Medical Device Sector [Member] \| Term Loan (9.50% cash (Prime + 6.25%; Floor 9.50%), 4.00% ETP, Due 6/1/25) One [Member] \| InfoBionic, Inc [Member]
Cash Rate		9.50%
Margin		6.25%
Floor		9.50%
Ceiling Rate		0.00%
ETP		4.00%
Maturity Date		Jun. 01, 2025
Principal Amount		$ 1,000
Investments at cost		963
Investments at fair value		$ 963
Medical Device Sector [Member] \| Term Loan (12.50% cash (Prime + 6.25%; Floor 9.50%), 6.0% ETP, Due 4/1/26) Two [Member] \| Aerobiotix, LLC [Member]
Cash Rate	12.50%
Margin	6.25%
Floor	9.50%
Ceiling Rate	0.00%
ETP	6.00%
Maturity Date	Apr. 01, 2026
Principal Amount	$ 2,500
Investments at cost	2,462
Investments at fair value	$ 2,365
Medical Device Sector [Member] \| Term Loan (10.08% cash (Libor + 7.68%; Floor 10.08%), 6.00% ETP, Due 9/1/23) One [Member] \| MacuLogix, Inc [Member]
Cash Rate		10.08%
Margin		7.68%
Floor		10.08%
Ceiling Rate		0.00%
ETP		6.00%
Maturity Date		Sep. 01, 2023
Principal Amount		$ 7,500
Investments at cost		7,447
Investments at fair value		$ 4,481
Medical Device Sector [Member] \| Term Loan (11.25% cash (Prime + 5.75%; Floor 9.00%), 7.00% ETP, Due 11/1/24) One [Member] \| Canary Medical Inc. [Member]
Cash Rate	11.25%
Margin	5.75%
Floor	9.00%
Ceiling Rate	0.00%
ETP	7.00%
Maturity Date	Nov. 01, 2024
Principal Amount	$ 2,500
Investments at cost	2,438
Investments at fair value	$ 2,438
Medical Device Sector [Member] \| Term Loan (10.08% cash (Libor + 7.68%; Floor 10.08%), 6.00% ETP, Due 9/1/23) Two [Member] \| MacuLogix, Inc [Member]
Cash Rate		10.08%
Margin		7.68%
Floor		10.08%
Ceiling Rate		0.00%
ETP		6.00%
Maturity Date		Sep. 01, 2023
Principal Amount		$ 4,050
Investments at cost		4,022
Investments at fair value		$ 2,420
Medical Device Sector [Member] \| Term Loan (11.25% cash (Prime + 5.75%; Floor 9.00%), 7.00% ETP, Due 11/1/24) Two [Member] \| Canary Medical Inc. [Member]
Cash Rate	11.25%
Margin	5.75%
Floor	9.00%
Ceiling Rate	0.00%
ETP	7.00%
Maturity Date	Nov. 01, 2024
Principal Amount	$ 2,500
Investments at cost	2,486
Investments at fair value	$ 2,486
Medical Device Sector [Member] \| Term Loan (9.75% cash (Prime + 5.00%; Floor 9.75%), 4.00% ETP, Due 3/1/25) One [Member] \| Magnolia Medical Technologies, Inc [Member]
Cash Rate		9.75%
Margin		5.00%
Floor		9.75%
Ceiling Rate		0.00%
ETP		4.00%
Maturity Date		Mar. 01, 2025
Principal Amount		$ 5,000
Investments at cost		4,952
Investments at fair value		$ 4,952
Medical Device Sector [Member] \| Term Loan (11.25% cash (Prime + 5.75%; Floor 9.00%), 7.00% ETP, Due 11/1/24) Three [Member] \| Canary Medical Inc. [Member]
Cash Rate	11.25%
Margin	5.75%
Floor	9.00%
Ceiling Rate	0.00%
ETP	7.00%
Maturity Date	Nov. 01, 2024
Principal Amount	$ 2,500
Investments at cost	2,466
Investments at fair value	$ 2,466
Medical Device Sector [Member] \| Term Loan (9.75% cash (Prime + 5.00%; Floor 9.75%), 4.00% ETP, Due 3/1/25) Two [Member] \| Magnolia Medical Technologies, Inc [Member]
Cash Rate		9.75%
Margin		5.00%
Floor		9.75%
Ceiling Rate		0.00%
ETP		4.00%
Maturity Date		Mar. 01, 2025
Principal Amount		$ 5,000
Investments at cost		4,952
Investments at fair value		$ 4,952
Medical Device Sector [Member] \| Term Loan (9.00% cash (Prime + 3.75%; Floor 8.25%), 5.50% ETP, Due 10/1/24) One [Member] \| Ceribell, Inc. [Member]
Cash Rate	9.00%
Margin	3.75%
Floor	8.25%
Ceiling Rate	0.00%
ETP	5.50%
Maturity Date	Oct. 01, 2024
Principal Amount	$ 5,000
Investments at cost	4,965
Investments at fair value	$ 4,965
Medical Device Sector [Member] \| Term Loan (9.75% cash (Prime + 5.00%; Floor 9.75%), 4.00% ETP, Due 3/1/25) Three [Member] \| Magnolia Medical Technologies, Inc [Member]
Cash Rate		9.75%
Margin		5.00%
Floor		9.75%
Ceiling Rate		0.00%
ETP		4.00%
Maturity Date		Mar. 01, 2025
Principal Amount		$ 5,000
Investments at cost		4,944
Investments at fair value		$ 4,944
Medical Device Sector [Member] \| Term Loan (9.00% cash (Prime + 3.75%; Floor 8.25%), 5.50% ETP, Due 10/1/24) Two [Member] \| Ceribell, Inc. [Member]
Cash Rate	9.00%
Margin	3.75%
Floor	8.25%
Ceiling Rate	0.00%
ETP	5.50%
Maturity Date	Oct. 01, 2024
Principal Amount	$ 5,000
Investments at cost	4,969
Investments at fair value	$ 4,969
Medical Device Sector [Member] \| Term Loan (9.75% cash (Prime + 5.00%; Floor 9.75%), 4.00% ETP, Due 3/1/25) Four [Member] \| Magnolia Medical Technologies, Inc [Member]
Cash Rate		9.75%
Margin		5.00%
Floor		9.75%
Ceiling Rate		0.00%
ETP		4.00%
Maturity Date		Mar. 01, 2025
Principal Amount		$ 5,000
Investments at cost		4,944
Investments at fair value		4,944
Medical Device Sector [Member] \| Term Loan (9.00% cash (Prime + 3.75%; Floor 8.25%), 5.50% ETP, Due 10/1/24) Three [Member] \| Ceribell, Inc. [Member]
Cash Rate	9.00%
Margin	3.75%
Floor	8.25%
Ceiling Rate	0.00%
ETP	5.50%
Maturity Date	Oct. 01, 2024
Principal Amount	$ 2,500
Investments at cost	2,475
Investments at fair value	2,475
Medical Device Sector [Member] \| Royalty Agreement [Member] \| Lumithera, Inc. [Member]
Investments at cost	1,200
Investments at fair value	1,100
Medical Device Sector [Member] \| Royalty Agreement [Member] \| ZetrOZ, Inc [Member]
Investments at cost	0	0
Investments at fair value	$ 200	$ 200
Medical Device Sector [Member] \| Term Loan (9.25% cash (Prime + 6.00%; Floor 9.25%), 5.00% ETP, Due 6/1/24) One [Member] \| Sonex Health, Inc. [Member]
Cash Rate		9.25%
Margin		6.00%
Floor		9.25%
Ceiling Rate		0.00%
ETP		5.00%
Maturity Date		Jun. 01, 2024
Principal Amount		$ 2,500
Investments at cost		2,391
Investments at fair value		$ 2,391
Medical Device Sector [Member] \| Term Loan (9.00% cash (Prime + 3.75%; Floor 8.25%), 5.50% ETP, Due 10/1/24) Four [Member] \| Ceribell, Inc. [Member]
Cash Rate	9.00%
Margin	3.75%
Floor	8.25%
Ceiling Rate	0.00%
ETP	5.50%
Maturity Date	Oct. 01, 2024
Principal Amount	$ 2,500
Investments at cost	2,475
Investments at fair value	$ 2,475
Medical Device Sector [Member] \| Term Loan (9.25% cash (Prime + 6.00%; Floor 9.25%), 5.00% ETP, Due 6/1/24) Two [Member] \| Sonex Health, Inc. [Member]
Cash Rate		9.25%
Margin		6.00%
Floor		9.25%
Ceiling Rate		0.00%
ETP		5.00%
Maturity Date		Jun. 01, 2024
Principal Amount		$ 2,500
Investments at cost		2,472
Investments at fair value		$ 2,472
Medical Device Sector [Member] \| Term Loan (11.75% cash (Prime + 5.50%; Floor 8.75%), 6.0% ETP, Due 8/1/26) One [Member] \| Cognoa, Inc. [Member]
Cash Rate	11.75%
Margin	5.50%
Floor	8.75%
Ceiling Rate	0.00%
ETP	6.00%
Maturity Date	Aug. 01, 2026
Principal Amount	$ 5,000
Investments at cost	4,924
Investments at fair value	$ 4,924
Medical Device Sector [Member] \| Term Loan (9.25% cash (Prime + 6.00%; Floor 9.25%), 5.00% ETP, Due 6/1/24) Three [Member] \| Sonex Health, Inc. [Member]
Cash Rate		9.25%
Margin		6.00%
Floor		9.25%
Ceiling Rate		0.00%
ETP		5.00%
Maturity Date		Jun. 01, 2024
Principal Amount		$ 2,500
Investments at cost		2,472
Investments at fair value		$ 2,472
Medical Device Sector [Member] \| Term Loan (11.75% cash (Prime + 5.50%; Floor 8.75%), 6.0% ETP, Due 8/1/26) Two [Member] \| Cognoa, Inc. [Member]
Cash Rate	11.75%
Margin	5.50%
Floor	8.75%
Ceiling Rate	0.00%
ETP	6.00%
Maturity Date	Aug. 01, 2026
Principal Amount	$ 2,500
Investments at cost	2,462
Investments at fair value	$ 2,462
Medical Device Sector [Member] \| Term Loan (10.25% cash (Prime + 7.00%; Floor 10.25%), 1.00% ETP, Due 10/1/25) One [Member] \| Spineology, Inc [Member]
Cash Rate		10.25%
Margin		7.00%
Floor		10.25%
Ceiling Rate		0.00%
ETP		1.00%
Maturity Date		Oct. 01, 2025
Principal Amount		$ 5,000
Investments at cost		4,928
Investments at fair value		$ 4,928
Medical Device Sector [Member] \| Term Loan (10.55% cash (Libor + 8.00%; Floor 9.25%), 10.36% ETP, Due 7/1/25) One [Member] \| Conventus Orthopaedics, Inc [Member]
Cash Rate	10.55%
Margin	8.00%
Floor	9.25%
Ceiling Rate	0.00%
ETP	10.36%
Maturity Date	Jul. 01, 2025
Principal Amount	$ 3,960
Investments at cost	3,892
Investments at fair value	3,892
Medical Device Sector [Member] \| Common Stock [Member] \| Lumithera, Inc. [Member]
Investments at cost	2,000
Investments at fair value	$ 1,700
Number of Shares (in shares)	392,651
Medical Device Sector [Member] \| Term Loan (10.55% cash (Libor + 8.00%; Floor 9.25%), 10.36% ETP, Due 7/1/25) Two [Member] \| Conventus Orthopaedics, Inc [Member]
Cash Rate	10.55%
Margin	8.00%
Floor	9.25%
Ceiling Rate	0.00%
ETP	10.36%
Maturity Date	Jul. 01, 2025
Principal Amount	$ 3,960
Investments at cost	3,892
Investments at fair value	$ 3,892
Medical Device Sector [Member] \| Term Loan (10.75% cash (Prime + 5.25%; Floor 8.50%), 20.00% ETP, Due 9/15/22) One [Member] \| Corinth Medtech, Inc [Member]
Cash Rate	10.75%
Margin	5.25%
Floor	8.50%
Ceiling Rate	0.00%
ETP	20.00%
Maturity Date	Sep. 15, 2022
Principal Amount	$ 2,500
Investments at cost	2,500
Investments at fair value	$ 2,500
Medical Device Sector [Member] \| Term Loan (10.75% cash (Prime + 5.25%; Floor 8.50%), 20.00% ETP, Due 9/15/22) Two [Member] \| Corinth Medtech, Inc [Member]
Cash Rate	10.75%
Margin	5.25%
Floor	8.50%
Ceiling Rate	0.00%
ETP	20.00%
Maturity Date	Sep. 15, 2022
Principal Amount	$ 2,500
Investments at cost	2,500
Investments at fair value	$ 2,500
Medical Device Sector [Member] \| Term Loan (10.75% cash (Libor + 8.20%; Floor 10.00%), 5.00% ETP, Due 1/1/24) One [Member] \| CSA Medical, Inc [Member]
Cash Rate	10.75%
Margin	8.20%
Floor	10.00%
Ceiling Rate	0.00%
ETP	5.00%
Maturity Date	Jan. 01, 2024
Principal Amount	$ 2,000
Investments at cost	1,981
Investments at fair value	$ 1,981
Medical Device Sector [Member] \| Term Loan (10.75% cash (Libor + 8.20%; Floor 10.00%), 5.00% ETP, Due 1/1/24) Two [Member] \| CSA Medical, Inc [Member]
Cash Rate	10.75%
Margin	8.20%
Floor	10.00%
Ceiling Rate	0.00%
ETP	5.00%
Maturity Date	Jan. 01, 2024
Principal Amount	$ 133
Investments at cost	132
Investments at fair value	$ 132
Medical Device Sector [Member] \| Term Loan (10.75% cash (Libor + 8.20%; Floor 10.00%), 5.00% ETP, Due 3/1/24) [Member] \| CSA Medical, Inc [Member]
Cash Rate	10.75%
Margin	8.20%
Floor	10.00%
Ceiling Rate	0.00%
ETP	5.00%
Maturity Date	Mar. 01, 2024
Principal Amount	$ 2,400
Investments at cost	2,379
Investments at fair value	$ 2,379
Medical Device Sector [Member] \| Term Loan (12.75% cash (Prime + 6.50%; Floor 9.75%), 28.00% ETP, Due 8/1/26) [Member] \| Embody, Inc. [Member]
Cash Rate	12.75%
Margin	6.50%
Floor	9.75%
Ceiling Rate	0.00%
ETP	28.00%
Maturity Date	Aug. 01, 2026
Principal Amount	$ 2,500
Investments at cost	2,461
Investments at fair value	$ 2,461
Medical Device Sector [Member] \| Term Loan (11.75% cash (Prime + 6.25%; Floor 9.50%), 4.00% ETP, Due 10/1/24) [Member] \| InfoBionic, Inc [Member]
Cash Rate	11.75%
Margin	6.25%
Floor	9.50%
Ceiling Rate	0.00%
ETP	4.00%
Maturity Date	Oct. 01, 2024
Principal Amount	$ 3,500
Investments at cost	3,425
Investments at fair value	$ 3,425
Medical Device Sector [Member] \| Term Loan (11.75% cash (Prime + 6.25%; Floor 9.50%), 4.00% ETP, Due 6/1/25) [Member] \| InfoBionic, Inc [Member]
Cash Rate	11.75%
Margin	6.25%
Floor	9.50%
Ceiling Rate	0.00%
ETP	4.00%
Maturity Date	Jun. 01, 2025
Principal Amount	$ 1,000
Investments at cost	971
Investments at fair value	$ 971
Medical Device Sector [Member] \| Term Loan (10.50% cash (Prime + 5.00%; Floor 9.75%), 4.00% ETP, Due 3/1/25) One [Member] \| Magnolia Medical Technologies, Inc [Member]
Cash Rate	10.50%
Margin	5.00%
Floor	9.75%
Ceiling Rate	0.00%
ETP	4.00%
Maturity Date	Mar. 01, 2025
Principal Amount	$ 5,000
Investments at cost	4,810
Investments at fair value	$ 4,810
Medical Device Sector [Member] \| Term Loan (10.50% cash (Prime + 5.00%; Floor 9.75%), 4.00% ETP, Due 3/1/25) Two [Member] \| Magnolia Medical Technologies, Inc [Member]
Cash Rate	10.50%
Margin	5.00%
Floor	9.75%
Ceiling Rate	0.00%
ETP	4.00%
Maturity Date	Mar. 01, 2025
Principal Amount	$ 5,000
Investments at cost	4,932
Investments at fair value	$ 4,932
Medical Device Sector [Member] \| Term Loan (10.50% cash (Prime + 5.00%; Floor 9.75%), 4.00% ETP, Due 3/1/25) Three [Member] \| Magnolia Medical Technologies, Inc [Member]
Cash Rate	10.50%
Margin	5.00%
Floor	9.75%
Ceiling Rate	0.00%
ETP	4.00%
Maturity Date	Mar. 01, 2025
Principal Amount	$ 5,000
Investments at cost	4,925
Investments at fair value	$ 4,925
Medical Device Sector [Member] \| Term Loan (10.50% cash (Prime + 5.00%; Floor 9.75%), 4.00% ETP, Due 3/1/25) Four [Member] \| Magnolia Medical Technologies, Inc [Member]
Cash Rate	10.50%
Margin	5.00%
Floor	9.75%
Ceiling Rate	0.00%
ETP	4.00%
Maturity Date	Mar. 01, 2025
Principal Amount	$ 5,000
Investments at cost	4,926
Investments at fair value	$ 4,926
Medical Device Sector [Member] \| Term Loan (10.25% cash (Prime + 4.75%; Floor 8.50%), 5.00% ETP, Due 1/1/27) One [Member] \| Scientia Vascular, Inc. [Member]
Cash Rate	10.25%
Margin	4.75%
Floor	8.50%
Ceiling Rate	0.00%
ETP	5.00%
Maturity Date	Jan. 01, 2027
Principal Amount	$ 3,750
Investments at cost	3,593
Investments at fair value	$ 3,593
Medical Device Sector [Member] \| Term Loan (10.25% cash (Prime + 4.75%; Floor 8.50%), 5.00% ETP, Due 1/1/27) Two [Member] \| Scientia Vascular, Inc. [Member]
Cash Rate	10.25%
Margin	4.75%
Floor	8.50%
Ceiling Rate	0.00%
ETP	5.00%
Maturity Date	Jan. 01, 2027
Principal Amount	$ 3,750
Investments at cost	3,702
Investments at fair value	$ 3,702
Medical Device Sector [Member] \| Term Loan (12.00% cash (Prime + 6.50%; Floor 9.75%), 5.00% ETP, Due 6/1/25) One [Member] \| Sonex Health, Inc. [Member]
Cash Rate	12.00%
Margin	6.50%
Floor	9.75%
Ceiling Rate	0.00%
ETP	5.00%
Maturity Date	Jun. 01, 2025
Principal Amount	$ 2,500
Investments at cost	2,428
Investments at fair value	$ 2,428
Medical Device Sector [Member] \| Term Loan (9.00% cash (Prime + 5.75%; Floor 9.00%), 7.00% ETP, Due 11/1/24) One [Member] \| Canary Medical Inc. [Member]
Cash Rate		9.00%
Margin		5.75%
Floor		9.00%
Ceiling Rate		0.00%
ETP		7.00%
Maturity Date		Nov. 01, 2024
Principal Amount		$ 2,500
Investments at cost		2,394
Investments at fair value		$ 2,394
Medical Device Sector [Member] \| Term Loan (12.00% cash (Prime + 6.50%; Floor 9.75%), 5.00% ETP, Due 6/1/25) Two [Member] \| Sonex Health, Inc. [Member]
Cash Rate	12.00%
Margin	6.50%
Floor	9.75%
Ceiling Rate	0.00%
ETP	5.00%
Maturity Date	Jun. 01, 2025
Principal Amount	$ 2,500
Investments at cost	2,473
Investments at fair value	$ 2,473
Medical Device Sector [Member] \| Term Loan (8.25% cash (Libor + 6.70%; Floor 8.25%), 5.50% ETP, Due 10/1/24) One [Member] \| Ceribell, Inc. [Member]
Cash Rate		8.25%
Margin		6.70%
Floor		8.25%
Ceiling Rate		0.00%
ETP		5.50%
Maturity Date		Oct. 01, 2024
Principal Amount		$ 5,000
Investments at cost		4,926
Investments at fair value		$ 4,926
Medical Device Sector [Member] \| Term Loan (12.00% cash (Prime + 6.50%; Floor 9.75%), 5.00% ETP, Due 6/1/25) Three [Member] \| Sonex Health, Inc. [Member]
Cash Rate	12.00%
Margin	6.50%
Floor	9.75%
Ceiling Rate	0.00%
ETP	5.00%
Maturity Date	Jun. 01, 2025
Principal Amount	$ 2,500
Investments at cost	2,473
Investments at fair value	$ 2,473
Medical Device Sector [Member] \| Term Loan (8.25% cash (Libor + 6.70%; Floor 8.25%), 5.50% ETP, Due 10/1/24) Two [Member] \| Ceribell, Inc. [Member]
Cash Rate		8.25%
Margin		6.70%
Floor		8.25%
Ceiling Rate		0.00%
ETP		5.50%
Maturity Date		Oct. 01, 2024
Principal Amount		$ 5,000
Investments at cost		4,957
Investments at fair value		$ 4,957
Medical Device Sector [Member] \| Term Loan (12.00% cash (Prime + 6.50%; Floor 9.75%), 8.00% ETP, Due 4/1/26) [Member] \| Sonex Health, Inc. [Member]
Cash Rate	12.00%
Margin	6.50%
Floor	9.75%
Ceiling Rate	0.00%
ETP	8.00%
Maturity Date	Apr. 01, 2026
Principal Amount	$ 2,500
Investments at cost	2,455
Investments at fair value	$ 2,455
Medical Device Sector [Member] \| Term Loan (8.25% cash (Libor + 6.70%; Floor 8.25%), 5.50% ETP, Due 10/1/24) Three [Member] \| Ceribell, Inc. [Member]
Cash Rate		8.25%
Margin		6.70%
Floor		8.25%
Ceiling Rate		0.00%
ETP		5.50%
Maturity Date		Oct. 01, 2024
Principal Amount		$ 2,500
Investments at cost		2,466
Investments at fair value		$ 2,466
Medical Device Sector [Member] \| Term Loan (13.25% cash (Prime + 7.00%; Floor 10.25%), 1.00% ETP, Due 10/1/25) [Member] \| Spineology, Inc [Member]
Cash Rate	13.25%
Margin	7.00%
Floor	10.25%
Ceiling Rate	0.00%
ETP	1.00%
Maturity Date	Oct. 01, 2025
Principal Amount	$ 5,000
Investments at cost	4,963
Investments at fair value	$ 4,963
Medical Device Sector [Member] \| Term Loan (8.25% cash (Libor + 6.70%; Floor 8.25%), 5.50% ETP, Due 10/1/24) Four [Member] \| Ceribell, Inc. [Member]
Cash Rate		8.25%
Margin		6.70%
Floor		8.25%
Ceiling Rate		0.00%
ETP		5.50%
Maturity Date		Oct. 01, 2024
Principal Amount		$ 2,500
Investments at cost		2,466
Investments at fair value		$ 2,466
Medical Device Sector [Member] \| Term Loan (13.25% cash (Prime + 7.00%; Floor 10.25%), 1.00% ETP, Due 4/1/26) [Member] \| Spineology, Inc [Member]
Cash Rate	13.25%
Margin	7.00%
Floor	10.25%
Ceiling Rate	0.00%
ETP	1.00%
Maturity Date	Apr. 01, 2026
Principal Amount	$ 2,500
Investments at cost	2,479
Investments at fair value	2,479
Medical Device Sector [Member] \| Term Loan (9.25% cash (Libor + 8.00%; Floor 9.25%), 10.36% ETP, Due 7/1/25) One [Member] \| Conventus Orthopaedics, Inc [Member]
Cash Rate		9.25%
Margin		8.00%
Floor		9.25%
Ceiling Rate		0.00%
ETP		10.36%
Maturity Date		Jul. 01, 2025
Principal Amount		$ 4,056
Investments at cost		4,009
Investments at fair value		$ 4,009
Medical Device Sector [Member] \| Term Loan (9.25% cash (Libor + 8.00%; Floor 9.25%), 10.36% ETP, Due 7/1/25) Two [Member] \| Conventus Orthopaedics, Inc [Member]
Cash Rate		9.25%
Margin		8.00%
Floor		9.25%
Ceiling Rate		0.00%
ETP		10.36%
Maturity Date		Jul. 01, 2025
Principal Amount		$ 4,056
Investments at cost		4,009
Investments at fair value		$ 4,009
Medical Device Sector [Member] \| Term Loan (8.50% cash (Prime + 5.25%; Floor 8.50%), 20.00% ETP, Due 4/1/22) One [Member] \| Corinth Medtech, Inc [Member]
Cash Rate		8.50%
Margin		5.25%
Floor		8.50%
Ceiling Rate		0.00%
ETP		20.00%
Maturity Date		Apr. 01, 2022
Principal Amount		$ 2,500
Investments at cost		2,495
Investments at fair value		$ 2,495
Medical Device Sector [Member] \| Term Loan (8.50% cash (Prime + 5.25%; Floor 8.50%), 20.00% ETP, Due 4/1/22) Two [Member] \| Corinth Medtech, Inc [Member]
Cash Rate		8.50%
Margin		5.25%
Floor		8.50%
Ceiling Rate		0.00%
ETP		20.00%
Maturity Date		Apr. 01, 2022
Principal Amount		$ 2,500
Investments at cost		2,495
Investments at fair value		$ 2,495
Medical Device Sector [Member] \| Term Loan (10.00% cash (Libor + 8.20%; Floor 10.00%), 5.00% ETP, Due 1/1/24) One [Member] \| CSA Medical, Inc [Member]
Cash Rate		10.00%
Margin		8.20%
Floor		10.00%
Ceiling Rate		0.00%
ETP		5.00%
Maturity Date		Jan. 01, 2024
Principal Amount		$ 3,125
Investments at cost		3,095
Investments at fair value		$ 3,095
Medical Device Sector [Member] \| Term Loan (10.00% cash (Libor + 8.20%; Floor 10.00%), 5.00% ETP, Due 1/1/24) Two [Member] \| CSA Medical, Inc [Member]
Cash Rate		10.00%
Margin		8.20%
Floor		10.00%
Ceiling Rate		0.00%
ETP		5.00%
Maturity Date		Jan. 01, 2024
Principal Amount		$ 208
Investments at cost		206
Investments at fair value		206
Consumer-related Technologies [Member] \| Common Stock Warrants [Member] \| Aterian, Inc [Member]
Investments at cost	195	195
Investments at fair value	$ 0	$ 1
Number of Shares (in shares)	76,923	76,923
Consumer-related Technologies [Member] \| Common Stock Warrants [Member] \| Updater, Inc [Member]
Investments at cost	$ 34	$ 34
Investments at fair value	$ 12	$ 31
Number of Shares (in shares)	108,333	108,333
Consumer-related Technologies [Member] \| Term Loan (11.25% cash (Prime + 6.00%; Floor 9.50%), 3.00% ETP, Due 7/1/27) One [Member] \| Divergent Technologies, Inc. [Member]
Cash Rate	11.25%
Margin	6.00%
Floor	9.50%
Ceiling Rate	11.25%
ETP	3.00%
Maturity Date	Jul. 01, 2027
Principal Amount	$ 3,750
Investments at cost	3,397
Investments at fair value	3,397
Consumer-related Technologies [Member] \| Term Loan (9.75% cash (Prime + 6.50%; Floor 9.75%), 4.00% ETP, Due 1/1/26), Two [Member] \| Interior Define, Inc. [Member]
Cash Rate		9.75%
Margin		6.50%
Floor		9.75%
Ceiling Rate		0.00%
ETP		4.00%
Maturity Date		Jan. 01, 2026
Principal Amount		$ 6,000
Investments at cost		5,775
Investments at fair value		5,775
Consumer-related Technologies [Member] \| Preferred Stock Warrants [Member] \| Divergent Technologies, Inc. [Member]
Investments at cost	30
Investments at fair value	$ 35
Number of Shares (in shares)	25,758
Consumer-related Technologies [Member] \| Preferred Stock Warrants [Member] \| Interior Define, Inc. [Member]
Investments at cost	$ 103	103
Investments at fair value	$ 0	$ 103
Number of Shares (in shares)	553,710	553,710
Consumer-related Technologies [Member] \| Preferred Stock Warrants [Member] \| NextCar Holding Company, Inc [Member]
Investments at cost	$ 188	$ 47
Investments at fair value	$ 116	$ 47
Number of Shares (in shares)	630,626	310,463
Consumer-related Technologies [Member] \| Preferred Stock Warrants [Member] \| Alula Holdings, Inc [Member]
Investments at cost	$ 93	$ 93
Investments at fair value	$ 57	$ 70
Number of Shares (in shares)	20,000	20,000
Consumer-related Technologies [Member] \| Preferred Stock Warrants [Member] \| Primary Kids, Inc [Member]
Investments at cost	$ 57	$ 57
Investments at fair value	$ 425	$ 51
Number of Shares (in shares)	553,778	553,778
Consumer-related Technologies [Member] \| Preferred Stock Warrants [Member] \| Better Place Forests Co. [Member]
Investments at cost	$ 27	$ 23
Investments at fair value	$ 32	$ 23
Number of Shares (in shares)	10,690	9,353
Consumer-related Technologies [Member] \| Preferred Stock Warrants [Member] \| Caastle, Inc [Member]
Investments at cost	$ 68	$ 68
Investments at fair value	$ 1,068	$ 823
Number of Shares (in shares)	268,591	268,591
Consumer-related Technologies [Member] \| Preferred Stock Warrants [Member] \| CAMP NYC, Inc [Member]
Investments at cost	$ 24	$ 22
Investments at fair value	$ 61	$ 22
Number of Shares (in shares)	17,605	17,605
Consumer-related Technologies [Member] \| Preferred Stock Warrants [Member] \| Quip NYC Inc [Member]
Investments at cost	$ 324	$ 324
Investments at fair value	$ 525	$ 503
Number of Shares (in shares)	6,191	6,191
Consumer-related Technologies [Member] \| Preferred Stock Warrants [Member] \| Clara Foods Co [Member]
Investments at cost	$ 31	$ 30
Investments at fair value	$ 378	$ 368
Number of Shares (in shares)	46,745	46,745
Consumer-related Technologies [Member] \| Preferred Stock Warrants [Member] \| Unagi, Inc [Member]
Investments at cost	$ 32	$ 25
Investments at fair value	$ 38	$ 24
Number of Shares (in shares)	171,081	134,421
Consumer-related Technologies [Member] \| Preferred Stock Warrants [Member] \| Getaround, Inc [Member]
Investments at cost	$ 450	$ 450
Investments at fair value	$ 199	$ 367
Number of Shares (in shares)	651,040	651,040
Consumer-related Technologies [Member] \| Preferred Stock Warrants [Member] \| MyForest Foods Co [Member]
Investments at cost	$ 29
Investments at fair value	$ 33
Number of Shares (in shares)	143
Consumer-related Technologies [Member] \| Preferred Stock Warrants [Member] \| Optoro, Inc. [Member]
Investments at cost	$ 104
Investments at fair value	$ 104
Number of Shares (in shares)	6,600
Consumer-related Technologies [Member] \| Term Loan (11.25% cash (Prime + 6.00%; Floor 9.50%), 3.00% ETP, Due 7/1/27) Two [Member] \| Divergent Technologies, Inc. [Member]
Cash Rate	11.25%
Margin	6.00%
Floor	9.50%
Ceiling Rate	11.25%
ETP	3.00%
Maturity Date	Jul. 01, 2027
Principal Amount	$ 1,250
Investments at cost	1,237
Investments at fair value	$ 1,237
Consumer-related Technologies [Member] \| Term Loan (10.00% cash (Prime + 6.75%; Floor 10.00%), 9.75% ETP, Due 1/1/24) [Member] \| Lyrical Foods, Inc [Member]
Cash Rate		10.00%
Margin		6.75%
Floor		10.00%
Ceiling Rate		0.00%
ETP		9.75%
Maturity Date		Jan. 01, 2024
Principal Amount		$ 2,500
Investments at cost		2,480
Investments at fair value		$ 2,480
Consumer-related Technologies [Member] \| Term Loan (11.25% cash (Prime + 6.00%; Floor 9.50%), 3.00% ETP, Due 7/1/27) Three [Member] \| Divergent Technologies, Inc. [Member]
Cash Rate	11.25%
Margin	6.00%
Floor	9.50%
Ceiling Rate	11.25%
ETP	3.00%
Maturity Date	Jul. 01, 2027
Principal Amount	$ 3,750
Investments at cost	3,712
Investments at fair value	$ 3,712
Consumer-related Technologies [Member] \| Term Loan (9.00% cash (Prime + 5.75%; Floor 9.00%), 10.10% ETP, Due 1/1/26), One [Member] \| NextCar Holding Company, Inc [Member]
Cash Rate		9.00%
Margin		5.75%
Floor		9.00%
Ceiling Rate		0.00%
ETP		10.10%
Maturity Date		Jan. 01, 2026
Principal Amount		$ 5,000
Investments at cost		4,935
Investments at fair value		$ 4,935
Consumer-related Technologies [Member] \| Term Loan (11.25% cash (Prime + 6.00%; Floor 9.50%), 3.00% ETP, Due 7/1/27) Four [Member] \| Divergent Technologies, Inc. [Member]
Cash Rate	11.25%
Margin	6.00%
Floor	9.50%
Ceiling Rate	11.25%
ETP	3.00%
Maturity Date	Jul. 01, 2027
Principal Amount	$ 1,250
Investments at cost	1,237
Investments at fair value	$ 1,237
Consumer-related Technologies [Member] \| Term Loan (9.00% cash (Prime + 5.75%; Floor 9.00%), 10.10% ETP, Due 1/1/26), Two [Member] \| NextCar Holding Company, Inc [Member]
Cash Rate		9.00%
Margin		5.75%
Floor		9.00%
Ceiling Rate		0.00%
ETP		10.10%
Maturity Date		Jan. 01, 2026
Principal Amount		$ 2,000
Investments at cost		1,920
Investments at fair value		$ 1,920
Consumer-related Technologies [Member] \| Term Loan (11.25% cash (Prime + 6.00%; Floor 9.50%), 3.00% ETP, Due 7/1/27) Five [Member] \| Divergent Technologies, Inc. [Member]
Cash Rate	11.25%
Margin	6.00%
Floor	9.50%
Ceiling Rate	11.25%
ETP	3.00%
Maturity Date	Jul. 01, 2027
Principal Amount	$ 3,750
Investments at cost	3,712
Investments at fair value	$ 3,712
Consumer-related Technologies [Member] \| Term Loan (10.50% cash (Prime + 7.25%; Floor 10.50%), 3.00% ETP, Due 3/1/25), One [Member] \| Primary Kids, Inc [Member]
Cash Rate		10.50%
Margin		7.25%
Floor		10.50%
Ceiling Rate		0.00%
ETP		3.00%
Maturity Date		Mar. 01, 2025
Principal Amount		$ 3,000
Investments at cost		2,961
Investments at fair value		$ 2,961
Consumer-related Technologies [Member] \| Term Loan (11.25% cash (Prime + 6.00%; Floor 9.50%), 3.00% ETP, Due 7/1/27) Six [Member] \| Divergent Technologies, Inc. [Member]
Cash Rate	11.25%
Margin	6.00%
Floor	9.50%
Ceiling Rate	11.25%
ETP	3.00%
Maturity Date	Jul. 01, 2027
Principal Amount	$ 1,250
Investments at cost	1,237
Investments at fair value	$ 1,237
Consumer-related Technologies [Member] \| Term Loan (10.50% cash (Prime + 7.25%; Floor 10.50%), 3.00% ETP, Due 3/1/25), Two [Member] \| Primary Kids, Inc [Member]
Cash Rate		10.50%
Margin		7.25%
Floor		10.50%
Ceiling Rate		0.00%
ETP		3.00%
Maturity Date		Mar. 01, 2025
Principal Amount		$ 3,000
Investments at cost		2,961
Investments at fair value		$ 2,961
Consumer-related Technologies [Member] \| Term Loan (12.75% cash (Prime + 6.50%; Floor 9.75%), 4.00% ETP, Due 1/1/26) One [Member] \| Interior Define, Inc. [Member]
Cash Rate	12.75%
Margin	6.50%
Floor	9.75%
Ceiling Rate	0.00%
ETP	4.00%
Maturity Date	Jan. 01, 2026
Principal Amount	$ 6,500
Investments at cost	6,417
Investments at fair value	$ 5,215
Consumer-related Technologies [Member] \| Term Loan (10.50% cash (Prime + 7.25%; Floor 10.50%), 3.00% ETP, Due 9/1/25) [Member] \| Primary Kids, Inc [Member]
Cash Rate		10.50%
Margin		7.25%
Floor		10.50%
Ceiling Rate		0.00%
ETP		3.00%
Maturity Date		Sep. 01, 2025
Principal Amount		$ 3,000
Investments at cost		2,955
Investments at fair value		$ 2,955
Consumer-related Technologies [Member] \| Term Loan (12.75% cash (Prime + 6.50%; Floor 9.75%), 4.00% ETP, Due 1/1/26) Two [Member] \| Interior Define, Inc. [Member]
Cash Rate	12.75%
Margin	6.50%
Floor	9.75%
Ceiling Rate	0.00%
ETP	4.00%
Maturity Date	Jan. 01, 2026
Principal Amount	$ 6,000
Investments at cost	5,858
Investments at fair value	$ 4,760
Consumer-related Technologies [Member] \| Term Loan (11.25% cash (Prime + 8.00%; Floor 11.25%), 3.00% ETP, Due 4/1/26) [Member] \| Quip NYC Inc [Member]
Cash Rate		11.25%
Margin		8.00%
Floor		11.25%
Ceiling Rate		0.00%
ETP		3.00%
Maturity Date		Apr. 01, 2026
Principal Amount		$ 10,000
Investments at cost		9,639
Investments at fair value		$ 9,639
Consumer-related Technologies [Member] \| Term Loan (13.00% cash (Prime + 6.75%; Floor 10.00%), 9.75% ETP, Due 1/1/24) [Member] \| Lyrical Foods, Inc [Member]
Cash Rate	13.00%
Margin	6.75%
Floor	10.00%
Ceiling Rate	0.00%
ETP	9.75%
Maturity Date	Jan. 01, 2024
Principal Amount	$ 2,500
Investments at cost	2,585
Investments at fair value	$ 2,219
Consumer-related Technologies [Member] \| Term Loan (11.00% cash (Prime + 7.75%; Floor 11.00%), Due 7/1/25), One [Member] \| Unagi, Inc [Member]
Cash Rate		11.00%
Margin		7.75%
Floor		11.00%
Ceiling Rate		0.00%
ETP		0.00%
Maturity Date		Jul. 01, 2025
Principal Amount		$ 2,500
Investments at cost		2,446
Investments at fair value		$ 2,446
Consumer-related Technologies [Member] \| Term Loan (13.00% cash (Prime + 6.75%; Floor 10.00%), 3.00% ETP, Due 10/1/25) One [Member] \| MyForest Foods Co [Member]
Cash Rate	13.00%
Margin	6.75%
Floor	10.00%
Ceiling Rate	0.00%
ETP	3.00%
Maturity Date	Oct. 01, 2025
Principal Amount	$ 5,000
Investments at cost	4,947
Investments at fair value	$ 4,947
Consumer-related Technologies [Member] \| Term Loan (11.00% cash (Prime + 7.75%; Floor 11.00%), Due 7/1/25), Two [Member] \| Unagi, Inc [Member]
Cash Rate		11.00%
Margin		7.75%
Floor		11.00%
Ceiling Rate		0.00%
ETP		0.00%
Maturity Date		Jul. 01, 2025
Principal Amount		$ 1,250
Investments at cost		1,234
Investments at fair value		$ 1,234
Consumer-related Technologies [Member] \| Term Loan (13.00% cash (Prime + 6.75%; Floor 10.00%), 3.00% ETP, Due 10/1/25) Two [Member] \| MyForest Foods Co [Member]
Cash Rate	13.00%
Margin	6.75%
Floor	10.00%
Ceiling Rate	0.00%
ETP	3.00%
Maturity Date	Oct. 01, 2025
Principal Amount	$ 2,500
Investments at cost	2,474
Investments at fair value	$ 2,474
Consumer-related Technologies [Member] \| Term Loan (12.00% cash (Prime + 5.75%; Floor 12.00%, Ceiling 14.00%),0.56% ETP, Due 12/20/24), One [Member] \| Updater, Inc [Member]
Cash Rate		12.00%
Margin		5.75%
Floor		12.00%
Ceiling Rate		14.00%
ETP		0.56%
Maturity Date		Dec. 20, 2024
Principal Amount		$ 5,000
Investments at cost		4,961
Investments at fair value		$ 4,961
Consumer-related Technologies [Member] \| Term Loan (11.25% cash (Prime + 5.75%; Floor 9.00%), 2.00% ETP, Due 1/1/26) One [Member] \| NextCar Holding Company, Inc [Member]
Cash Rate	11.25%
Margin	5.75%
Floor	9.00%
Ceiling Rate	0.00%
ETP	2.00%
Maturity Date	Jan. 01, 2026
Principal Amount	$ 5,000
Investments at cost	4,947
Investments at fair value	$ 4,947
Consumer-related Technologies [Member] \| Term Loan (12.00% cash (Prime + 5.75%; Floor 12.00%, Ceiling 14.00%),0.56% ETP, Due 12/20/24), Two [Member] \| Updater, Inc [Member]
Cash Rate		12.00%
Margin		5.75%
Floor		12.00%
Ceiling Rate		14.00%
ETP		0.56%
Maturity Date		Dec. 20, 2024
Principal Amount		$ 5,000
Investments at cost		4,961
Investments at fair value		$ 4,961
Consumer-related Technologies [Member] \| Term Loan (11.25% cash (Prime + 5.75%; Floor 9.00%), 2.00% ETP, Due 1/1/26) Two [Member] \| NextCar Holding Company, Inc [Member]
Cash Rate	11.25%
Margin	5.75%
Floor	9.00%
Ceiling Rate	0.00%
ETP	2.00%
Maturity Date	Jan. 01, 2026
Principal Amount	$ 2,000
Investments at cost	1,979
Investments at fair value	$ 1,979
Consumer-related Technologies [Member] \| Term Loan (12.00% cash (Prime + 5.75%; Floor 12.00%, Ceiling 14.00%),0.56% ETP, Due 12/20/24), Three [Member] \| Updater, Inc [Member]
Cash Rate		12.00%
Margin		5.75%
Floor		12.00%
Ceiling Rate		14.00%
ETP		0.56%
Maturity Date		Dec. 20, 2024
Principal Amount		$ 10,000
Investments at cost		9,922
Investments at fair value		9,922
Consumer-related Technologies [Member] \| Term Loan (11.25% cash (Prime + 5.75%; Floor 9.00%), 2.00% ETP, Due 1/1/26) Three [Member] \| NextCar Holding Company, Inc [Member]
Cash Rate	11.25%
Margin	5.75%
Floor	9.00%
Ceiling Rate	0.00%
ETP	2.00%
Maturity Date	Jan. 01, 2026
Principal Amount	$ 2,500
Investments at cost	2,474
Investments at fair value	2,474
Consumer-related Technologies [Member] \| Common Stock [Member] \| SnagAJob.com, Inc [Member]
Investments at cost	8	9
Investments at fair value	$ 83	$ 83
Number of Shares (in shares)	829,674	82,974
Consumer-related Technologies [Member] \| Term Loan (11.25% cash (Prime + 5.75%; Floor 9.00%), 2.00% ETP, Due 1/1/26) Four [Member] \| NextCar Holding Company, Inc [Member]
Cash Rate	11.25%
Margin	5.75%
Floor	9.00%
Ceiling Rate	0.00%
ETP	2.00%
Maturity Date	Jan. 01, 2026
Principal Amount	$ 3,000
Investments at cost	2,968
Investments at fair value	$ 2,968
Consumer-related Technologies [Member] \| Term Loan (11.25% cash (Prime + 5.75%; Floor 9.00%), 2.00% ETP, Due 1/1/26) Five [Member] \| NextCar Holding Company, Inc [Member]
Cash Rate	11.25%
Margin	5.75%
Floor	9.00%
Ceiling Rate	0.00%
ETP	2.00%
Maturity Date	Jan. 01, 2026
Principal Amount	$ 2,500
Investments at cost	2,453
Investments at fair value	$ 2,453
Consumer-related Technologies [Member] \| Term Loan (11.25% cash (Prime + 5.75%; Floor 9.00%), 2.00% ETP, Due 1/1/26) Six [Member] \| NextCar Holding Company, Inc [Member]
Cash Rate	11.25%
Margin	5.75%
Floor	9.00%
Ceiling Rate	0.00%
ETP	2.00%
Maturity Date	Jan. 01, 2026
Principal Amount	$ 2,500
Investments at cost	2,453
Investments at fair value	$ 2,453
Consumer-related Technologies [Member] \| Term Loan (11.25% cash (Prime + 5.75%; Floor 9.00%), 2.00% ETP, Due 1/1/26) Seven [Member] \| NextCar Holding Company, Inc [Member]
Cash Rate	11.25%
Margin	5.75%
Floor	9.00%
Ceiling Rate	0.00%
ETP	2.00%
Maturity Date	Jan. 01, 2026
Principal Amount	$ 5,000
Investments at cost	4,904
Investments at fair value	$ 4,904
Consumer-related Technologies [Member] \| Term Loan (11.25% cash (Prime + 5.75%; Floor 9.00%), 2.00% ETP, Due 1/1/26) Eight [Member] \| NextCar Holding Company, Inc [Member]
Cash Rate	11.25%
Margin	5.75%
Floor	9.00%
Ceiling Rate	0.00%
ETP	2.00%
Maturity Date	Jan. 01, 2026
Principal Amount	$ 2,500
Investments at cost	2,450
Investments at fair value	$ 2,450
Consumer-related Technologies [Member] \| Term Loan (11.75% cash (Prime + 6.25%; Floor 9.50%), 4.00% ETP, Due 8/1/27) [Member] \| Optoro, Inc. [Member]
Cash Rate	11.75%
Margin	6.25%
Floor	9.50%
Ceiling Rate	0.00%
ETP	4.00%
Maturity Date	Aug. 01, 2027
Principal Amount	$ 2,500
Investments at cost	2,339
Investments at fair value	$ 2,339
Consumer-related Technologies [Member] \| Term Loan (12.75% cash (Prime + 7.25%; Floor 10.50%), 3.00% ETP, Due 3/1/25) One [Member] \| Primary Kids, Inc [Member]
Cash Rate	12.75%
Margin	7.25%
Floor	10.50%
Ceiling Rate	0.00%
ETP	3.00%
Maturity Date	Mar. 01, 2025
Principal Amount	$ 2,900
Investments at cost	2,870
Investments at fair value	$ 2,870
Consumer-related Technologies [Member] \| Term Loan (12.75% cash (Prime + 7.25%; Floor 10.50%), 3.00% ETP, Due 3/1/25) Two [Member] \| Primary Kids, Inc [Member]
Cash Rate	12.75%
Margin	7.25%
Floor	10.50%
Ceiling Rate	0.00%
ETP	3.00%
Maturity Date	Mar. 01, 2025
Principal Amount	$ 2,900
Investments at cost	2,870
Investments at fair value	$ 2,870
Consumer-related Technologies [Member] \| Term Loan (12.75% cash (Prime + 7.25%; Floor 10.50%), 3.00% ETP, Due 9/1/25) [Member] \| Primary Kids, Inc [Member]
Cash Rate	12.75%
Margin	7.25%
Floor	10.50%
Ceiling Rate	0.00%
ETP	3.00%
Maturity Date	Sep. 01, 2025
Principal Amount	$ 3,000
Investments at cost	2,964
Investments at fair value	$ 2,964
Consumer-related Technologies [Member] \| Term Loan (14.00% cash (Prime + 7.75%; Floor 11.00%), Due 7/1/25) One [Member] \| Unagi, Inc [Member]
Cash Rate	14.00%
Margin	7.25%
Floor	11.00%
Ceiling Rate	0.00%
ETP	0.00%
Maturity Date	Jul. 01, 2025
Principal Amount	$ 2,500
Investments at cost	2,471
Investments at fair value	$ 2,317
Consumer-related Technologies [Member] \| Term Loan (12.25% cash (Prime + 6.75%; Floor 10.00%), 3.00% ETP, Due 1/1/25) One [Member] \| Alula Holdings, Inc [Member]
Cash Rate	12.25%
Margin	6.75%
Floor	10.00%
Ceiling Rate	0.00%
ETP	3.00%
Maturity Date	Jan. 01, 2025
Principal Amount	$ 5,000
Investments at cost	4,961
Investments at fair value	$ 4,961
Consumer-related Technologies [Member] \| Term Loan (14.00% cash (Prime + 7.75%; Floor 11.00%), Due 7/1/25) Two [Member] \| Unagi, Inc [Member]
Cash Rate	14.00%
Margin	7.25%
Floor	11.00%
Ceiling Rate	0.00%
ETP	0.00%
Maturity Date	Jul. 01, 2025
Principal Amount	$ 1,250
Investments at cost	1,235
Investments at fair value	$ 1,158
Consumer-related Technologies [Member] \| Term Loan (12.25% cash (Prime + 6.75%; Floor 10.00%), 3.00% ETP, Due 1/1/25) Two [Member] \| Alula Holdings, Inc [Member]
Cash Rate	12.25%
Margin	6.75%
Floor	10.00%
Ceiling Rate	0.00%
ETP	3.00%
Maturity Date	Jan. 01, 2025
Principal Amount	$ 5,000
Investments at cost	4,961
Investments at fair value	$ 4,961
Consumer-related Technologies [Member] \| Term Loan (14.00% cash (Prime + 7.75%; Floor 11.00%), Due 7/1/25) Three [Member] \| Unagi, Inc [Member]
Cash Rate	14.00%
Margin	7.25%
Floor	11.00%
Ceiling Rate	0.00%
ETP	0.00%
Maturity Date	Jul. 01, 2025
Principal Amount	$ 1,250
Investments at cost	1,234
Investments at fair value	$ 1,157
Consumer-related Technologies [Member] \| Term Loan (12.25% cash (Prime + 6.75%; Floor 10.00%), 3.00% ETP, Due 1/1/25) Three [Member] \| Alula Holdings, Inc [Member]
Cash Rate	12.25%
Margin	6.75%
Floor	10.00%
Ceiling Rate	0.00%
ETP	3.00%
Maturity Date	Jan. 01, 2025
Principal Amount	$ 3,000
Investments at cost	2,977
Investments at fair value	$ 2,977
Consumer-related Technologies [Member] \| Term Loan (12.25% cash (Prime + 6.75%; Floor 10.00%), 3.00% ETP, Due 12/1/25) [Member] \| Alula Holdings, Inc [Member]
Cash Rate	12.25%
Margin	6.75%
Floor	10.00%
Ceiling Rate	0.00%
ETP	3.00%
Maturity Date	Dec. 01, 2025
Principal Amount	$ 1,000
Investments at cost	974
Investments at fair value	$ 974
Consumer-related Technologies [Member] \| Term Loan (12.25% cash (Prime + 6.75%; Floor 10.00%), 3.00% ETP, Due 2/1/26) [Member] \| Alula Holdings, Inc [Member]
Cash Rate	12.25%
Margin	6.75%
Floor	10.00%
Ceiling Rate	0.00%
ETP	3.00%
Maturity Date	Feb. 01, 2026
Principal Amount	$ 1,000
Investments at cost	974
Investments at fair value	$ 974
Consumer-related Technologies [Member] \| Term Loan (10.00% cash (Prime + 6.75%; Floor 10.00%), 3.00% ETP, Due 1/1/25), One [Member] \| Alula Holdings, Inc [Member]
Cash Rate		10.00%
Margin		6.75%
Floor		10.00%
Ceiling Rate		0.00%
ETP		3.00%
Maturity Date		Jan. 01, 2025
Principal Amount		$ 5,000
Investments at cost		4,935
Investments at fair value		$ 4,935
Consumer-related Technologies [Member] \| Term Loan (12.50% cash (Prime + 6.25%; Floor 9.50%), 1.85% ETP, Due 7/1/25) [Member] \| Better Place Forests Co. [Member]
Cash Rate	12.50%
Margin	6.25%
Floor	9.50%
Ceiling Rate	0.00%
ETP	1.85%
Maturity Date	Jul. 01, 2025
Principal Amount	$ 5,000
Investments at cost	4,944
Investments at fair value	$ 4,944
Consumer-related Technologies [Member] \| Term Loan (10.00% cash (Prime + 6.75%; Floor 10.00%), 3.00% ETP, Due 1/1/25), Two [Member] \| Alula Holdings, Inc [Member]
Cash Rate		10.00%
Margin		6.75%
Floor		10.00%
Ceiling Rate		0.00%
ETP		3.00%
Maturity Date		Jan. 01, 2025
Principal Amount		$ 5,000
Investments at cost		4,949
Investments at fair value		$ 4,949
Consumer-related Technologies [Member] \| Term Loan (12.50% cash (Prime + 6.25%; Floor 9.50%), 1.85% ETP, Due 10/1/25) [Member] \| Better Place Forests Co. [Member]
Cash Rate	12.50%
Margin	6.25%
Floor	9.50%
Ceiling Rate	0.00%
ETP	1.85%
Maturity Date	Oct. 01, 2025
Principal Amount	$ 2,500
Investments at cost	2,474
Investments at fair value	$ 2,474
Consumer-related Technologies [Member] \| Term Loan (10.00% cash (Prime + 6.75%; Floor 10.00%), 3.00% ETP, Due 1/1/25), Three [Member] \| Alula Holdings, Inc [Member]
Cash Rate		10.00%
Margin		6.75%
Floor		10.00%
Ceiling Rate		0.00%
ETP		3.00%
Maturity Date		Jan. 01, 2025
Principal Amount		$ 3,000
Investments at cost		2,969
Investments at fair value		$ 2,969
Consumer-related Technologies [Member] \| Term Loan (13.50% cash (Prime + 7.25%; Floor 10.50%), 3.00% ETP, Due 5/1/26) [Member] \| CAMP NYC, Inc [Member]
Cash Rate	13.50%
Margin	7.25%
Floor	10.50%
Ceiling Rate	0.00%
ETP	3.00%
Maturity Date	May 01, 2026
Principal Amount	$ 3,500
Investments at cost	3,458
Investments at fair value	$ 3,458
Consumer-related Technologies [Member] \| Term Loan (10.00% cash (Prime + 6.75%; Floor 10.00%), 3.00% ETP, Due 12/1/25) [Member] \| Alula Holdings, Inc [Member]
Cash Rate		10.00%
Margin		6.75%
Floor		10.00%
Ceiling Rate		0.00%
ETP		3.00%
Maturity Date		Dec. 01, 2025
Principal Amount		$ 1,000
Investments at cost		968
Investments at fair value		$ 968
Consumer-related Technologies [Member] \| Term Loan (11.25% cash (Prime + 5.75%; Floor 9.00%), 5.50% ETP, Due 8/1/25) One [Member] \| Clara Foods Co [Member]
Cash Rate	11.25%
Margin	5.75%
Floor	9.00%
Ceiling Rate	0.00%
ETP	5.50%
Maturity Date	Aug. 01, 2025
Principal Amount	$ 2,500
Investments at cost	2,481
Investments at fair value	$ 2,481
Consumer-related Technologies [Member] \| Term Loan (9.50% cash (Prime + 6.25%; Floor 9.50%), 1.85% ETP, Due 7/1/25) [Member] \| Better Place Forests Co. [Member]
Cash Rate		9.50%
Margin		6.25%
Floor		9.50%
Ceiling Rate		0.00%
ETP		1.85%
Maturity Date		Jul. 01, 2025
Principal Amount		$ 5,000
Investments at cost		4,928
Investments at fair value		$ 4,928
Consumer-related Technologies [Member] \| Term Loan (11.25% cash (Prime + 5.75%; Floor 9.00%), 5.50% ETP, Due 8/1/25) Two [Member] \| Clara Foods Co [Member]
Cash Rate	11.25%
Margin	5.75%
Floor	9.00%
Ceiling Rate	0.00%
ETP	5.50%
Maturity Date	Aug. 01, 2025
Principal Amount	$ 2,500
Investments at cost	2,481
Investments at fair value	2,481
Consumer-related Technologies [Member] \| Term Loan (10.50% cash (Prime + 7.25%; Floor 10.50%), 3.00% ETP, Due 5/1/26) [Member] \| CAMP NYC, Inc [Member]
Cash Rate		10.50%
Margin		7.25%
Floor		10.50%
Ceiling Rate		0.00%
ETP		3.00%
Maturity Date		May 01, 2026
Principal Amount		$ 3,500
Investments at cost		3,430
Investments at fair value		$ 3,430
Consumer-related Technologies [Member] \| Term Loan (9.00% cash (Prime + 5.75%; Floor 9.00%), 5.50% ETP, Due 8/1/25), One [Member] \| Clara Foods Co [Member]
Cash Rate		9.00%
Margin		5.75%
Floor		9.00%
Ceiling Rate		0.00%
ETP		5.50%
Maturity Date		Aug. 01, 2025
Principal Amount		$ 2,500
Investments at cost		2,476
Investments at fair value		$ 2,476
Consumer-related Technologies [Member] \| Term Loan (9.00% cash (Prime + 5.75%; Floor 9.00%), 5.50% ETP, Due 8/1/25), Two [Member] \| Alula Holdings, Inc [Member]
Cash Rate		9.00%
Margin		5.75%
Floor		9.00%
Ceiling Rate		0.00%
ETP		5.50%
Maturity Date		Aug. 01, 2025
Principal Amount		$ 2,500
Investments at cost		2,476
Investments at fair value		$ 2,476
Consumer-related Technologies [Member] \| Term Loan (9.75% cash (Prime + 6.50%; Floor 9.75%), 4.00% ETP, Due 1/1/26), One [Member] \| Interior Define, Inc. [Member]
Cash Rate		9.75%
Margin		6.50%
Floor		9.75%
Ceiling Rate		0.00%
ETP		4.00%
Maturity Date		Jan. 01, 2026
Principal Amount		$ 6,500
Investments at cost		6,397
Investments at fair value		6,397
Software Sector [Member]
Investments at cost	108,910	60,902
Investments at fair value	107,441	60,807
Software Sector [Member] \| Common Stock Warrants [Member] \| DropOff, Inc. [Member]
Investments at cost	455	397
Investments at fair value	$ 187	$ 395
Number of Shares (in shares)	516,732	482,283
Software Sector [Member] \| Common Stock Warrants [Member] \| Branded Online, Inc [Member]
Investments at cost		$ 370
Investments at fair value		$ 443
Number of Shares (in shares)		16,678
Software Sector [Member] \| Common Stock Warrants [Member] \| Decisyon, Inc [Member]
Investments at cost	$ 46	$ 46
Investments at fair value	$ 0	$ 0
Number of Shares (in shares)	82,967	82,967
Software Sector [Member] \| Common Stock Warrants [Member] \| E La Carte, Inc [Member]
Investments at cost	$ 60
Investments at fair value	$ 1
Number of Shares (in shares)	152,908
Software Sector [Member] \| Term Loan (12.75% cash (Prime + 6.50%; Floor 9.75%), 3.50% ETP, Due 4/1/26) One [Member] \| DropOff, Inc. [Member]
Cash Rate	12.75%
Margin	6.50%
Floor	9.75%
Ceiling Rate	0.00%
ETP	3.50%
Maturity Date	Apr. 01, 2026
Principal Amount	$ 6,500
Investments at cost	6,147
Investments at fair value	6,147
Software Sector [Member] \| Preferred Stock Warrants [Member] \| Kodiak Robotics, Inc. [Member]
Investments at cost	273
Investments at fair value	$ 273
Number of Shares (in shares)	639,918
Software Sector [Member] \| Preferred Stock Warrants [Member] \| BrightInsight, Inc. [Member]
Investments at cost	$ 157
Investments at fair value	$ 157
Number of Shares (in shares)	80,544
Software Sector [Member] \| Preferred Stock Warrants [Member] \| Medsphere Systems Corporation [Member]
Investments at cost	$ 60	$ 60
Investments at fair value	$ 341	$ 195
Number of Shares (in shares)	7,097,792	7,097,792
Software Sector [Member] \| Preferred Stock Warrants [Member] \| Lemongrass Holdings, Inc [Member]
Investments at cost	$ 34
Investments at fair value	$ 38
Number of Shares (in shares)	101,308
Software Sector [Member] \| Preferred Stock Warrants [Member] \| Lytics, Inc. [Member]
Investments at cost	$ 11	$ 12
Investments at fair value	$ 14	$ 12
Number of Shares (in shares)	26,733	26,733
Software Sector [Member] \| Preferred Stock Warrants [Member] \| Reputation Institute, Inc [Member]
Investments at cost	$ 56	$ 54
Investments at fair value	$ 35	$ 52
Number of Shares (in shares)	3,731	3,731
Software Sector [Member] \| Preferred Stock Warrants [Member] \| Slingshot Aerospace, Inc. [Member]
Investments at cost	$ 123
Investments at fair value	$ 123
Number of Shares (in shares)	309,208
Software Sector [Member] \| Preferred Stock Warrants [Member] \| Supply Network Visiblity Holdings LLC [Member]
Investments at cost	$ 64	$ 64
Investments at fair value	$ 74	$ 62
Number of Shares (in shares)	682	682
Software Sector [Member] \| Preferred Stock Warrants [Member] \| Britecore Holdings, Inc. [Member]
Investments at cost	$ 21	$ 5
Investments at fair value	$ 64	$ 37
Number of Shares (in shares)	77,828	55,591
Software Sector [Member] \| Preferred Stock Warrants [Member] \| E La Carte, Inc [Member]
Investments at cost		$ 61
Investments at fair value		$ 53
Number of Shares (in shares)		181,947
Software Sector [Member] \| Preferred Stock Warrants [Member] \| Lotame Solutions, Inc. [Member]
Investments at cost	$ 22	$ 23
Investments at fair value	$ 306	$ 276
Number of Shares (in shares)	288,115	288,115
Software Sector [Member] \| Preferred Stock Warrants [Member] \| Revinate Holdings, Inc [Member]
Investments at cost	$ 47	$ 44
Investments at fair value	$ 81	$ 66
Number of Shares (in shares)	498,241	615,475
Software Sector [Member] \| Preferred Stock Warrants [Member] \| Riv Data Corp [Member]
Investments at cost	$ 12	$ 12
Investments at fair value	$ 296	$ 292
Number of Shares (in shares)	321,428	321,428
Software Sector [Member] \| Preferred Stock Warrants [Member] \| SIGNiX, Inc [Member]
Investments at cost	$ 225	$ 224
Investments at fair value	$ 0	$ 0
Number of Shares (in shares)	186,235	186,235
Software Sector [Member] \| Preferred Stock Warrants [Member] \| Topia Mobility, Inc [Member]
Investments at cost	$ 135	$ 138
Investments at fair value	$ 0	$ 0
Number of Shares (in shares)	3,049,607	3,049,607
Software Sector [Member] \| Preferred Stock Warrants [Member] \| xAd, Inc [Member]
Investments at cost	$ 177	$ 179
Investments at fair value	$ 2	$ 1
Number of Shares (in shares)	4,343,348	4,343,348
Software Sector [Member] \| Term Loan (12.75% cash (Prime + 6.50%; Floor 9.75%), 3.50% ETP, Due 4/1/26) Two [Member] \| DropOff, Inc. [Member]
Cash Rate	12.75%
Margin	6.50%
Floor	9.75%
Ceiling Rate	0.00%
ETP	3.50%
Maturity Date	Apr. 01, 2026
Principal Amount	$ 6,000
Investments at cost	5,847
Investments at fair value	$ 5,847
Software Sector [Member] \| Term Loan (12.75% cash (Prime + 6.50%; Floor 9.75%), 3.50% ETP, Due 8/1/26) [Member] \| DropOff, Inc. [Member]
Cash Rate	12.75%
Margin	6.50%
Floor	9.75%
Ceiling Rate	0.00%
ETP	3.50%
Maturity Date	Aug. 01, 2026
Principal Amount	$ 2,500
Investments at cost	2,431
Investments at fair value	$ 2,431
Software Sector [Member] \| Term Loan (11.75% cash (Prime + 6.25%; Floor 9.75%), 4.50% ETP, Due 7/1/27) One [Member] \| Engage3, LLC [Member]
Cash Rate	12.75%
Margin	6.25%
Floor	9.75%
Ceiling Rate	0.00%
ETP	4.50%
Maturity Date	Jul. 01, 2027
Principal Amount	$ 3,750
Investments at cost	3,675
Investments at fair value	$ 3,675
Software Sector [Member] \| Term Loan (11.75% cash (Prime + 6.25%; Floor 9.75%), 4.50% ETP, Due 7/1/27) Two [Member] \| Engage3, LLC [Member]
Cash Rate	11.75%
Margin	6.25%
Floor	9.75%
Ceiling Rate	0.00%
ETP	4.50%
Maturity Date	Jul. 01, 2027
Principal Amount	$ 3,750
Investments at cost	3,715
Investments at fair value	$ 3,715
Software Sector [Member] \| Term Loan (11.75% cash (Prime + 5.50%; Floor 10.25%), 4.00% ETP, Due 4/1/26) One [Member] \| Kodiak Robotics, Inc. [Member]
Cash Rate	11.75%
Margin	5.50%
Floor	10.25%
Ceiling Rate	0.00%
ETP	4.00%
Maturity Date	Apr. 01, 2026
Principal Amount	$ 10,000
Investments at cost	9,809
Investments at fair value	$ 9,809
Software Sector [Member] \| Term Loan (11.75% cash (Prime + 5.50%; Floor 10.25%), 4.00% ETP, Due 4/1/26) Two [Member] \| Kodiak Robotics, Inc. [Member]
Cash Rate	11.75%
Margin	5.50%
Floor	10.25%
Ceiling Rate	0.00%
ETP	4.00%
Maturity Date	Apr. 01, 2026
Principal Amount	$ 10,000
Investments at cost	9,809
Investments at fair value	$ 9,809
Software Sector [Member] \| Term Loan (11.75% cash (Prime + 5.50%; Floor 10.25%), 4.00% ETP, Due 4/1/26) Three [Member] \| Kodiak Robotics, Inc. [Member]
Cash Rate	11.75%
Margin	5.50%
Floor	10.25%
Ceiling Rate	0.00%
ETP	4.00%
Maturity Date	Apr. 01, 2026
Principal Amount	$ 5,000
Investments at cost	4,904
Investments at fair value	4,904
Software Sector [Member] \| Warrant [Member] \| Skyword, Inc [Member]
Investments at cost	48	$ 49
Investments at fair value	$ 9	$ 4
Number of Shares (in shares)	301,055	301,055
Software Sector [Member] \| Term Loan (11.75% cash (Prime + 5.50%; Floor 10.25%), 4.00% ETP, Due 4/1/26) Four [Member] \| Kodiak Robotics, Inc. [Member]
Cash Rate	11.75%
Margin	5.50%
Floor	10.25%
Ceiling Rate	0.00%
ETP	4.00%
Maturity Date	Apr. 01, 2026
Principal Amount	$ 5,000
Investments at cost	4,904
Investments at fair value	$ 4,904
Software Sector [Member] \| Term Loan (12.75% cash (Prime + 6.50%; Floor 9.75%), 2.50% ETP, Due 3/1/26) One [Member] \| Lemongrass Holdings, Inc [Member]
Cash Rate	12.75%
Margin	6.50%
Floor	9.75%
Ceiling Rate	0.00%
ETP	2.50%
Maturity Date	Mar. 01, 2026
Principal Amount	$ 5,000
Investments at cost	4,941
Investments at fair value	$ 4,941
Software Sector [Member] \| Term Loan (12.75% cash (Prime + 6.50%; Floor 9.75%), 2.50% ETP, Due 3/1/26) Two [Member] \| Lemongrass Holdings, Inc [Member]
Cash Rate	12.75%
Margin	6.50%
Floor	9.75%
Ceiling Rate	0.00%
ETP	2.50%
Maturity Date	Mar. 01, 2026
Principal Amount	$ 2,500
Investments at cost	2,471
Investments at fair value	$ 2,471
Software Sector [Member] \| Term Loan (11.50% cash (Prime + 6.00%; Floor 9.25%), 3.00% ETP, Due 7/1/25) [Member] \| Lytics, Inc. [Member]
Cash Rate	11.50%
Margin	6.00%
Floor	9.25%
Ceiling Rate	0.00%
ETP	3.00%
Maturity Date	Jul. 01, 2025
Principal Amount	$ 2,500
Investments at cost	2,472
Investments at fair value	$ 2,472
Software Sector [Member] \| Term Loan (12.75% cash (Prime + 7.25%; Floor 10.50%), 3.00% ETP, Due 8/1/25) [Member] \| Reputation Institute, Inc [Member]
Cash Rate	12.75%
Margin	7.25%
Floor	10.50%
Ceiling Rate	0.00%
ETP	3.00%
Maturity Date	Aug. 01, 2025
Principal Amount	$ 5,000
Investments at cost	4,926
Investments at fair value	$ 4,926
Software Sector [Member] \| Term Loan (12.00% cash (Prime +5.75%; Floor 9.75%), 5.00% ETP, Due 8/1/26) One [Member] \| Slingshot Aerospace, Inc. [Member]
Cash Rate	12.00%
Margin	5.75%
Floor	9.75%
Ceiling Rate	0.00%
ETP	5.00%
Maturity Date	Aug. 01, 2026
Principal Amount	$ 5,000
Investments at cost	4,927
Investments at fair value	4,927
Software Sector [Member] \| Common Stock [Member] \| Branded Online, Inc [Member]
Investments at cost	1,079
Investments at fair value	$ 146
Number of Shares (in shares)	108,004
Software Sector [Member] \| Term Loan (12.00% cash (Prime +5.75%; Floor 9.75%), 5.00% ETP, Due 8/1/26) Two [Member] \| Slingshot Aerospace, Inc. [Member]
Cash Rate	12.00%
Margin	5.75%
Floor	9.75%
Ceiling Rate	0.00%
ETP	5.00%
Maturity Date	Aug. 01, 2026
Principal Amount	$ 5,000
Investments at cost	4,927
Investments at fair value	$ 4,927
Software Sector [Member] \| Term Loan (12.00% cash (Prime +5.75%; Floor 9.75%), 5.00% ETP, Due 8/1/26) Three [Member] \| Slingshot Aerospace, Inc. [Member]
Cash Rate	12.00%
Margin	5.75%
Floor	9.75%
Ceiling Rate	0.00%
ETP	5.00%
Maturity Date	Aug. 01, 2026
Principal Amount	$ 5,000
Investments at cost	4,863
Investments at fair value	$ 4,863
Software Sector [Member] \| Term Loan (12.00% cash (Prime +5.75%; Floor 9.75%), 5.00% ETP, Due 8/1/26) Four [Member] \| Slingshot Aerospace, Inc. [Member]
Cash Rate	12.00%
Margin	5.75%
Floor	9.75%
Ceiling Rate	0.00%
ETP	5.00%
Maturity Date	Aug. 01, 2026
Principal Amount	$ 5,000
Investments at cost	4,927
Investments at fair value	4,927
Software Sector [Member] \| Preferred and Common Stock [Member] \| Decisyon, Inc [Member]
Investments at cost	230	$ 230
Investments at fair value	$ 0	$ 120
Number of Shares (in shares)	72,638,663	72,638,663
Software Sector [Member] \| Term Loan (12.00% cash (Prime + 6.50%; Floor 9.75%), 4.00% ETP, Due 2/1/25) One [Member] \| Supply Network Visiblity Holdings LLC [Member]
Cash Rate	12.00%
Margin	6.50%
Floor	9.75%
Ceiling Rate	0.00%
ETP	4.00%
Maturity Date	Feb. 01, 2025
Principal Amount	$ 3,500
Investments at cost	3,469
Investments at fair value	$ 3,469
Software Sector [Member] \| Term Loan (12.00% cash (Prime + 6.50%; Floor 9.75%), 4.00% ETP, Due 2/1/25) Two [Member] \| Supply Network Visiblity Holdings LLC [Member]
Cash Rate	12.00%
Margin	6.50%
Floor	9.75%
Ceiling Rate	0.00%
ETP	4.00%
Maturity Date	Feb. 01, 2025
Principal Amount	$ 3,500
Investments at cost	3,469
Investments at fair value	$ 3,469
Software Sector [Member] \| Term Loan (9.50% cash (Prime + 6.25%; Floor 9.50%), 6.00% ETP, Due 9/1/26) [Member] \| Branded Online, Inc [Member]
Cash Rate		9.50%
Margin		6.25%
Floor		9.50%
Ceiling Rate		0.00%
ETP		6.00%
Maturity Date		Sep. 01, 2026
Principal Amount		$ 5,000
Investments at cost		4,719
Investments at fair value		$ 4,719
Software Sector [Member] \| Term Loan (12.00% cash (Prime + 6.50%; Floor 9.75%), 4.00% ETP, Due 12/1/25) One [Member] \| Supply Network Visiblity Holdings LLC [Member]
Cash Rate	12.00%
Margin	6.50%
Floor	9.75%
Ceiling Rate	0.00%
ETP	4.00%
Maturity Date	Dec. 01, 2025
Principal Amount	$ 2,500
Investments at cost	2,470
Investments at fair value	$ 2,470
Software Sector [Member] \| Term Loan (9.50% cash (Prime + 6.25%; Floor 9.50%), 6.00% ETP, Due 11/1/26) [Member] \| Branded Online, Inc [Member]
Cash Rate		9.50%
Margin		6.25%
Floor		9.50%
Ceiling Rate		0.00%
ETP		6.00%
Maturity Date		Nov. 01, 2026
Principal Amount		$ 2,500
Investments at cost		2,355
Investments at fair value		$ 2,355
Software Sector [Member] \| Term Loan (12.00% cash (Prime + 6.50%; Floor 9.75%), 4.00% ETP, Due 12/1/25) Two [Member] \| Supply Network Visiblity Holdings LLC [Member]
Cash Rate	12.00%
Margin	6.50%
Floor	9.75%
Ceiling Rate	0.00%
ETP	4.00%
Maturity Date	Dec. 01, 2025
Principal Amount	$ 2,500
Investments at cost	2,470
Investments at fair value	$ 2,470
Software Sector [Member] \| Term Loan (9.50% cash (Prime + 6.25%; Floor 9.50%), 0% ETP, Due 7/1/23) [Member] \| Branded Online, Inc [Member]
Cash Rate		9.50%
Margin		6.25%
Floor		9.50%
Ceiling Rate		0.00%
ETP		0.00%
Maturity Date		Jul. 01, 2023
Principal Amount		$ 5,000
Investments at cost		5,000
Investments at fair value		$ 5,000
Software Sector [Member] \| Term Loan (10.50% cash (Prime + 7.25%; Floor 10.50%), 4.00% ETP, Due 10/1/24), One [Member] \| Britecore Holdings, Inc. [Member]
Cash Rate		10.50%
Margin		7.25%
Floor		10.50%
Ceiling Rate		0.00%
ETP		4.00%
Maturity Date		Oct. 01, 2024
Principal Amount		$ 2,500
Investments at cost		2,481
Investments at fair value		$ 2,481
Software Sector [Member] \| Term Loan (10.50% cash (Prime + 7.25%; Floor 10.50%), 4.00% ETP, Due 10/1/24), Two [Member] \| Britecore Holdings, Inc. [Member]
Cash Rate		10.50%
Margin		7.25%
Floor		10.50%
Ceiling Rate		0.00%
ETP		4.00%
Maturity Date		Oct. 01, 2024
Principal Amount		$ 2,500
Investments at cost		2,481
Investments at fair value		$ 2,481
Software Sector [Member] \| Term Loan (12.68% cash (Prime + 9.23%; Floor 12.68%), 50.43% ETP, Due 1/1/23) [Member] \| Decisyon, Inc [Member]
Cash Rate		12.68%
Margin		9.23%
Floor		12.68%
Ceiling Rate		0.00%
ETP		50.43%
Maturity Date		Jan. 01, 2023
Principal Amount		$ 3,470
Investments at cost		3,470
Investments at fair value		$ 3,470
Software Sector [Member] \| Term Loan (9.75% cash (Prime + 6.50%; Floor 9.75%), 3.50% ETP, Due 4/1/26), One [Member] \| DropOff, Inc. [Member]
Cash Rate		9.75%
Margin		6.50%
Floor		9.75%
Ceiling Rate		0.00%
ETP		3.50%
Maturity Date		Apr. 01, 2026
Principal Amount		$ 6,500
Investments at cost		6,087
Investments at fair value		$ 6,087
Software Sector [Member] \| Term Loan (9.75% cash (Prime + 6.50%; Floor 9.75%), 3.50% ETP, Due 4/1/26), Two [Member] \| DropOff, Inc. [Member]
Cash Rate		9.75%
Margin		6.50%
Floor		9.75%
Ceiling Rate		0.00%
ETP		3.50%
Maturity Date		Apr. 01, 2026
Principal Amount		$ 6,000
Investments at cost		5,816
Investments at fair value		$ 5,816
Software Sector [Member] \| Term Loan (9.75% cash (Prime + 6.50%; Floor 9.75%), 4.00% ETP, Due 10/1/25), One [Member] \| E La Carte, Inc [Member]
Cash Rate		9.75%
Margin		6.50%
Floor		9.75%
Ceiling Rate		0.00%
ETP		4.00%
Maturity Date		Oct. 01, 2025
Principal Amount		$ 3,000
Investments at cost		2,937
Investments at fair value		$ 2,937
Software Sector [Member] \| Term Loan (11.00% cash (Prime + 5.50%; Floor 9.50%), 3.00% ETP, Due 8/1/27) One [Member] \| BrightInsight, Inc. [Member]
Cash Rate	11.00%
Margin	5.50%
Floor	9.50%
Ceiling Rate	0.00%
ETP	3.00%
Maturity Date	Aug. 01, 2027
Principal Amount	$ 7,000
Investments at cost	6,612
Investments at fair value	$ 6,612
Software Sector [Member] \| Term Loan (9.75% cash (Prime + 6.50%; Floor 9.75%), 4.00% ETP, Due 10/1/25), Two [Member] \| E La Carte, Inc [Member]
Cash Rate		9.75%
Margin		6.50%
Floor		9.75%
Ceiling Rate		0.00%
ETP		4.00%
Maturity Date		Oct. 01, 2025
Principal Amount		$ 3,000
Investments at cost		2,958
Investments at fair value		$ 2,958
Software Sector [Member] \| Term Loan (11.00% cash (Prime + 5.50%; Floor 9.50%), 3.00% ETP, Due 8/1/27) Two [Member] \| BrightInsight, Inc. [Member]
Cash Rate	11.00%
Margin	5.50%
Floor	9.50%
Ceiling Rate	0.00%
ETP	3.00%
Maturity Date	Aug. 01, 2027
Principal Amount	$ 3,500
Investments at cost	3,445
Investments at fair value	$ 3,445
Software Sector [Member] \| Term Loan (9.75% cash (Prime + 6.50%; Floor 9.75%), 4.00% ETP, Due 10/1/25), Three [Member] \| E La Carte, Inc [Member]
Cash Rate		9.75%
Margin		6.50%
Floor		9.75%
Ceiling Rate		0.00%
ETP		4.00%
Maturity Date		Oct. 01, 2025
Principal Amount		$ 1,500
Investments at cost		1,479
Investments at fair value		$ 1,479
Software Sector [Member] \| Term Loan (11.00% cash (Prime + 5.50%; Floor 9.50%), 3.00% ETP, Due 8/1/27) Three [Member] \| BrightInsight, Inc. [Member]
Cash Rate	11.00%
Margin	5.50%
Floor	9.50%
Ceiling Rate	0.00%
ETP	3.00%
Maturity Date	Aug. 01, 2027
Principal Amount	$ 3,500
Investments at cost	3,445
Investments at fair value	$ 3,445
Software Sector [Member] \| Term Loan (9.25% cash (Prime + 6.00%; Floor 9.25%), 4.00% ETP, Due 7/1/25) [Member] \| Lytics, Inc. [Member]
Cash Rate		9.25%
Margin		6.00%
Floor		9.25%
Ceiling Rate		0.00%
ETP		4.00%
Maturity Date		Jul. 01, 2025
Principal Amount		$ 2,500
Investments at cost		2,464
Investments at fair value		$ 2,464
Software Sector [Member] \| Term Loan (10.50% cash (Prime + 7.25%; Floor 10.50%), 3.00% ETP, Due 8/1/25) [Member] \| Reputation Institute, Inc [Member]
Cash Rate		10.50%
Margin		7.25%
Floor		10.50%
Ceiling Rate		0.00%
ETP		3.00%
Maturity Date		Aug. 01, 2025
Principal Amount		$ 5,000
Investments at cost		4,905
Investments at fair value		$ 4,905
Software Sector [Member] \| Term Loan (12.25% cash (Prime + 6.75%; Floor 10.00%), 4.00% ETP, Due 10/1/24) One [Member] \| Britecore Holdings, Inc. [Member]
Cash Rate	12.25%
Margin	6.75%
Floor	10.00%
Ceiling Rate	0.00%
ETP	4.00%
Maturity Date	Oct. 01, 2024
Principal Amount	$ 2,500
Investments at cost	2,420
Investments at fair value	$ 2,420
Software Sector [Member] \| Term Loan (9.75% cash (Prime + 6.50%; Floor 9.75%), 4.00% ETP, Due 2/1/25) [Member] \| Supply Network Visiblity Holdings LLC [Member]
Cash Rate		9.75%
Margin		6.50%
Floor		9.75%
Ceiling Rate		0.00%
ETP		4.00%
Maturity Date		Feb. 01, 2025
Principal Amount		$ 3,500
Investments at cost		3,458
Investments at fair value		$ 3,458
Software Sector [Member] \| Term Loan (12.25% cash (Prime + 6.75%; Floor 10.00%), 4.00% ETP, Due 10/1/24) Two [Member] \| Britecore Holdings, Inc. [Member]
Cash Rate	12.25%
Margin	6.75%
Floor	10.00%
Ceiling Rate	0.00%
ETP	4.00%
Maturity Date	Oct. 01, 2024
Principal Amount	$ 2,500
Investments at cost	2,486
Investments at fair value	$ 2,486
Software Sector [Member] \| Term Loan (9.75% cash (Prime + 6.50%; Floor 9.75%), 4.00% ETP, Due 2/1/25), Two [Member] \| Supply Network Visiblity Holdings LLC [Member]
Cash Rate		9.75%
Margin		6.50%
Floor		9.75%
Ceiling Rate		0.00%
ETP		4.00%
Maturity Date		Feb. 01, 2025
Principal Amount		$ 3,500
Investments at cost		3,458
Investments at fair value		$ 3,458
Software Sector [Member] \| Term Loan (15.68% cash (Prime + 9.43%; Floor 12.68%), 50.43% ETP, Due 12/31/22) [Member] \| Decisyon, Inc [Member]
Cash Rate	15.68%
Margin	9.43%
Floor	12.68%
Ceiling Rate	0.00%
ETP	50.43%
Maturity Date	Dec. 31, 2022
Principal Amount	$ 3,313
Investments at cost	3,313
Investments at fair value	3,313
Software Sector [Member] \| Term Loan (9.75% cash (Prime + 6.50%; Floor 9.75%), 4.00% ETP, Due 12/1/25), One [Member] \| Supply Network Visiblity Holdings LLC [Member]
Cash Rate		9.75%
Margin		6.50%
Floor		9.75%
Ceiling Rate		0.00%
ETP		4.00%
Maturity Date		Dec. 01, 2025
Principal Amount		$ 2,500
Investments at cost		2,463
Investments at fair value		$ 2,463
Software Sector [Member] \| Term Loan (9.75% cash (Prime + 6.50%; Floor 9.75%), 4.00% ETP, Due 12/1/25), Two [Member] \| Supply Network Visiblity Holdings LLC [Member]
Cash Rate		9.75%
Margin		6.50%
Floor		9.75%
Ceiling Rate		0.00%
ETP		4.00%
Maturity Date		Dec. 01, 2025
Principal Amount		$ 2,500
Investments at cost		2,463
Investments at fair value		2,463
Diagnostics Sector [Member]
Investments at cost	9,840	12,393
Investments at fair value	9,844	12,377
Diagnostics Sector [Member] \| Preferred Stock Warrants [Member] \| Hound Labs, Inc. [Member]
Investments at cost	47
Investments at fair value	$ 51
Number of Shares (in shares)	159,893
Diagnostics Sector [Member] \| Preferred Stock Warrants [Member] \| IDbyDNA, Inc. [Member]
Investments at cost		112
Investments at fair value		$ 95
Number of Shares (in shares)		472,006
Diagnostics Sector [Member] \| Term Loan (12.25% cash (Prime + 6.00%; Floor 9.25%), 3.50% ETP, Due 6/1/26) One [Member] \| Hound Labs, Inc. [Member]
Cash Rate	12.25%
Margin	6.00%
Floor	9.25%
Ceiling Rate	0.00%
ETP	3.50%
Maturity Date	Jun. 01, 2026
Principal Amount	$ 2,500
Investments at cost	2,383
Investments at fair value	$ 2,383
Diagnostics Sector [Member] \| Term Loan (12.25% cash (Prime + 6.00%; Floor 9.25%), 3.50% ETP, Due 6/1/26) Two [Member] \| Hound Labs, Inc. [Member]
Cash Rate	12.25%
Margin	6.00%
Floor	9.25%
Ceiling Rate	0.00%
ETP	3.50%
Maturity Date	Jun. 01, 2026
Principal Amount	$ 2,500
Investments at cost	2,470
Investments at fair value	$ 2,470
Diagnostics Sector [Member] \| Term Loan (12.25% cash (Prime + 6.00%; Floor 9.25%), 3.50% ETP, Due 6/1/26) Three [Member] \| Hound Labs, Inc. [Member]
Cash Rate	12.25%
Margin	6.00%
Floor	9.25%
Ceiling Rate	0.00%
ETP	3.50%
Maturity Date	Jun. 01, 2026
Principal Amount	$ 5,000
Investments at cost	4,940
Investments at fair value	4,940
Diagnostics Sector [Member] \| Term Loan (9.00% cash (Prime + 5.75%; Floor 9.00%), 5.50% ETP, Due 1/1/25), One [Member] \| IDbyDNA, Inc. [Member]
Cash Rate		9.00%
Margin		5.75%
Floor		9.00%
Ceiling Rate		0.00%
ETP		5.50%
Maturity Date		Jan. 01, 2025
Principal Amount		$ 5,000
Investments at cost		4,902
Investments at fair value		$ 4,902
Diagnostics Sector [Member] \| Term Loan (9.00% cash (Prime + 5.75%; Floor 9.00%), 5.50% ETP, Due 1/1/25), Two [Member] \| IDbyDNA, Inc. [Member]
Cash Rate		9.00%
Margin		5.75%
Floor		9.00%
Ceiling Rate		0.00%
ETP		5.50%
Maturity Date		Jan. 01, 2025
Principal Amount		$ 5,000
Investments at cost		4,936
Investments at fair value		$ 4,936
Diagnostics Sector [Member] \| Term Loan (9.00% cash (Prime + 5.75%; Floor 9.00%), 5.50% ETP, Due 1/1/26) [Member] \| IDbyDNA, Inc. [Member]
Cash Rate		9.00%
Margin		5.75%
Floor		9.00%
Ceiling Rate		0.00%
ETP		5.50%
Maturity Date		Jan. 01, 2026
Principal Amount		$ 2,500
Investments at cost		2,444
Investments at fair value		2,444
Life Science [Member] \| Debt Securities [Member] \| Non-affiliate [Member]
Investments at cost	255,997
Investments at fair value	255,525
Other Healthcare Sector [Member] \| Preferred Stock Warrants [Member] \| Kate Farms, Inc [Member]
Investments at cost	103	101
Investments at fair value	$ 1,217	$ 1,177
Number of Shares (in shares)	82,965	82,965
Other Healthcare Sector [Member] \| Preferred Stock Warrants [Member] \| Watermark Medical, Inc [Member]
Investments at cost	$ 73	$ 74
Investments at fair value	$ 0	$ 0
Number of Shares (in shares)	27,373	27,373
Other Healthcare Sector [Member] \| Preferred Stock Warrants [Member] \| Secure Transfusion Services, Inc [Member]
Investments at cost	$ 48
Investments at fair value	$ 68
Number of Shares (in shares)	77,690
Other Healthcare Sector [Member] \| Term Loan (12.00% cash (Prime + 5.75%; Floor 9.00%), 4.00% ETP, Due 10/1/25) [Member] \| Secure Transfusion Services, Inc [Member]
Cash Rate	12.00%
Margin	5.75%
Floor	9.00%
Ceiling Rate	0.00%
ETP	4.00%
Maturity Date	Oct. 01, 2025
Principal Amount	$ 5,000
Investments at cost	4,934
Investments at fair value	$ 4,934
Other Healthcare Sector [Member] \| Term Loan (12.00% cash (Prime + 5.75%; Floor 9.00%), 4.00% ETP, Due 12/31/25) [Member] \| Secure Transfusion Services, Inc [Member]
Cash Rate	12.00%
Margin	5.75%
Floor	9.00%
Ceiling Rate	0.00%
ETP	4.00%
Maturity Date	Dec. 31, 2025
Principal Amount	$ 2,500
Investments at cost	2,463
Investments at fair value	2,463
Other Sustainability Sector [Member]
Investments at cost	77,024	$ 46,595
Investments at fair value	77,700	47,011
Other Sustainability Sector [Member] \| Common Stock Warrants [Member] \| Nexii Building Solutions, Inc [Member]
Investments at cost	489	356
Investments at fair value	$ 888	$ 331
Number of Shares (in shares)	209,669	142,405
Other Sustainability Sector [Member] \| Common Stock Warrants [Member] \| LiquiGlide, Inc [Member]
Investments at cost	$ 39	$ 39
Investments at fair value	$ 45	$ 36
Number of Shares (in shares)	61,539	61,359
Other Sustainability Sector [Member] \| Preferred Stock Warrants [Member] \| Dream Holdings, Inc [Member]
Investments at cost	$ 61
Investments at fair value	$ 68
Number of Shares (in shares)	70,539
Other Sustainability Sector [Member] \| Preferred Stock Warrants [Member] \| Soli Organic, Inc [Member]
Investments at cost	$ 214
Investments at fair value	$ 345
Number of Shares (in shares)	681
Other Sustainability Sector [Member] \| Preferred Stock Warrants [Member] \| Temperpack Technologies, Inc [Member]
Investments at cost	$ 126	$ 107
Investments at fair value	$ 259	$ 552
Number of Shares (in shares)	35,906	48,756
Other Sustainability Sector [Member] \| Debt Securities [Member] \| Non-affiliate [Member]
Investments at cost	$ 76,095
Investments at fair value	$ 76,095
Other Sustainability Sector [Member] \| Term Loan (13.00% cash (Prime + 6.75%; Floor 10.00%), 3.00% ETP, Due 4/1/26) One [Member] \| Dream Holdings, Inc [Member]
Cash Rate	13.00%
Margin	6.75%
Floor	10.00%
Ceiling Rate	0.00%
ETP	3.00%
Maturity Date	Apr. 01, 2026
Principal Amount	$ 3,750
Investments at cost	3,692
Investments at fair value	$ 3,692
Other Sustainability Sector [Member] \| Term Loan (13.00% cash (Prime + 6.75%; Floor 10.00%), 3.00% ETP, Due 4/1/26) Two [Member] \| Dream Holdings, Inc [Member]
Cash Rate	13.00%
Margin	6.75%
Floor	10.00%
Ceiling Rate	0.00%
ETP	3.00%
Maturity Date	Apr. 01, 2026
Principal Amount	$ 3,750
Investments at cost	3,692
Investments at fair value	$ 3,692
Other Sustainability Sector [Member] \| Term Loan (13.25% cash (Prime + 7.00%; Floor 10.25%), 2.50% ETP, Due 9/1/25) One [Member] \| Nexii Building Solutions, Inc [Member]
Cash Rate	13.25%
Margin	7.00%
Floor	10.25%
Ceiling Rate	0.00%
ETP	2.50%
Maturity Date	Sep. 01, 2025
Principal Amount	$ 7,500
Investments at cost	7,359
Investments at fair value	$ 7,359
Other Sustainability Sector [Member] \| Term Loan (13.25% cash (Prime + 7.00%; Floor 10.25%), 2.50% ETP, Due 9/1/25) Two [Member] \| Nexii Building Solutions, Inc [Member]
Cash Rate	13.25%
Margin	7.00%
Floor	10.25%
Ceiling Rate	0.00%
ETP	2.50%
Maturity Date	Sep. 01, 2025
Principal Amount	$ 7,500
Investments at cost	7,359
Investments at fair value	$ 7,359
Other Sustainability Sector [Member] \| Term Loan (13.25% cash (Prime + 7.00%; Floor 10.25%), 2.50% ETP, Due 9/1/25) Three [Member] \| Nexii Building Solutions, Inc [Member]
Cash Rate	13.25%
Margin	7.00%
Floor	10.25%
Ceiling Rate	0.00%
ETP	2.50%
Maturity Date	Sep. 01, 2025
Principal Amount	$ 7,500
Investments at cost	7,359
Investments at fair value	$ 7,359
Other Sustainability Sector [Member] \| Term Loan (13.25% cash (Prime + 7.00%; Floor 10.25%), 2.50% ETP, Due 7/1/26) One [Member] \| Nexii Building Solutions, Inc [Member]
Cash Rate	13.25%
Margin	7.00%
Floor	10.25%
Ceiling Rate	0.00%
ETP	2.50%
Maturity Date	Jul. 01, 2026
Principal Amount	$ 5,000
Investments at cost	4,893
Investments at fair value	$ 4,893
Other Sustainability Sector [Member] \| Term Loan (13.25% cash (Prime + 7.00%; Floor 10.25%), 2.50% ETP, Due 7/1/26) Two [Member] \| Nexii Building Solutions, Inc [Member]
Cash Rate	13.25%
Margin	7.00%
Floor	10.25%
Ceiling Rate	0.00%
ETP	2.50%
Maturity Date	Jul. 01, 2026
Principal Amount	$ 5,000
Investments at cost	4,893
Investments at fair value	$ 4,893
Other Sustainability Sector [Member] \| Term Loan (13.00% cash (Prime + 6.75%; Floor 10.00%), 2.75% ETP, Due 4/1/26) One [Member] \| Soli Organic, Inc [Member]
Cash Rate	13.00%
Margin	6.75%
Floor	10.00%
Ceiling Rate	0.00%
ETP	2.75%
Maturity Date	Apr. 01, 2026
Principal Amount	$ 5,000
Investments at cost	4,919
Investments at fair value	$ 4,919
Other Sustainability Sector [Member] \| Term Loan (13.00% cash (Prime + 6.75%; Floor 10.00%), 2.75% ETP, Due 4/1/26) Two [Member] \| Soli Organic, Inc [Member]
Cash Rate	13.00%
Margin	6.75%
Floor	10.00%
Ceiling Rate	0.00%
ETP	2.75%
Maturity Date	Apr. 01, 2026
Principal Amount	$ 2,500
Investments at cost	2,313
Investments at fair value	$ 2,313
Other Sustainability Sector [Member] \| Term Loan (13.00% cash (Prime + 6.75%; Floor 10.00%), 2.75% ETP, Due 5/1/26) One [Member] \| Soli Organic, Inc [Member]
Cash Rate	13.00%
Margin	6.75%
Floor	10.00%
Ceiling Rate	0.00%
ETP	2.75%
Maturity Date	May 01, 2026
Principal Amount	$ 5,000
Investments at cost	4,916
Investments at fair value	$ 4,916
Other Sustainability Sector [Member] \| Term Loan (13.00% cash (Prime + 6.75%; Floor 10.00%), 2.75% ETP, Due 5/1/26) Two [Member] \| Soli Organic, Inc [Member]
Cash Rate	13.00%
Margin	6.75%
Floor	10.00%
Ceiling Rate	0.00%
ETP	2.75%
Maturity Date	May 01, 2026
Principal Amount	$ 2,500
Investments at cost	2,458
Investments at fair value	$ 2,458
Other Sustainability Sector [Member] \| Term Loan (13.00% cash (Prime + 6.75%; Floor 10.00%), 2.50% ETP, Due 6/1/25) One [Member] \| Temperpack Technologies, Inc [Member]
Cash Rate	13.00%
Margin	6.75%
Floor	10.00%
Ceiling Rate	0.00%
ETP	2.50%
Maturity Date	Jun. 01, 2025
Principal Amount	$ 3,750
Investments at cost	3,694
Investments at fair value	$ 3,694
Other Sustainability Sector [Member] \| Term Loan (9.50% cash (Prime + 6.25%; Floor 9.50%), 5.00% ETP, Due 1/1/25) [Member] \| LiquiGlide, Inc [Member]
Cash Rate		9.50%
Margin		6.25%
Floor		9.50%
Ceiling Rate		0.00%
ETP		5.00%
Maturity Date		Jan. 01, 2025
Principal Amount		$ 2,000
Investments at cost		1,928
Investments at fair value		$ 1,928
Other Sustainability Sector [Member] \| Term Loan (13.00% cash (Prime + 6.75%; Floor 10.00%), 2.50% ETP, Due 6/1/25) Two [Member] \| Temperpack Technologies, Inc [Member]
Cash Rate	13.00%
Margin	6.75%
Floor	10.00%
Ceiling Rate	0.00%
ETP	2.50%
Maturity Date	Jun. 01, 2025
Principal Amount	$ 3,750
Investments at cost	3,713
Investments at fair value	$ 3,713
Other Sustainability Sector [Member] \| Term Loan (10.25% cash (Prime + 7.00%; Floor 10.25%), 2.50% ETP, Due 9/1/25), One [Member] \| Nexii Building Solutions, Inc [Member]
Cash Rate		10.25%
Margin		7.00%
Floor		10.25%
Ceiling Rate		0.00%
ETP		2.50%
Maturity Date		Sep. 01, 2025
Principal Amount		$ 7,500
Investments at cost		7,322
Investments at fair value		$ 7,322
Other Sustainability Sector [Member] \| Term Loan (13.00% cash (Prime + 6.75%; Floor 10.00%), 2.50% ETP, Due 10/1/25) One [Member] \| Temperpack Technologies, Inc [Member]
Cash Rate	13.00%
Margin	6.75%
Floor	10.00%
Ceiling Rate	0.00%
ETP	2.50%
Maturity Date	Oct. 01, 2025
Principal Amount	$ 7,500
Investments at cost	7,417
Investments at fair value	$ 7,417
Other Sustainability Sector [Member] \| Term Loan (10.25% cash (Prime + 7.00%; Floor 10.25%), 2.50% ETP, Due 9/1/25), Two [Member] \| Nexii Building Solutions, Inc [Member]
Cash Rate		10.25%
Margin		7.00%
Floor		10.25%
Ceiling Rate		0.00%
ETP		2.50%
Maturity Date		Sep. 01, 2025
Principal Amount		$ 7,500
Investments at cost		7,322
Investments at fair value		$ 7,322
Other Sustainability Sector [Member] \| Term Loan (13.00% cash (Prime + 6.75%; Floor 10.00%), 2.50% ETP, Due 10/1/25) Two [Member] \| Temperpack Technologies, Inc [Member]
Cash Rate	13.00%
Margin	6.75%
Floor	10.00%
Ceiling Rate	0.00%
ETP	2.50%
Maturity Date	Oct. 01, 2025
Principal Amount	$ 3,750
Investments at cost	3,709
Investments at fair value	$ 3,709
Other Sustainability Sector [Member] \| Term Loan (10.25% cash (Prime + 7.00%; Floor 10.25%), 2.50% ETP, Due 9/1/25), Three [Member] \| Nexii Building Solutions, Inc [Member]
Cash Rate		10.25%
Margin		7.00%
Floor		10.25%
Ceiling Rate		0.00%
ETP		2.50%
Maturity Date		Sep. 01, 2025
Principal Amount		$ 7,500
Investments at cost		7,322
Investments at fair value		$ 7,322
Other Sustainability Sector [Member] \| Term Loan (13.00% cash (Prime + 6.75%; Floor 10.00%), 2.50% ETP, Due 10/1/25) Three [Member] \| Temperpack Technologies, Inc [Member]
Cash Rate	13.00%
Margin	6.75%
Floor	10.00%
Ceiling Rate	0.00%
ETP	2.50%
Maturity Date	Oct. 01, 2025
Principal Amount	$ 3,750
Investments at cost	3,709
Investments at fair value	3,709
Other Sustainability Sector [Member] \| Term Loan (10.00% cash (Prime + 6.75%; Floor 10.00%), 2.50% ETP, Due 6/1/25), One [Member] \| Temperpack Technologies, Inc [Member]
Cash Rate		10.00%
Margin		6.75%
Floor		10.00%
Ceiling Rate		0.00%
ETP		2.50%
Maturity Date		Jun. 01, 2025
Principal Amount		$ 3,750
Investments at cost		3,703
Investments at fair value		$ 3,703
Other Sustainability Sector [Member] \| Term Loan (10.00% cash (Prime + 6.75%; Floor 10.00%), 2.50% ETP, Due 6/1/25), Two [Member] \| Temperpack Technologies, Inc [Member]
Cash Rate		10.00%
Margin		6.75%
Floor		10.00%
Ceiling Rate		0.00%
ETP		2.50%
Maturity Date		Jun. 01, 2025
Principal Amount		$ 3,750
Investments at cost		3,703
Investments at fair value		$ 3,703
Other Sustainability Sector [Member] \| Term Loan (10.00% cash (Prime + 6.75%; Floor 10.00%), 2.50% ETP, Due 10/1/25), One [Member] \| Temperpack Technologies, Inc [Member]
Cash Rate		10.00%
Margin		6.75%
Floor		10.00%
Ceiling Rate		0.00%
ETP		2.50%
Maturity Date		Oct. 01, 2025
Principal Amount		$ 7,500
Investments at cost		7,396
Investments at fair value		$ 7,396
Other Sustainability Sector [Member] \| Term Loan (10.00% cash (Prime + 6.75%; Floor 10.00%), 2.50% ETP, Due 10/1/25), Two [Member] \| Temperpack Technologies, Inc [Member]
Cash Rate		10.00%
Margin		6.75%
Floor		10.00%
Ceiling Rate		0.00%
ETP		2.50%
Maturity Date		Oct. 01, 2025
Principal Amount		$ 3,750
Investments at cost		3,698
Investments at fair value		$ 3,698
Other Sustainability Sector [Member] \| Term Loan (10.00% cash (Prime + 6.75%; Floor 10.00%), 2.50% ETP, Due 10/1/25), Three [Member] \| Temperpack Technologies, Inc [Member]
Cash Rate		10.00%
Margin		6.75%
Floor		10.00%
Ceiling Rate		0.00%
ETP		2.50%
Maturity Date		Oct. 01, 2025
Principal Amount		$ 3,750
Investments at cost		3,698
Investments at fair value		3,698
Life Science Segment [Member] \| Warrant [Member] \| Non-affiliate [Member]
Investments at cost	3,869	2,893
Investments at fair value	5,634	$ 2,600
Number of Shares (in shares)
Life Science Segment [Member] \| Debt Investments [Member] \| Non-affiliate [Member]
Investments at cost		$ 194,237
Investments at fair value		189,669
Healthcare Information and Services Segment [Member] \| Debt Securities [Member] \| Non-affiliate [Member]
Investments at cost	30,692
Investments at fair value	30,692
Healthcare Information and Services Segment [Member] \| Warrant [Member] \| Non-affiliate [Member]
Investments at cost	488	347
Investments at fair value	1,834	1,467
Healthcare Information and Services Segment [Member] \| Debt Investments [Member] \| Non-affiliate [Member]
Investments at cost		12,282
Investments at fair value		12,282
Sustainability Segment [Member] \| Warrant [Member] \| Non-affiliate [Member]
Investments at cost	929	502
Investments at fair value	1,605	$ 919
Number of Shares (in shares)
Sustainability Segment [Member] \| Debt Investments [Member] \| Non-affiliate [Member]
Investments at cost		$ 46,092
Investments at fair value		46,092
Networking Sector [Member]
Investments at cost	13,551	17,390
Investments at fair value	13,413	17,964
Networking Sector [Member] \| Preferred Stock Warrants [Member] \| Liqid, Inc [Member]
Investments at cost	364	364
Investments at fair value	$ 226	$ 938
Number of Shares (in shares)	344,102	344,102
Networking Sector [Member] \| Term Loan (9.50% cash (Prime + 6.25%; Floor 9.50%), 4.00% ETP, Due 9/1/24), One [Member] \| Liqid, Inc [Member]
Cash Rate		9.50%
Margin		6.25%
Floor		9.50%
Ceiling Rate		0.00%
ETP		4.00%
Maturity Date		Sep. 01, 2024
Principal Amount		$ 5,000
Investments at cost		4,770
Investments at fair value		$ 4,770
Networking Sector [Member] \| Term Loan (9.50% cash (Prime + 6.25%; Floor 9.50%), 4.00% ETP, Due 9/1/24), Two [Member] \| Liqid, Inc [Member]
Cash Rate		9.50%
Margin		6.25%
Floor		9.50%
Ceiling Rate		0.00%
ETP		4.00%
Maturity Date		Sep. 01, 2024
Principal Amount		$ 5,000
Investments at cost		4,924
Investments at fair value		$ 4,924
Networking Sector [Member] \| Term Loan (9.50% cash (Prime + 6.25%; Floor 9.50%), 4.00% ETP, Due 9/1/24), Three [Member] \| Liqid, Inc [Member]
Cash Rate		9.50%
Margin		6.25%
Floor		9.50%
Ceiling Rate		0.00%
ETP		4.00%
Maturity Date		Sep. 01, 2024
Principal Amount		$ 2,500
Investments at cost		2,459
Investments at fair value		$ 2,459
Networking Sector [Member] \| Term Loan (9.50% cash (Prime + 6.25%; Floor 9.50%), 4.00% ETP, Due 9/1/24), Four [Member] \| Liqid, Inc [Member]
Cash Rate		9.50%
Margin		6.25%
Floor		9.50%
Ceiling Rate		0.00%
ETP		4.00%
Maturity Date		Sep. 01, 2024
Principal Amount		$ 2,500
Investments at cost		2,459
Investments at fair value		$ 2,459
Networking Sector [Member] \| Term Loan (9.50% cash (Prime + 6.25%; Floor 9.50%), 4.00% ETP, Due 9/1/24), Five [Member] \| Liqid, Inc [Member]
Cash Rate		9.50%
Margin		6.25%
Floor		9.50%
Ceiling Rate		0.00%
ETP		4.00%
Maturity Date		Sep. 01, 2024
Principal Amount		$ 2,500
Investments at cost		2,414
Investments at fair value		2,414
Networking Sector [Member] \| Term Loan (11.75% cash (Prime + 6.25%; Floor 9.50%), 4.00% ETP, Due 9/1/24) One [Member] \| Liqid, Inc [Member]
Cash Rate	11.75%
Margin	6.25%
Floor	9.50%
Ceiling Rate	0.00%
ETP	4.00%
Maturity Date	Sep. 01, 2024
Principal Amount	$ 3,833
Investments at cost	3,779
Investments at fair value	$ 3,779
Networking Sector [Member] \| Term Loan (11.75% cash (Prime + 6.25%; Floor 9.50%), 4.00% ETP, Due 9/1/24) Two [Member] \| Liqid, Inc [Member]
Cash Rate	11.75%
Margin	6.25%
Floor	9.50%
Ceiling Rate	0.00%
ETP	4.00%
Maturity Date	Sep. 01, 2024
Principal Amount	$ 3,833
Investments at cost	3,779
Investments at fair value	$ 3,779
Networking Sector [Member] \| Term Loan (11.75% cash (Prime + 6.25%; Floor 9.50%), 4.00% ETP, Due 9/1/24) Three [Member] \| Liqid, Inc [Member]
Cash Rate	11.75%
Margin	6.25%
Floor	9.50%
Ceiling Rate	0.00%
ETP	4.00%
Maturity Date	Sep. 01, 2024
Principal Amount	$ 1,917
Investments at cost	1,887
Investments at fair value	$ 1,887
Networking Sector [Member] \| Term Loan (11.75% cash (Prime + 6.25%; Floor 9.50%), 4.00% ETP, Due 9/1/24) Four [Member] \| Liqid, Inc [Member]
Cash Rate	11.75%
Margin	6.25%
Floor	9.50%
Ceiling Rate	0.00%
ETP	4.00%
Maturity Date	Sep. 01, 2024
Principal Amount	$ 1,917
Investments at cost	1,887
Investments at fair value	$ 1,887
Networking Sector [Member] \| Term Loan (11.75% cash (Prime + 6.25%; Floor 9.50%), 4.00% ETP, Due 9/1/24) Five [Member] \| Liqid, Inc [Member]
Cash Rate	11.75%
Margin	6.25%
Floor	9.50%
Ceiling Rate	0.00%
ETP	4.00%
Maturity Date	Sep. 01, 2024
Principal Amount	$ 1,917
Investments at cost	1,855
Investments at fair value	1,855
Data Storage [Member] \| Preferred Stock Warrants [Member] \| CPG Beyond, Inc [Member]
Investments at cost		242
Investments at fair value		$ 859
Number of Shares (in shares)		500,000
Data Storage [Member] \| Warrant [Member] \| Silk, Inc [Member]
Investments at cost		$ 234
Investments at fair value		$ 188
Number of Shares (in shares)		44,211,003
Internet and Media Sector [Member]
Investments at cost	329	$ 569
Investments at fair value	1,299	3,305
Internet and Media Sector [Member] \| Preferred Stock Warrants [Member] \| Global Worldwide LLC [Member]
Investments at cost	75	75
Investments at fair value	$ 0	$ 6
Number of Shares (in shares)	245,810	245,810
Internet and Media Sector [Member] \| Preferred Stock Warrants [Member] \| Rocket Lawyer Incorporated [Member]
Investments at cost	$ 92	$ 92
Investments at fair value	$ 500	$ 741
Number of Shares (in shares)	261,721	261,721
Internet and Media Sector [Member] \| Preferred Stock Warrants [Member] \| Skillshare, Inc [Member]
Investments at cost	$ 162	$ 162
Investments at fair value	$ 799	$ 2,403
Number of Shares (in shares)	139,074	139,074
Internet and Media Sector [Member] \| Common Stock [Member] \| Zeta Global Holdings Corp [Member]
Investments at cost		$ 240
Investments at fair value		$ 155
Number of Shares (in shares)		18,405
Technology Segment [Member] \| Debt Securities [Member] \| Non-affiliate [Member]
Investments at cost	$ 249,694
Investments at fair value	246,720
Technology Segment [Member] \| Warrant [Member] \| Non-affiliate [Member]
Investments at cost	6,685	$ 6,281
Investments at fair value	13,040	15,214
Technology Segment [Member] \| Debt Investments [Member] \| Non-affiliate [Member]
Investments at cost		189,274
Investments at fair value		189,274
Power Management Sector [Member]
Investments at cost	1,585	1,585
Investments at fair value	2,254	2,609
Power Management Sector [Member] \| Preferred Stock Warrants [Member] \| Kinestral, Inc [Member]
Investments at cost		1,585
Investments at fair value		$ 2,609
Number of Shares (in shares)		5,002,574
Power Management Sector [Member] \| Preferred Stock Warrants [Member] \| Halio, Inc [Member]
Investments at cost	1,585
Investments at fair value	$ 2,254
Number of Shares (in shares)	5,002,574
Semiconductor Sector [Member]
Investments at cost	$ 56	$ 101
Investments at fair value	0	0
Semiconductor Sector [Member] \| Warrant [Member] \| Avalanche Technology, Inc [Member]
Investments at cost	56	101
Investments at fair value	$ 0	$ 0
Number of Shares (in shares)	6,081	6,753
Data Storage Sector [Member]
Investments at cost	$ 476	$ 476
Investments at fair value	1,211	$ 1,047
Data Storage Sector [Member] \| Preferred Stock Warrants [Member] \| CPG Beyond, Inc [Member]
Investments at cost	242
Investments at fair value	$ 895
Number of Shares (in shares)	500,000
Data Storage Sector [Member] \| Warrant [Member] \| Silk, Inc [Member]
Investments at cost	$ 234
Investments at fair value	$ 316
Number of Shares (in shares)	442,110

Consolidated Schedule of Investments (Unaudited) - Investments (Details) (Parentheticals)	Sep. 30, 2022	Dec. 31, 2021
NAV %	206.30%	186.70%
Non-affiliate [Member]
NAV %	206.20%	186.70%
Controlled Affiliate [Member]
NAV %		0.00%
Warrant [Member] \| Non-affiliate [Member]
NAV %	7.20%	8.20%
Warrant [Member] \| Non-affiliate [Member] \| Healthcare Information and Services Segment [Member]
NAV %	0.60%	0.60%
Warrant [Member] \| Non-affiliate [Member] \| Life Science Segment [Member]
NAV %	1.80%
Warrant [Member] \| Non-affiliate [Member] \| Life Science [Member]
NAV %		1.00%
Warrant [Member] \| Non-affiliate [Member] \| Sustainability Segment [Member]
NAV %	0.50%	0.40%
Warrant [Member] \| Non-affiliate [Member] \| Technology Segment [Member]
NAV %	4.20%	6.20%
Other Long-Term Investments [Member] \| Non-affiliate [Member]
NAV %	0.40%	0.10%
Other Long-Term Investments [Member] \| Controlled Affiliate [Member] \| Biotechnology Sector [Member]
NAV %		0.00%
Equity Securities [Member] \| Non-affiliate [Member]
NAV %	0.70%	0.10%
Unrestricted Short Term Investments [Member]
NAV %	2.50%	3.20%
Restricted Short Term Investments [Member]
NAV %	0.50%	0.60%
Debt Securities [Member] \| Non-affiliate [Member]
NAV %		178.30%
Debt Securities [Member] \| Non-affiliate [Member] \| Healthcare Information and Services Segment [Member]
NAV %	10.00%
Debt Securities [Member] \| Non-affiliate [Member] \| Life Science Segment [Member]
NAV %		77.30%
Debt Securities [Member] \| Non-affiliate [Member] \| Sustainability Segment [Member]
NAV %		18.80%
Debt Securities [Member] \| Non-affiliate [Member] \| Technology Segment [Member]
NAV %		77.20%
Debt Investments [Member] \| Non-affiliate [Member]
NAV %	179.90%
Debt Investments [Member] \| Non-affiliate [Member] \| Healthcare Information and Services Segment [Member]
NAV %		5.00%
Debt Investments [Member] \| Non-affiliate [Member] \| Life Science Segment [Member]
NAV %	83.00%
Debt Investments [Member] \| Non-affiliate [Member] \| Sustainability Segment [Member]
NAV %	24.70%
Debt Investments [Member] \| Non-affiliate [Member] \| Technology Segment [Member]
NAV %	80.20%

Note 1 - Organization (Details Textual) - USD ($) $ / shares in Units, $ in Thousands		9 Months Ended
	Mar. 14, 2022	Sep. 30, 2022	Sep. 30, 2021
Proceeds from Issuance of Common Stock		$ 67,525	$ 17,312
Public Offering [Member]
Stock Issued During Period, Shares, New Issues (in shares)	2,500,000
Shares Issued, Price Per Share (in dollars per share)	$ 14.35
Proceeds from Issuance of Common Stock	$ 34,300

Note 2 - Basis of Presentation and Significant Accounting Policies (Details Textual) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended		5 Months Ended	9 Months Ended		12 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2022	Sep. 30, 2021	Dec. 31, 2021	Apr. 29, 2022	Aug. 02, 2021	Jul. 30, 2020
Investments, Cost, Nonaccrual Status	$ 0		$ 0	$ 0
Investments, Fair Value, Nonaccrual Status	0		0	0
Investments, Nonaccrual, Interest Income	$ 0	$ 0		$ 0	$ 1,300
Investment, Nonaccrual, Income Not Received in Cash, Percent	7.00%	5.20%		7.50%	6.70%
Debt Issuance Costs, Net, Total	$ 5,600		5,600	$ 5,600		$ 4,300
Deferred Finance Costs, Accumulated Amortization	4,400		$ 4,400	4,400		3,200
Amortization of Debt Issuance Costs	$ 400	$ 200		$ 1,142	$ 744
Adjustments to Additional Paid in Capital, Non-deductible Excise Taxes Paid						400
Federal Excise Tax, Percent	4.00%		4.00%	4.00%
Excise and Sales Taxes	$ 100	$ 56		$ 306	174
Unrecognized Tax Benefits, Ending Balance	$ 0		$ 0	$ 0		0
Open Tax Year				2021 2020 2019
Proceeds from Issuance of Common Stock				$ 67,525	$ 17,312
Stock Repurchase Program, Remaining Authorized Repurchase Amount							$ 5,000
Stock Repurchased During Period, Shares (in shares)	0	0	167,465	0	0
Stock Repurchased During Period, Per Share (in dollars per share)			$ 11.22
Stock Repurchased During Period, Value			$ 1,900
The 2020 Equity Distribution Agreement [Member]
Equity Sales Agreement, Maximum Value									$ 100,000
The 2021 Equity Distribution Agreement [Member]
Equity Sales Agreement, Maximum Value								$ 100,000
Stock Issued During Period, Shares, New Issues (in shares)	1,523,519			2,641,920
Proceeds from Issuance of Common Stock	$ 19,000			$ 33,200
Payments of Stock Issuance Costs	400			600
Equity Sales Agreement, Remaining Amount Available for Issuance	$ 48,900		$ 48,900	$ 48,900
The 2020 Equity Distribution Agreement and the 2021 Equity Distribution Agreement [Member]
Stock Issued During Period, Shares, New Issues (in shares)		395,068			1,122,516
Proceeds from Issuance of Common Stock		$ 6,600			$ 17,300
Payments of Stock Issuance Costs		$ 200			$ 500
One Investment [Member]
Investments, Cost, Nonaccrual Status						11,500
Investments, Fair Value, Nonaccrual Status						$ 6,900

Note 3 - Related Party Transactions (Details Textual) - USD ($) $ in Thousands		3 Months Ended		9 Months Ended
	Oct. 22, 2021	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021	Dec. 31, 2021
Management Fee Payable		$ 1,870		$ 1,870		$ 706
Management Fee Expense		2,788	$ 1,997	7,555	$ 5,595
Performance Based Incentive Fee		2,784	2,012	6,353	5,040
Incentive Fee Payable		2,784		2,784		2,015
Administrative Fees Expense		412	251	1,147	829
Investment Management Agreement [Member]
Base Management Fee, Annual, Percent	2.00%
Base Management Fee, Annual, Percent, Gross Assets Exceeding $250 Million	1.60%
Management Fee Payable		1,900		1,900		700
Management Fee Expense		2,800	2,000	7,600	5,600
Incentive Fee to Pre-incentive Net Investment Income	20.00%
Pre-Incentive Fee Net Investment Income, Hurdle Rate	1.75%
Pre-Incentive Fee Net Investment Income, Hurdle Rate, Annualized	7.00%
Pre-Incentive Fee Net Investment Income, Catch-up, Percent	100.00%
Pre-Incentive Fee Net Investment Income, Maximum Rate to Trigger Catch-up	2.1875%
Pre-Incentive Fee Net Investment Income, Maximum Rate to Trigger Catch-up, Annualized	8.75%
Performance Based Incentive Fee		2,800	2,000	6,400	5,000
Incentive Fee Payable		2,800		2,800		$ 2,000
Administration Agreement [Member]
Administrative Fees Expense		$ 400	$ 300	$ 1,100	$ 800

Note 4 - Investments - Investments (Details) - USD ($) $ in Thousands	Sep. 30, 2022	Dec. 31, 2021
Investments at cost	$ 629,216	$ 453,837
Investments at fair value	634,624	458,075
Biotechnology Sector [Member]
Investments at cost	148,952	109,899
Investments at fair value	147,442	107,902
Medical Device Sector [Member]
Investments at cost	114,364	88,681
Investments at fair value	116,967	84,567
Communications Sector [Member]
Investments at cost	22,883	22,853
Investments at fair value	26,070	25,920
Consumer-related Sector [Member]
Investments at cost	109,906	92,158
Investments at fair value	108,301	93,194
Data Storage Sector [Member]
Investments at cost	476	476
Investments at fair value	1,211	1,047
Internet and Media Sector [Member]
Investments at cost	329	569
Investments at fair value	1,299	3,305
Networking Sector [Member]
Investments at cost	13,551	17,390
Investments at fair value	13,413	17,964
Power Management Sector [Member]
Investments at cost	1,585	1,585
Investments at fair value	2,254	2,609
Semiconductor Sector [Member]
Investments at cost	56	101
Investments at fair value	0	0
Software Sector [Member]
Investments at cost	108,910	60,902
Investments at fair value	107,441	60,807
Other Sustainability Sector [Member]
Investments at cost	77,024	46,595
Investments at fair value	77,700	47,011
Diagnostics Sector [Member]
Investments at cost	9,840	12,393
Investments at fair value	9,844	12,377
Other Sector [Member]
Investments at cost	7,621	175
Investments at fair value	8,682	1,177
Software, Healthcare Information and Service [Member]
Investments at cost	13,719	60
Investments at fair value	14,000	195
Debt [Member]
Investments at cost	612,478	441,885
Investments at fair value	609,032	437,317
Warrant [Member]
Investments at cost	11,971	10,023
Investments at fair value	22,113	20,200
Other Debt Obligations [Member]
Investments at cost	1,200	1,450
Investments at fair value	1,300	200
Equity Securities [Member]
Investments at cost	3,567	479
Investments at fair value	$ 2,179	$ 358

Note 5 - Transactions With Affiliated Companies - Investments in Controlled Affiliated Companies (Details) - USD ($)
$ in Thousands

3 Months Ended

9 Months Ended

12 Months Ended

Sep. 30, 2022

Sep. 30, 2021

Sep. 30, 2022

Sep. 30, 2021

Dec. 31, 2021

Net unrealized (depreciation) appreciation on investments

$ 3,442

$ 3,376

$ 1,169

$ 8,122

Net realized (loss) gain on investments

(8,585)

$ 1,344

(9,484)

(2,372)

Note 1 - Organization	9 Months Ended
Note 1 - Organization	Sep. 30, 2022
Notes to Financial Statements
Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]	Note 1. Organization Horizon Technology Finance Corporation (the “Company”) was organized as a Delaware corporation on March 16, 2010 and is an externally managed, non-diversified, closed-end investment company. The Company has elected to be regulated as a business development company (“BDC”) under the 1940 Act. In addition, for tax purposes, the Company has elected to be treated as a regulated investment company (“RIC”) as defined under Subchapter M of the Internal Revenue Code of 1986, as amended (the “Code”). As a RIC, the Company generally is not subject to corporate-level federal income tax on the portion of its taxable income (including net capital gains) the Company distributes to its stockholders. The Company primarily makes secured debt investments to development-stage companies in the technology, life science, healthcare information and services and sustainability industries. All of the Company’s debt investments consist of loans secured by all of, or a portion of, the applicable debtor company’s tangible and intangible assets. On October 28, 2010, the Company completed an initial public offering (“IPO”) and its common stock trades on the Nasdaq Global Select Market under the symbol “HRZN”. Horizon Credit II LLC (“Credit II”) was formed as a Delaware limited liability company on June 28, 2011, with the Company as its sole equity member. Credit II is a special purpose bankruptcy-remote entity and is a separate legal entity from the Company. Any assets conveyed to Credit II are not available to creditors of the Company or any other entity other than Credit II’s lenders. The Company formed Horizon Funding 2019‑1 LLC (“2019‑1 LLC”) as a Delaware limited liability company on May 2, 2019 and Horizon Funding Trust 2019‑1 on May 15, 2019 (“2019‑1 Trust” and, together with the 2019‑1 LLC, the “2019‑1 Entities”). The 2019‑1 Entities are special purpose bankruptcy remote entities and are separate legal entities from the Company. The Company formed the 2019‑1 Entities for purposes of securitizing the Asset-Backed Notes. The Company and Arena Sunset SPV, LLC (“Arena”) formed Horizon Funding I, LLC (“HFI”) as a Delaware limited liability company on May 9, 2018, with Horizon Secured Loan Fund I LLC, a Delaware limited liability company (“HSLFI”) as its sole member. HFI is a special purpose bankruptcy-remote entity and is a separate legal entity from HSLFI. Any assets conveyed to HFI are not available to creditors of HSLFI or any other entity other than HFI’s lenders. On April 21, 2020, the Company purchased all of the limited liability company interests of Arena in HSLFI, including, without limitation, undistributed amounts owed to Arena and interest accrued and unpaid on the debt investments of HSLFI through the date of purchase. As of April 21, 2020, HSLFI and its subsidiary, HFI, are consolidated by the Company. The Company has also established an additional wholly owned subsidiary, which is structured as a Delaware limited liability company, to hold the assets of a portfolio company acquired in connection with foreclosure or bankruptcy, which is a separate legal entity from the Company. The Company’s investment strategy is to maximize the investment portfolio’s return by generating current income from the debt investments the Company makes and capital appreciation from the warrants the Company receives when making such debt investments. The Company has entered into an investment management agreement (the “Investment Management Agreement”) with Horizon Technology Finance Management LLC (the “Advisor”) under which the Advisor manages the day-to-day operations of, and provides investment advisory services to, the Company. On March 14, 2022, the Company completed a follow-on public offering of 2,500,000 shares of its common stock at a public offering price of $14.35 per share, for total net proceeds to the Company of $34.3 million, after deducting underwriting commission and discounts and other offering expenses.

Note 6 - Fair Value (Details Textual) $ / shares in Units, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2022 USD ($) $ / shares	Sep. 30, 2021 USD ($)	Sep. 30, 2022 USD ($) $ / shares	Sep. 30, 2021 USD ($)	Dec. 31, 2021
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Transfers, Net, Total	$ (1,117)	$ 0	$ (1,117)	$ (120)
Unrealized Gain (Loss) on Investments	3,442	$ 3,376	1,169	8,122
Warrant [Member]
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Transfers, Net, Total	(1,117)		(1,117)	(71)
Debt [Member]
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Transfers, Net, Total	0		0	0
Equity Securities [Member]
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Transfers, Net, Total	0		0	(49)
Fair Value, Inputs, Level 2 [Member] \| Warrant [Member]
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Transfers out of Level 3	40		40	100
Fair Value, Inputs, Level 1 [Member] \| Warrant [Member]
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Transfers out of Level 3	$ 1,100		1,100
Fair Value, Inputs, Level 1 [Member] \| Equity Securities [Member]
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Transfers out of Level 3				100
Fair Value, Inputs, Level 3 [Member] \| Warrant [Member]
Unrealized Gain (Loss) on Investments			1,200	6,300
Fair Value, Inputs, Level 3 [Member] \| Debt [Member]
Unrealized Gain (Loss) on Investments			3,500	300
Fair Value, Inputs, Level 3 [Member] \| Equity Securities [Member]
Unrealized Gain (Loss) on Investments			$ 400	$ 1,500
The 2026 Notes [Member]
Debt Instrument, Share Price (in dollars per share) \| $ / shares	$ 24.37		$ 24.37
The 2026 Notes [Member] \| Fair Value, Inputs, Level 2 [Member]
Debt Instrument, Fair Value Disclosure, Total	$ 56,100		$ 56,100
The 2027 Notes [Member]
Debt Instrument, Share Price (in dollars per share) \| $ / shares	$ 23.18		$ 23.18
The 2027 Notes [Member] \| Fair Value, Inputs, Level 1 [Member]
Debt Instrument, Fair Value Disclosure, Total	$ 53,300		$ 53,300
Asset-Backed Notes [Member] \| Fair Value, Inputs, Level 3 [Member]
Debt Instrument, Fair Value Disclosure, Total	$ 43,500		$ 43,500
Measurement Input, Hypothetical Market Yields [Member] \| Minimum [Member]
Debt Instrument, Measurement Input	0.03		0.03		0.03
Measurement Input, Hypothetical Market Yields [Member] \| Maximum [Member]
Debt Instrument, Measurement Input	0.25		0.25		0.23

Note 6 - Fair Value - Significant Level 3 Fair Value Measurment Inputs (Details) - Fair Value, Inputs, Level 3 [Member] $ in Thousands	Sep. 30, 2022 USD ($)	Dec. 31, 2021 USD ($)
Investments, fair value	$ 634,259	$ 457,557
Debt [Member] \| Valuation Technique, Discounted Cash Flow [Member]
Investments, fair value	$ 605,719	$ 430,417
Debt [Member] \| Valuation Technique, Discounted Cash Flow [Member] \| Minimum [Member] \| Hypothetical Market Yield [Member]
Investments, measurement input	0.03
Debt [Member] \| Valuation Technique, Discounted Cash Flow [Member] \| Maximum [Member] \| Hypothetical Market Yield [Member]
Investments, measurement input	0.25
Debt [Member] \| Valuation Technique, Discounted Cash Flow [Member] \| Weighted Average [Member] \| Hypothetical Market Yield [Member]
Investments, measurement input	0.14	12
Debt [Member] \| Multiple Probability Weighted Cash Flow Model [Member]
Investments, fair value	$ 3,313	$ 6,900
Debt [Member] \| Multiple Probability Weighted Cash Flow Model [Member] \| Probability Weighting [Member]
Investments, measurement input	0.25
Debt [Member] \| Multiple Probability Weighted Cash Flow Model [Member] \| Minimum [Member] \| Probability Weighting [Member]
Investments, measurement input		20
Debt [Member] \| Multiple Probability Weighted Cash Flow Model [Member] \| Maximum [Member] \| Probability Weighting [Member]
Investments, measurement input		50
Debt [Member] \| Multiple Probability Weighted Cash Flow Model [Member] \| Weighted Average [Member] \| Probability Weighting [Member]
Investments, measurement input	0.25	33
Warrant [Member] \| Black-scholes Valuation Model [Member]
Investments, fair value	$ 21,894	$ 19,837
Warrant [Member] \| Black-scholes Valuation Model [Member] \| Measurement Input, Price Volatility [Member]
Investments, measurement input	0.25	25
Warrant [Member] \| Black-scholes Valuation Model [Member] \| Measurement Input, Discount for Lack of Marketability [Member]
Investments, measurement input	0.20	20
Warrant [Member] \| Black-scholes Valuation Model [Member] \| Minimum [Member] \| Measurement Input, Share Price [Member]
Investments, measurement input	0.00	0.00
Warrant [Member] \| Black-scholes Valuation Model [Member] \| Minimum [Member] \| Estimated Time to Exit [Member]
Investments, measurement input	1	1
Warrant [Member] \| Black-scholes Valuation Model [Member] \| Maximum [Member] \| Measurement Input, Share Price [Member]
Investments, measurement input	1,899	980.00
Warrant [Member] \| Black-scholes Valuation Model [Member] \| Maximum [Member] \| Estimated Time to Exit [Member]
Investments, measurement input	4	4
Warrant [Member] \| Black-scholes Valuation Model [Member] \| Weighted Average [Member] \| Measurement Input, Share Price [Member]
Investments, measurement input	64.53	20.35
Warrant [Member] \| Black-scholes Valuation Model [Member] \| Weighted Average [Member] \| Measurement Input, Price Volatility [Member]
Investments, measurement input	0.25	25
Warrant [Member] \| Black-scholes Valuation Model [Member] \| Weighted Average [Member] \| Measurement Input, Discount for Lack of Marketability [Member]
Investments, measurement input	0.20	20
Warrant [Member] \| Black-scholes Valuation Model [Member] \| Weighted Average [Member] \| Estimated Time to Exit [Member]
Investments, measurement input	2	2
Other Investments [Member] \| Multiple Probability Weighted Cash Flow Model [Member]
Investments, fair value	$ 1,300	$ 200
Other Investments [Member] \| Multiple Probability Weighted Cash Flow Model [Member] \| Probability Weighting [Member]
Investments, measurement input	1
Other Investments [Member] \| Multiple Probability Weighted Cash Flow Model [Member] \| Measurement Input, Discount Rate [Member]
Investments, measurement input	0.25	25
Other Investments [Member] \| Multiple Probability Weighted Cash Flow Model [Member] \| Weighted Average [Member] \| Probability Weighting [Member]
Investments, measurement input	1	100
Other Investments [Member] \| Multiple Probability Weighted Cash Flow Model [Member] \| Weighted Average [Member] \| Measurement Input, Discount Rate [Member]
Investments, measurement input	0.25	25
Equity Securities [Member] \| Last Equity Financing [Member]
Investments, fair value	$ 2,033	$ 203
Equity Securities [Member] \| Last Equity Financing [Member] \| Minimum [Member] \| Measurement Input, Share Price [Member]
Investments, measurement input	1.00	0.00
Equity Securities [Member] \| Last Equity Financing [Member] \| Maximum [Member] \| Measurement Input, Share Price [Member]
Investments, measurement input	215.03	1.00
Equity Securities [Member] \| Last Equity Financing [Member] \| Weighted Average [Member] \| Measurement Input, Share Price [Member]
Investments, measurement input	30.09	0.41

Note 6 - Fair Value - Assets at Fair Value on a Recurring Basis (Details) - USD ($) $ in Thousands	Sep. 30, 2022	Dec. 31, 2021
Fair Value, Recurring [Member]
Investments, fair value	$ 634,624	$ 458,075
Fair Value, Recurring [Member] \| Money Market Funds [Member]
Investments, fair value	7,732	7,868
Fair Value, Recurring [Member] \| Money Market Funds, Restricted Investments [Member]
Investments, fair value	1,617	1,359
Fair Value, Recurring [Member] \| Debt [Member]
Investments, fair value	609,032	437,317
Fair Value, Recurring [Member] \| Warrant [Member]
Investments, fair value	22,113	20,200
Fair Value, Recurring [Member] \| Other Investments [Member]
Investments, fair value	1,300	200
Fair Value, Recurring [Member] \| Equity Securities [Member]
Investments, fair value	2,179	358
Fair Value, Inputs, Level 1 [Member] \| Fair Value, Recurring [Member]
Investments, fair value	146	155
Fair Value, Inputs, Level 1 [Member] \| Fair Value, Recurring [Member] \| Money Market Funds [Member]
Investments, fair value	0	0
Fair Value, Inputs, Level 1 [Member] \| Fair Value, Recurring [Member] \| Money Market Funds, Restricted Investments [Member]
Investments, fair value	0	0
Fair Value, Inputs, Level 1 [Member] \| Fair Value, Recurring [Member] \| Debt [Member]
Investments, fair value	0	0
Fair Value, Inputs, Level 1 [Member] \| Fair Value, Recurring [Member] \| Warrant [Member]
Investments, fair value	0	0
Fair Value, Inputs, Level 1 [Member] \| Fair Value, Recurring [Member] \| Other Investments [Member]
Investments, fair value	0	0
Fair Value, Inputs, Level 1 [Member] \| Fair Value, Recurring [Member] \| Equity Securities [Member]
Investments, fair value	146	155
Fair Value, Inputs, Level 2 [Member] \| Fair Value, Recurring [Member]
Investments, fair value	219	363
Fair Value, Inputs, Level 2 [Member] \| Fair Value, Recurring [Member] \| Money Market Funds [Member]
Investments, fair value	7,732	7,868
Fair Value, Inputs, Level 2 [Member] \| Fair Value, Recurring [Member] \| Money Market Funds, Restricted Investments [Member]
Investments, fair value	1,617	1,359
Fair Value, Inputs, Level 2 [Member] \| Fair Value, Recurring [Member] \| Debt [Member]
Investments, fair value	0	0
Fair Value, Inputs, Level 2 [Member] \| Fair Value, Recurring [Member] \| Warrant [Member]
Investments, fair value	219	363
Fair Value, Inputs, Level 2 [Member] \| Fair Value, Recurring [Member] \| Other Investments [Member]
Investments, fair value	0	0
Fair Value, Inputs, Level 2 [Member] \| Fair Value, Recurring [Member] \| Equity Securities [Member]
Investments, fair value	0	0
Fair Value, Inputs, Level 3 [Member]
Investments, fair value	634,259	457,557
Fair Value, Inputs, Level 3 [Member] \| Fair Value, Recurring [Member]
Investments, fair value	634,259	457,557
Fair Value, Inputs, Level 3 [Member] \| Fair Value, Recurring [Member] \| Money Market Funds [Member]
Investments, fair value	0	0
Fair Value, Inputs, Level 3 [Member] \| Fair Value, Recurring [Member] \| Money Market Funds, Restricted Investments [Member]
Investments, fair value	0	0
Fair Value, Inputs, Level 3 [Member] \| Fair Value, Recurring [Member] \| Debt [Member]
Investments, fair value	609,032	437,317
Fair Value, Inputs, Level 3 [Member] \| Fair Value, Recurring [Member] \| Warrant [Member]
Investments, fair value	21,894	19,837
Fair Value, Inputs, Level 3 [Member] \| Fair Value, Recurring [Member] \| Other Investments [Member]
Investments, fair value	1,300	200
Fair Value, Inputs, Level 3 [Member] \| Fair Value, Recurring [Member] \| Equity Securities [Member]
Investments, fair value	$ 2,033	$ 203

Note 7 - Borrowings (Details Textual) - USD ($) $ / shares in Units, $ in Thousands					3 Months Ended		9 Months Ended
	Feb. 25, 2022	Jun. 22, 2021	Apr. 24, 2021	Apr. 21, 2020	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021	Jun. 15, 2022	Dec. 31, 2021	Mar. 30, 2021	Sep. 15, 2019	Aug. 13, 2019	Oct. 11, 2017	Sep. 29, 2017
Asset Coverage to Borrowings, Ratio, Percent							185.00%
Debt Instrument, Face Amount					$ 483,461		$ 483,461			$ 353,000
Interest Paid, Excluding Capitalized Interest, Operating Activities							11,543	$ 7,785
Long-Term Debt, Gross					362,711		362,711			260,250
Restricted Investments					1,617		1,617			1,359
Money Market Funds [Member]
Restricted Investments					$ 600		$ 600			900
Key Facility [Member]
Line of Credit Facility, Maximum Borrowing Capacity, Accordian Feature		$ 150,000
Line of Credit Facility, Maximum Borrowing Capacity		$ 125,000
Line of Credit Facility, Advance Rate of Eligible Debt Investments		60.00%
Long-Term Debt, Weighted Average Interest Rate, over Time					5.60%	4.25%	4.75%	4.25%
Line of Credit Facility, Unused Capacity, Commitment Fee Percentage							0.50%
Line of Credit Facility, Current Borrowing Capacity					$ 57,500		$ 57,500			71,500
Line of Credit Facility, Remaining Borrowing Capacity					28,000		28,000			19,800
Debt Instrument, Face Amount					125,000		125,000			125,000
Long-Term Debt, Gross					$ 67,500		$ 67,500			$ 53,500
Key Facility [Member] \| London Interbank Offered Rate (LIBOR) [Member]
Debt Instrument, Basis Spread on Variable Rate		3.25%
Key Facility [Member] \| Prime Rate [Member]
Debt Instrument, Basis Spread on Variable Rate							0.25%
Debt Instrument, Variable Rate					6.25%		6.25%			3.25%
The 6.25 % Notes Due 2022 [Member]
Debt Instrument, Face Amount															$ 32,500
Debt Instrument, Interest Rate, Stated Percentage															6.25%
Adittional 2022 Notes [Member]
Debt Instrument, Face Amount														$ 4,900
The 2022 Notes [Member]
Debt Instrument, Interest Rate, Stated Percentage												6.25%
Debt Instrument, Convertible, Conversion Price (in dollars per share)												$ 25
Repayments of Debt			$ 37,400
Interest Paid, Excluding Capitalized Interest, Operating Activities			300
Payments of Debt Issuance Costs			$ 400
The 2026 Notes [Member]
Debt Instrument, Face Amount					$ 57,500		$ 57,500			$ 57,500	$ 57,500
Debt Instrument, Interest Rate, Stated Percentage											4.875%
Long-Term Debt, Gross					57,500		57,500			57,500
The 2026 Notes Underwriter Option [Member]
Debt Instrument, Face Amount											$ 7,500
Debt Instrument, Convertible, Conversion Price (in dollars per share)											$ 25
The 2027 Notes [Member]
Debt Instrument, Face Amount					57,500		57,500		$ 50,000	0
Debt Instrument, Interest Rate, Stated Percentage									6.25%
Long-Term Debt, Gross					57,500		57,500			0
The 2027 Notes Underwriter Option [Member]
Debt Instrument, Face Amount									$ 7,500
Debt Instrument, Convertible, Conversion Price (in dollars per share)									$ 25
Asset-Backed Notes [Member]
Debt Instrument, Face Amount					43,461		43,461			70,500			$ 160,000
Debt Instrument, Interest Rate, Stated Percentage													4.21%
Long-Term Debt, Gross					43,461		43,461			70,500
NYL Facility [Member]
Line of Credit Facility, Maximum Borrowing Capacity	$ 200,000			$ 100,000
Line of Credit Facility, Current Borrowing Capacity					63,200		63,200			21,200
Line of Credit Facility, Remaining Borrowing Capacity					49,200		49,200			5,700
Debt Instrument, Face Amount					200,000		200,000			100,000
Long-Term Debt, Gross					136,750		136,750			78,750
Line of Credit Facility, Maximum Borrowing Capacity, Accordion Feature				$ 200,000
Line of Credit Facility, Advance Rate				67.00%
Line of Credit Facility, Change in Maximum Borrowing Capacity	$ 100,000
Long-Term Line of Credit, Total					$ 136,800		$ 136,800			$ 78,800
Line of Credit Facility, Interest Rate at Period End					5.11%		5.11%			4.62%
NYL Facility [Member] \| USD Mid-market Wwap Rate [Member]
Debt Instrument, Basis Spread on Variable Rate	3.00%
Minimum [Member]
Asset Coverage to Borrowings, Ratio, Percent							150.00%
Minimum [Member] \| Key Facility [Member] \| London Interbank Offered Rate (LIBOR) [Member]
Debt Instrument, Basis Spread on Variable Rate		1.00%
Minimum [Member] \| Key Facility [Member] \| Prime Rate [Member]
Debt Instrument, Basis Spread on Variable Rate							4.25%
Minimum [Member] \| NYL Facility [Member] \| USD Mid-market Wwap Rate [Member]
Debt Instrument, Basis Spread on Variable Rate				3.55%
Maximum [Member] \| NYL Facility [Member] \| USD Mid-market Wwap Rate [Member]
Debt Instrument, Basis Spread on Variable Rate				5.15%

Note 7 - Borrowings - Borrowings (Details) - USD ($) $ in Thousands	Sep. 30, 2022	Jun. 15, 2022	Dec. 31, 2021	Mar. 30, 2021	Aug. 13, 2019
Total commitment	$ 483,461		$ 353,000
Balance outstanding	362,711		260,250
Unused commitment	120,750		92,750
Unamortized debt issuance costs attributable to term borrowings	(3,700)		(2,637)
Total borrowings outstanding, net	359,011		257,613
Key Facility [Member]
Total commitment	125,000		125,000
Balance outstanding	67,500		53,500
Unused commitment	57,500		71,500
NYL Facility [Member]
Total commitment	200,000		100,000
Balance outstanding	136,750		78,750
Unused commitment	63,250		21,250
Asset-Backed Notes [Member]
Total commitment	43,461		70,500		$ 160,000
Balance outstanding	43,461		70,500
Unused commitment	0		0
The 2027 Notes [Member]
Total commitment	57,500	$ 50,000	0
Balance outstanding	57,500		0
Unused commitment	0		0
The 2026 Notes [Member]
Total commitment	57,500		57,500	$ 57,500
Balance outstanding	57,500		57,500
Unused commitment	$ 0		$ 0

Note 8 - Financial Instruments With Off-balance-sheet Risk (Details Textual) - USD ($) $ in Thousands	Sep. 30, 2022	Dec. 31, 2021
Fair Value Disclosure, off-Balance-Sheet Risks, Amount, Liability	$ 2,147
Commitments to Extend Credit [Member]
Other Commitment, Total	$ 214,500	$ 114,500

Note 8 - Financial Instruments With Off-balance-sheet Risk - Unfunded Commitments (Details) $ in Thousands	Sep. 30, 2022 USD ($)
Unfunded commitments, principal balance	$ 214,500
Fair value of unfunded commitment liability	2,147
Better Place Forests Co. [Member]
Unfunded commitments, principal balance	5,000
Fair value of unfunded commitment liability	6
BrightInsight, Inc. [Member]
Unfunded commitments, principal balance	21,000
Fair value of unfunded commitment liability	278
Britecore Holdings, Inc. [Member]
Unfunded commitments, principal balance	5,000
Fair value of unfunded commitment liability	66
Canary Medical Inc. [Member]
Unfunded commitments, principal balance	2,500
Fair value of unfunded commitment liability	34
Castle Creek Biosciences [Member]
Unfunded commitments, principal balance	4,000
Fair value of unfunded commitment liability	72
Ceribell, Inc. [Member]
Unfunded commitments, principal balance	2,500
Fair value of unfunded commitment liability	4
Divergent Technologies, Inc. [Member]
Unfunded commitments, principal balance	30,000
Fair value of unfunded commitment liability	315
DropOff, Inc. [Member]
Unfunded commitments, principal balance	7,500
Fair value of unfunded commitment liability	188
Embody, Inc. [Member]
Unfunded commitments, principal balance	2,000
Fair value of unfunded commitment liability	20
Engage3, LLC [Member]
Unfunded commitments, principal balance	8,000
Fair value of unfunded commitment liability	40
Hound Labs, Inc. [Member]
Unfunded commitments, principal balance	7,500
Fair value of unfunded commitment liability	87
Interior Define, Inc. [Member]
Unfunded commitments, principal balance	5,000
Fair value of unfunded commitment liability	65
KSQ Therapeutics, Inc. [Member]
Unfunded commitments, principal balance	10,000
Fair value of unfunded commitment liability	100
Lytics, Inc. [Member]
Unfunded commitments, principal balance	1,250
Fair value of unfunded commitment liability	0
Magnolia Medical Technologies, Inc [Member]
Unfunded commitments, principal balance	10,000
Fair value of unfunded commitment liability	122
Native Microbials, Inc. [Member]
Unfunded commitments, principal balance	8,750
Fair value of unfunded commitment liability	64
Optoro, Inc. [Member]
Unfunded commitments, principal balance	15,000
Fair value of unfunded commitment liability	38
PDS Biotechnology Corporation [Member]
Unfunded commitments, principal balance	10,000
Fair value of unfunded commitment liability	158
Scientia Vascular, Inc. [Member]
Unfunded commitments, principal balance	10,000
Fair value of unfunded commitment liability	110
Slingshot Aerospace, Inc. [Member]
Unfunded commitments, principal balance	5,000
Fair value of unfunded commitment liability	64
Soli, Inc. [Member]
Unfunded commitments, principal balance	7,500
Fair value of unfunded commitment liability	147
Sonex Health, Inc. [Member]
Unfunded commitments, principal balance	2,500
Fair value of unfunded commitment liability	45
Swift Health Systems Inc. [Member]
Unfunded commitments, principal balance	25,500
Fair value of unfunded commitment liability	105
Temperpack Technologies, Inc [Member]
Unfunded commitments, principal balance	9,000
Fair value of unfunded commitment liability	$ 19

Note 10 - Distributions (Details Textual) - $ / shares	3 Months Ended		9 Months Ended		12 Months Ended
Note 10 - Distributions (Details Textual) - $ / shares	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021	Dec. 31, 2021
Common Stock, Dividends, Per Share, Declared (in dollars per share)	$ 0.30	$ 0.30	$ 0.90	$ 0.90	$ 1.25
Earnings Per Share, Basic, Total (in dollars per share)	0.43	$ 0.40	$ 1.06	$ 1.02
Earnings Per Share, Basic, Undistributed (in dollars per share)	$ 0.67

Note 10 - Distributions - Distribution Activity (Details) - USD ($) $ / shares in Units, $ in Thousands		3 Months Ended		9 Months Ended		12 Months Ended
	Oct. 28, 2022	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021	Dec. 31, 2021
Distributions declared per share (in dollars per share)		$ 0.30	$ 0.30	$ 0.90	$ 0.90	$ 1.25
Dividends, cash				$ 17,083		$ 25,067
Dividends, shares (in shares)				32,590		28,057
Dividends, stock				$ 392		$ 460
Dividend Paid December 15, 2022 [Member]
Distributions declared per share (in dollars per share)	$ 0.05
Dividend Paid January 13, 2023 [Member]
Distributions declared per share (in dollars per share)	0.11
Dividend Paid February 15, 2023 [Member]
Distributions declared per share (in dollars per share)	0.11
First 7/29/2022 Dividend [Member]
Record date				Nov. 17, 2022
Payment date				Dec. 15, 2022
Distributions declared per share (in dollars per share)				$ 0.10
Dividends, cash				$ 0
Dividends, shares (in shares)				0
Dividends, stock				$ 0
Dividend Paid March 15, 2023 [Member]
Distributions declared per share (in dollars per share)	$ 0.11
Second 7/29/2022 Dividend [Member]
Record date				Oct. 18, 2022
Payment date				Nov. 15, 2022
Distributions declared per share (in dollars per share)				$ 0.10
Dividends, cash				$ 0
Dividends, shares (in shares)				0
Dividends, stock				$ 0
Third 7/29/2022 Dividend [Member]
Record date				Sep. 19, 2022
Payment date				Oct. 14, 2022
Distributions declared per share (in dollars per share)				$ 0.10
Dividends, cash				$ 2,558
Dividends, shares (in shares)				7,703
Dividends, stock				$ 81
First 4/29/22 Dividend [Member]
Record date				Aug. 18, 2022
Payment date				Sep. 15, 2022
Distributions declared per share (in dollars per share)				$ 0.10
Dividends, cash				$ 2,528
Dividends, shares (in shares)				4,925
Dividends, stock				$ 60
Second 4/29/2022 Dividend [Member]
Record date				Jul. 19, 2022
Payment date				Aug. 16, 2022
Distributions declared per share (in dollars per share)				$ 0.10
Dividends, cash				$ 2,484
Dividends, shares (in shares)				3,939
Dividends, stock				$ 55
Third 4/29/2022 Dividend [Member]
Record date				Jun. 17, 2022
Payment date				Jul. 15, 2022
Distributions declared per share (in dollars per share)				$ 0.10
Dividends, cash				$ 2,434
Dividends, shares (in shares)				4,286
Dividends, stock				$ 51
First 2/25/2022 Dividend [Member]
Record date				May 18, 2022
Payment date				Jun. 15, 2022
Distributions declared per share (in dollars per share)				$ 0.10
Dividends, cash				$ 2,378
Dividends, shares (in shares)				4,428
Dividends, stock				$ 50
Second 2/25/2022 Dividend [Member]
Record date				Apr. 19, 2022
Payment date				May 16, 2022
Distributions declared per share (in dollars per share)				$ 0.10
Dividends, cash				$ 2,349
Dividends, shares (in shares)				4,088
Dividends, stock				$ 49
Third 2/25/2022 Dividend [Member]
Record date				Mar. 18, 2022
Payment date				Apr. 14, 2022
Distributions declared per share (in dollars per share)				$ 0.10
Dividends, cash				$ 2,352
Dividends, shares (in shares)				3,221
Dividends, stock				$ 46
First 10/22/21 Dividend [Member]
Record date						Feb. 18, 2022
Payment date						Mar. 16, 2022
Distributions declared per share (in dollars per share)						$ 0.10
Dividends, cash						$ 2,100
Dividends, shares (in shares)						3,409
Dividends, stock						$ 46
Second 10/22/21 Dividend [Member]
Record date						Jan. 19, 2022
Payment date						Feb. 16, 2022
Distributions declared per share (in dollars per share)						$ 0.10
Dividends, cash						$ 2,096
Dividends, shares (in shares)						2,680
Dividends, stock						$ 43
Third 10/22/21 Dividend [Member]
Record date						Dec. 17, 2021
Payment date						Jan. 14, 2022
Distributions declared per share (in dollars per share)						$ 0.10
Dividends, cash						$ 2,031
Dividends, shares (in shares)						3,417
Dividends, stock						$ 56
Fourth 10/22/21 Dividend [Member]
Record date						Nov. 18, 2021
Payment date						Dec. 15, 2021
Distributions declared per share (in dollars per share)						$ 0.05
Dividends, cash						$ 1,013
Dividends, shares (in shares)						1,197
Dividends, stock						$ 20
First 7/23/21 Dividend [Member]
Record date						Nov. 18, 2021
Payment date						Dec. 15, 2021
Distributions declared per share (in dollars per share)						$ 0.10
Dividends, cash						$ 2,027
Dividends, shares (in shares)						2,395
Dividends, stock						$ 38
Second 7/23/21 Dividend [Member]
Record date						Oct. 19, 2021
Payment date						Nov. 16, 2021
Distributions declared per share (in dollars per share)						$ 0.10
Dividends, cash						$ 2,010
Dividends, shares (in shares)						1,907
Dividends, stock						$ 34
Third 7/23/21 Dividend [Member]
Record date						Sep. 17, 2021
Payment date						Oct. 15, 2021
Distributions declared per share (in dollars per share)						$ 0.10
Dividends, cash						$ 2,008
Dividends, shares (in shares)						2,068
Dividends, stock						$ 36
First 4/23/21 Dividend [Member]
Record date						Aug. 18, 2021
Payment date						Sep. 15, 2021
Distributions declared per share (in dollars per share)						$ 0.10
Dividends, cash						$ 1,996
Dividends, shares (in shares)						2,041
Dividends, stock						$ 34
Second 4/23/21 Dividend [Member]
Record date						Jul. 20, 2021
Payment date						Aug. 16, 2021
Distributions declared per share (in dollars per share)						$ 0.10
Dividends, cash						$ 1,983
Dividends, shares (in shares)						1,937
Dividends, stock						$ 34
Third 4/23/21 Dividend [Member]
Record date						Jun. 17, 2021
Payment date						Jul. 16, 2021
Distributions declared per share (in dollars per share)						$ 0.10
Dividends, cash						$ 1,964
Dividends, shares (in shares)						1,888
Dividends, stock						$ 33
First 2/26/21 Dividend [Member]
Record date						May 18, 2021
Payment date						Jun. 16, 2021
Distributions declared per share (in dollars per share)						$ 0.10
Dividends, cash						$ 1,964
Dividends, shares (in shares)						1,671
Dividends, stock						$ 29
Second 2/26/21 Dividend [Member]
Record date						Apr. 20, 2021
Payment date						May 14, 2021
Distributions declared per share (in dollars per share)						$ 0.10
Dividends, cash						$ 1,937
Dividends, shares (in shares)						1,794
Dividends, stock						$ 29
Third 2/26/21 Dividend [Member]
Record date						Mar. 18, 2021
Payment date						Apr. 16, 2021
Distributions declared per share (in dollars per share)						$ 0.10
Dividends, cash						$ 1,938
Dividends, shares (in shares)						1,653
Dividends, stock						$ 28